<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-111973" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Peyronie Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sandean</surname>
            <given-names>Darren P.</given-names>
          </name>
          <aff>University Hospitals of Leicester</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lotfollahzadeh</surname>
            <given-names>Saran</given-names>
          </name>
          <aff>Vascular Reserach, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA, Department of Surgery, vascular and endovascular surgery section, Boston Medical Center, Boston, MA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Darren Sandean declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saran Lotfollahzadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-111973.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Peyronie disease is a benign disorder causing pain and curvature of the penis during erections. This disease&#x000a0;is a disorder of wound healing, scarring, and plaque formation of the penile tunica albuginea, which results in fibrosis and varying degrees of penile angulation when erect.&#x000a0;The role of oral medications and supplements, traction therapy, vacuum erection devices, <italic toggle="yes">Clostridium histoliticum&#x000a0;</italic>collagenase and other intralesional injections, iontophoresis, surgery, and various restorative therapies,&#x000a0;such as platelet-rich plasma or stem cell penile injections&#x000a0;and extracorporeal shockwave therapy, are reviewed.&#x000a0;</p>
        <p>This activity reviews the etiology, pathophysiology, epidemiology, diagnosis, and treatment options for Peyronie disease, encompassing both surgical and nonsurgical approaches.The currently recommended evaluation and management strategies&#x000a0;for&#x000a0;this disorder are presented, highlighting the role of the interprofessional team in ensuring the best possible patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply recommended guidelines to the evaluation and treatment of Peyronie disease.</p></list-item><list-item><p>Compare and evaluate the medical options for treating Peyronie disease.</p></list-item><list-item><p>Determine the surgical options for treating Peyronie disease.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to ensure the best patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=111973&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=111973">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-111973.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Peyronie disease is a progressive and nonmalignant disorder of the penis resulting in an abnormal curvature during erection. The condition was observed in 1561 by Gabriele Fallopius and Andreas Vesalius but was named after Fran&#x000e7;ois Gigot de la Peyronie, the personal physician of King Louis XV and cofounder of the French Acad&#x000e9;mie Royale de Chirurgie, who was the first to fully describe the disease in 1743.<xref ref-type="bibr" rid="article-111973.r1">[1]</xref><xref ref-type="bibr" rid="article-111973.r2">[2]</xref></p>
        <p>Peyronie disease is a wound-healing disorder of the tunica albuginea&#x000a0;that results in localized fibrosis or scarring of the tunica albuginea.<xref ref-type="bibr" rid="article-111973.r3">[3]</xref>&#x000a0;The abnormal curvature is caused by localized scar tissue in the walls of the corpora; the exact mechanism responsible for forming this fibrotic area remains elusive.</p>
        <p>Peyronie disease&#x000a0;often causes significant distress to patients due to the deformity and resultant impaired appearance and function. In addition, it is&#x000a0;associated with erectile dysfunction, which is in itself a distressing condition.&#x000a0;</p>
      </sec>
      <sec id="article-111973.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>A basic understanding of the penile anatomy is required to appreciate the etiology and pathophysiology of Peyronie disease.<xref ref-type="bibr" rid="article-111973.r4">[4]</xref><xref ref-type="bibr" rid="article-111973.r5">[5]</xref>&#x000a0;The penis consists of 2 erectile bodies, the corpora cavernosa, that runs along the length of the penis. During an erection, these chambers fill with blood, increasing the size and rigidity of the penis. Each corpus cavernosum has a sheath of elastic fibers, the tunica albuginea, comprising predominantly type 1 collagen fibers. The corpora cavernosa are separated by a merger of the tunica albuginea in the midline, forming a septum that attaches ventrally and dorsally along the shaft of the penis.</p>
        <p>In Peyronie disease, a localized fibrous plaque forms in the tunica albuginea of the corpora cavernosa. This inelastic plaque changes the straight, erect penis to a more kinked or curved appearance in the direction of the involved tunical segment. The exact mechanism of plaque formation is yet to be definitively established; the most generally accepted theory is that the plaque forms as a result of some degree of penile injury or microtrauma, particularly in men who are genetically predisposed to the condition.<xref ref-type="bibr" rid="article-111973.r6">[6]</xref><xref ref-type="bibr" rid="article-111973.r7">[7]</xref><xref ref-type="bibr" rid="article-111973.r8">[8]</xref><xref ref-type="bibr" rid="article-111973.r9">[9]</xref>&#x000a0;Endothelial-dependent systemic arterial impairment is more frequently found in patients with Peyronie disease than healthy controls.<xref ref-type="bibr" rid="article-111973.r10">[10]</xref>&#x000a0;The significance of these findings in the etiology of Peyronie disease&#x000a0;is still being studied.</p>
        <p>Although it is not possible to definitively predict who will develop Peyronie disease, it appears to be more likely in susceptible men who engage in vigorous sexual or nonsexual activities,&#x000a0;such as certain sports, that cause penile microtrauma.&#x000a0;Further research is needed to improve our understanding of the true pathogenesis of Peyronie disease and the role of genetic and other factors in its clinical presentation.</p>
        <p>The known risk factors for Peyronie disease include:</p>
        <p>
<bold>Connective Tissue Disorders</bold>
</p>
        <p>Peyronie disease is commonly associated with several fibroproliferative diseases, such as Dupuytren contracture and plantar fasciitis,&#x000a0;suggesting a significant pathophysiologic and genetic overlap between these superficial fibrosing disorders.<xref ref-type="bibr" rid="article-111973.r9">[9]</xref><xref ref-type="bibr" rid="article-111973.r11">[11]</xref><xref ref-type="bibr" rid="article-111973.r12">[12]</xref><xref ref-type="bibr" rid="article-111973.r13">[13]</xref><xref ref-type="bibr" rid="article-111973.r14">[14]</xref><xref ref-type="bibr" rid="article-111973.r15">[15]</xref><xref ref-type="bibr" rid="article-111973.r16">[16]</xref>&#x000a0;For example, in a study&#x000a0;involving&#x000a0;415 men with Peyronie disease, 89 (22.1%) had Dupuytren contractures.<xref ref-type="bibr" rid="article-111973.r12">[12]</xref> Numerous studies have linked Peyronie disease to other systemic fibrotic disorders such as idiopathic pulmonary fibrosis, Paget disease of bone,&#x000a0;retroperitoneal fibrosis, polyfibromatosis, and systemic sclerosis (scleroderma).<xref ref-type="bibr" rid="article-111973.r17">[17]</xref><xref ref-type="bibr" rid="article-111973.r18">[18]</xref><xref ref-type="bibr" rid="article-111973.r19">[19]</xref><xref ref-type="bibr" rid="article-111973.r20">[20]</xref><xref ref-type="bibr" rid="article-111973.r21">[21]</xref><xref ref-type="bibr" rid="article-111973.r22">[22]</xref></p>
        <p>
<bold>Diabetes</bold>
</p>
        <p>Men with erectile dysfunction secondary to diabetes are 4 to 5 times more likely to develop Peyronie disease compared to the general population.<xref ref-type="bibr" rid="article-111973.r23">[23]</xref><xref ref-type="bibr" rid="article-111973.r24">[24]</xref><xref ref-type="bibr" rid="article-111973.r25">[25]</xref><xref ref-type="bibr" rid="article-111973.r26">[26]</xref><xref ref-type="bibr" rid="article-111973.r27">[27]</xref>&#x000a0;Diabetes is believed to aggravate the fibrotic process associated with Peyronie disease, impair wound healing, decrease tunica elasticity, worsen nociception, and increase connective tissue collagenization.<xref ref-type="bibr" rid="article-111973.r27">[27]</xref>&#x000a0;Better glycemic control tends to improve symptoms of Peyronie disease.<xref ref-type="bibr" rid="article-111973.r27">[27]</xref> Diabetic patients who have surgery for Peyronie disease are less likely to develop a recurrence of their penile curvature but are more likely to have postoperative erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r27">[27]</xref>&#x000a0;These patients are also more likely to develop an infection after a penile prosthesis implant.<xref ref-type="bibr" rid="article-111973.r27">[27]</xref></p>
        <p>
<bold>Family History</bold>
</p>
        <p>The genetic factors contributing to Peyronie disease are complex.<xref ref-type="bibr" rid="article-111973.r7">[7]</xref>&#x000a0;Evidence suggests a genetic link; the exact mechanism or responsible genes remain undetermined. The literature suggests that multiple genes, including HLA-B7, could be involved, which confer increased susceptibility to developing Peyronie disease.<xref ref-type="bibr" rid="article-111973.r6">[6]</xref><xref ref-type="bibr" rid="article-111973.r7">[7]</xref><xref ref-type="bibr" rid="article-111973.r9">[9]</xref><xref ref-type="bibr" rid="article-111973.r28">[28]</xref><xref ref-type="bibr" rid="article-111973.r29">[29]</xref>&#x000a0;Up to 4% of first-degree relatives develop the condition.<xref ref-type="bibr" rid="article-111973.r6">[6]</xref><xref ref-type="bibr" rid="article-111973.r29">[29]</xref><xref ref-type="bibr" rid="article-111973.r30">[30]</xref><xref ref-type="bibr" rid="article-111973.r31">[31]</xref></p>
        <p>
<bold>Hypogonadism</bold>
</p>
        <p>Androgens play an essential role in wound healing by modulating the matrix metalloproteinases.<xref ref-type="bibr" rid="article-111973.r32">[32]</xref>&#x000a0;In male hypogonadism, this normal healing process is disrupted, potentially increasing the risk of Peyronie disease. Although hypogonadism may increase the risk of developing Peyronie disease and the severity of the disorder, this link remains uncertain due to conflicting study results.</p>
        <p>In a study, 74.4% of male hypogonadal patients, defined as a serum testosterone levels &#x0003c;300 ng/dL, were found to have Peyronie disease.<xref ref-type="bibr" rid="article-111973.r33">[33]</xref>&#x000a0;The degree of curvature was higher in the hypogonadal group compared to men with Peyronie disease and normal testosterone levels.<xref ref-type="bibr" rid="article-111973.r33">[33]</xref> This effect was also found in several other studies but refuted in others, leaving it an unresolved, open question that requires further research.<xref ref-type="bibr" rid="article-111973.r4">[4]</xref><xref ref-type="bibr" rid="article-111973.r34">[34]</xref><xref ref-type="bibr" rid="article-111973.r35">[35]</xref></p>
        <p>
<bold>Penile Injury and Prior Urological Surgery</bold>
</p>
        <p>Previous injury to the penis is a strong predictor of developing Peyronie disease. Genital or perineal trauma and iatrogenic injury, including urethral catheterization, cystoscopy, and transurethral surgery, are all linked to an increased risk of Peyronie disease.<xref ref-type="bibr" rid="article-111973.r30">[30]</xref><xref ref-type="bibr" rid="article-111973.r36">[36]</xref>&#x000a0;A&#x000a0;study&#x000a0;involving 1011 patients reported that 15.9% of patients undergoing radical prostatectomy developed Peyronie disease.<xref ref-type="bibr" rid="article-111973.r37">[37]</xref>&#x000a0;In patients with no known history of trauma or surgery, repeated asymptomatic microtrauma from sexual activity may be involved when no other etiology can be determined.</p>
        <p>
<bold>Smoking and Alcohol</bold>
</p>
        <p>There is some evidence to suggest that smoking is related to Peyronie disease, although the correlation between the amount of smoking and risk is unclear. Similarly, the literature remains divisive concerning alcohol, with conflicting studies. A study by Bjekic&#x000a0;suggests a strong correlation, but a larger-scale report by La Pera et al disproves any such relationship.<xref ref-type="bibr" rid="article-111973.r36">[36]</xref><xref ref-type="bibr" rid="article-111973.r38">[38]</xref></p>
        <p>Other risk factors include age, hyperlipidemia, erectile dysfunction, obesity, penile trauma during intercourse, and psychological disorders.<xref ref-type="bibr" rid="article-111973.r36">[36]</xref><xref ref-type="bibr" rid="article-111973.r39">[39]</xref><xref ref-type="bibr" rid="article-111973.r40">[40]</xref><xref ref-type="bibr" rid="article-111973.r41">[41]</xref>&#x000a0;Erectile dysfunction is found in about 40% (30% to 60%) of all patients with Peyronie disease, especially in patients older than&#x000a0;40.<xref ref-type="bibr" rid="article-111973.r42">[42]</xref><xref ref-type="bibr" rid="article-111973.r43">[43]</xref><xref ref-type="bibr" rid="article-111973.r44">[44]</xref><xref ref-type="bibr" rid="article-111973.r45">[45]</xref><xref ref-type="bibr" rid="article-111973.r46">[46]</xref></p>
      </sec>
      <sec id="article-111973.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The reported prevalence of Peyronie disease ranges from 0.3% to 20.3%.<xref ref-type="bibr" rid="article-111973.r47">[47]</xref>&#x000a0;There is considerable variability by country, cohort, age, and ethnicity of patients included in the studies. Some of the variability stems from studies using different diagnostic criteria or data collection methods, such as inconsistent patient or physician reporting strategies.</p>
        <p>For example, Lindsay and associates&#x000a0;reported a 0.39% prevalence rate when studying a group in the United States.<xref ref-type="bibr" rid="article-111973.r48">[48]</xref> In contrast, Schwarzer et al reported a 3.2% prevalence after mailing a standardized questionnaire to 8000 men in France.<xref ref-type="bibr" rid="article-111973.r49">[49]</xref> A much larger three-phase study investigated the prevalence of Peyronie disease in 11420 males in the United States and reported rates of up to 13%.<xref ref-type="bibr" rid="article-111973.r50">[50]</xref>&#x000a0;</p>
        <p>White men have the highest reported incidence, but this may merely reflect the increased difficulty in obtaining information from other groups.&#x000a0;Men aged 50 to 59 are most commonly affected by Peyronie disease,&#x000a0;with an average age of 55 at the time of presentation.<xref ref-type="bibr" rid="article-111973.r39">[39]</xref><xref ref-type="bibr" rid="article-111973.r42">[42]</xref><xref ref-type="bibr" rid="article-111973.r48">[48]</xref><xref ref-type="bibr" rid="article-111973.r51">[51]</xref><xref ref-type="bibr" rid="article-111973.r52">[52]</xref>&#x000a0;However, Peyronie disease can still be present at any age in adulthood, with some reports in teenagers.<xref ref-type="bibr" rid="article-111973.r42">[42]</xref><xref ref-type="bibr" rid="article-111973.r53">[53]</xref>&#x000a0;When Peyronie disease is found in younger men, it is associated with an increased number of plaques, and the patients are more likely to have elevated levels of HbA1c compared to older patients.<xref ref-type="bibr" rid="article-111973.r53">[53]</xref></p>
        <p>Accurately determining the prevalence of Peyronie disease is challenging due to the embarrassment many patients feel about the condition.<xref ref-type="bibr" rid="article-111973.r54">[54]</xref>&#x000a0;The actual prevalence is, therefore, most likely much greater than reported and has been estimated to be as high as 18%.<xref ref-type="bibr" rid="article-111973.r2">[2]</xref><xref ref-type="bibr" rid="article-111973.r23">[23]</xref><xref ref-type="bibr" rid="article-111973.r54">[54]</xref><xref ref-type="bibr" rid="article-111973.r55">[55]</xref><xref ref-type="bibr" rid="article-111973.r56">[56]</xref>&#x000a0;Given the wide variation of reported prevalence rates, the best overall estimate of Peyronie disease is about 9% to 10% of adult males.<xref ref-type="bibr" rid="article-111973.r2">[2]</xref><xref ref-type="bibr" rid="article-111973.r57">[57]</xref><xref ref-type="bibr" rid="article-111973.r58">[58]</xref><xref ref-type="bibr" rid="article-111973.r59">[59]</xref></p>
      </sec>
      <sec id="article-111973.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The hallmark of Peyronie disease is the localized fibrosis of the tunica albuginea of the corpora cavernosum, leading to plaque formation and loss of elasticity, which results in the characteristic penile curvature.&#x000a0;The tunica albuginea comprises scattered type 1 collagen strands and an irregular network of elastic fibers.</p>
        <p>Repetitive minor trauma to the penis causing tunical mechanical stress and microvascular injury are the major contributory factors.<xref ref-type="bibr" rid="article-111973.r2">[2]</xref><xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;When the penis is squeezed or bent, such as during vigorous sexual activity, buckling forces result in overstretching and eventual delamination of the tunica albuginea fibers where the septum attaches.</p>
        <p>This trauma damages the microvasculature, resulting in blood extravasation, fibrin deposition, and a subsequent inflammatory cascade,&#x000a0;including fibrin trapping, extravascular infiltrate and protein accumulations, overexpression of cytokines, infiltration by macrophages, and the release of elastase, which converts the collagen in the tunica from type 1 to the more fibrous and type III.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r61">[61]</xref><xref ref-type="bibr" rid="article-111973.r62">[62]</xref><xref ref-type="bibr" rid="article-111973.r63">[63]</xref><xref ref-type="bibr" rid="article-111973.r64">[64]</xref><xref ref-type="bibr" rid="article-111973.r65">[65]</xref><xref ref-type="bibr" rid="article-111973.r66">[66]</xref><xref ref-type="bibr" rid="article-111973.r67">[67]</xref><xref ref-type="bibr" rid="article-111973.r68">[68]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r70">[70]</xref><xref ref-type="bibr" rid="article-111973.r71">[71]</xref></p>
        <p>Coital trauma may lead to&#x000a0;dorsal and ventral delamination of the tunica albuginea, resulting in fibrin deposition between the tunical layers and localized induration with inflammation.<xref ref-type="bibr" rid="article-111973.r3">[3]</xref>&#x000a0;When fibrin is not rapidly cleared from the relatively avascular tunica albuginea, various antifibrinolysis and fibrosis-promoting&#x000a0;chemical factors are released, such as plasminogen activator inhibitor type 1 (PAI-1), transforming growth factor-beta&#x000a0;1 (TGF- &#x000df;1<italic toggle="yes">),&#x000a0;</italic>platelet-derived growth factor (PDGF), interleukin-1 (IL-1), and IL-6.<xref ref-type="bibr" rid="article-111973.r62">[62]</xref><xref ref-type="bibr" rid="article-111973.r65">[65]</xref><xref ref-type="bibr" rid="article-111973.r67">[67]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r72">[72]</xref><xref ref-type="bibr" rid="article-111973.r73">[73]</xref><xref ref-type="bibr" rid="article-111973.r74">[74]</xref><xref ref-type="bibr" rid="article-111973.r75">[75]</xref>&#x000a0;Abnormal&#x000a0;fibrin has been found in 95% of Peyronie plaques and none in control samples.<xref ref-type="bibr" rid="article-111973.r61">[61]</xref>&#x000a0;Extravasated blood and cellular infiltrates result in prolonged inflammation, edema, and sensitized nerve endings, which may be the source of the pain associated with acute phase disease.<xref ref-type="bibr" rid="article-111973.r65">[65]</xref><xref ref-type="bibr" rid="article-111973.r67">[67]</xref><xref ref-type="bibr" rid="article-111973.r68">[68]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref></p>
        <p>Wound healing is delayed and becomes unregulated due to the prolonged inflammation. The enhancement of fibrous tissue production is mediated by TGF-&#x000df;1, PAI-1, PDGF, IL-1, and IL-6.<xref ref-type="bibr" rid="article-111973.r65">[65]</xref><xref ref-type="bibr" rid="article-111973.r67">[67]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r72">[72]</xref>&#x000a0;Abnormal inflammation and wound healing are believed to be responsible for the increased cellularity around the tunica, which results in a perivascular lymphocytic infiltrate around or within the tunica itself.<xref ref-type="bibr" rid="article-111973.r76">[76]</xref><xref ref-type="bibr" rid="article-111973.r77">[77]</xref><xref ref-type="bibr" rid="article-111973.r78">[78]</xref><xref ref-type="bibr" rid="article-111973.r79">[79]</xref><xref ref-type="bibr" rid="article-111973.r80">[80]</xref><xref ref-type="bibr" rid="article-111973.r81">[81]</xref></p>
        <p>Collagen deposition is enhanced by prolonged inflammation, the increased migration of fibroblasts to the affected area, and the proliferation of myofibroblasts from increased TGF-&#x000df;1 activity.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref>&#x000a0;Extracellular matrix proliferation from TGF-&#x000df;1 and myofibroblast activity&#x000a0;and the effect of matrix metalloproteinase inhibition block the dissolution of fibrin and excess collagen, further promoting fibrosis.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r72">[72]</xref><xref ref-type="bibr" rid="article-111973.r82">[82]</xref>&#x000a0;The prolonged inflammation activates nuclear factor-kappa beta (NF-&#x003ba;B), which releases additional inflammatory cytokines, further prolonging and extending the process.<xref ref-type="bibr" rid="article-111973.r83">[83]</xref>&#x000a0;</p>
        <p>These effects&#x000a0;collectively result in an inflammatory cascade that promotes localized fibrosis and plaque formation over normal wound consolidation.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref> This mechanism also&#x000a0;explains why Peyronies disease occurs following penile trauma, but many patients do not recall any history of significant penile injury.</p>
        <p>Other theories have been suggested to explain the formation of the plaques, including microtrauma, microvasculature injury, chromosomal instability of fibroblasts involved in plaque formation, aberrations in the inducible nitric oxide pathways, and patient HLA subtype.<xref ref-type="bibr" rid="article-111973.r5">[5]</xref><xref ref-type="bibr" rid="article-111973.r84">[84]</xref><xref ref-type="bibr" rid="article-111973.r85">[85]</xref>&#x000a0;Additional&#x000a0;factors involved are&#x000a0;the presence of&#x000a0;cytomegalovirus within the tunica, chromosomal instability in tunica-derived fibroblasts, cytokine overexpression, increased reactive oxygen production, and a high incidence of homozygous nucleotide polymorphisms involving the TGF-&#x003b2;1 gene.<xref ref-type="bibr" rid="article-111973.r64">[64]</xref><xref ref-type="bibr" rid="article-111973.r65">[65]</xref><xref ref-type="bibr" rid="article-111973.r86">[86]</xref><xref ref-type="bibr" rid="article-111973.r87">[87]</xref><xref ref-type="bibr" rid="article-111973.r88">[88]</xref><xref ref-type="bibr" rid="article-111973.r89">[89]</xref>&#x000a0;There is evidence that crosstalk may be involved between TGF-&#x003b2;, WNT/&#x003b2;-catenin, Hedgehog, YAP/TAZ, MAPK, ROCK, and PI3K/AKT signaling pathways.<xref ref-type="bibr" rid="article-111973.r90">[90]</xref>&#x000a0;Plaque calcification, primarily composed of calcium phosphate, occurs due to increased TGF-&#x000df;1 activity, which enhances osteogenesis and upregulates pleiotrophin, an osteogenic growth factor that stimulates fibroblast and osteoblast activity.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r91">[91]</xref><xref ref-type="bibr" rid="article-111973.r92">[92]</xref></p>
      </sec>
      <sec id="article-111973.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The tunica albuginea normally contains 2 layers of elastic fibers with a collagen layer in between.<xref ref-type="bibr" rid="article-111973.r93">[93]</xref> The outer layer is longitudinally oriented with an inner circular layer.<xref ref-type="bibr" rid="article-111973.r93">[93]</xref>&#x000a0;The fibrosis in Peyronie disease begins with the merging of inner septal fibers of the tunica albuginea.&#x000a0;The plaque is composed of disorganized collagen type I and type III fibers in dense clumps together with decreased, disordered, fragmented elastin fibers.<xref ref-type="bibr" rid="article-111973.r61">[61]</xref><xref ref-type="bibr" rid="article-111973.r64">[64]</xref><xref ref-type="bibr" rid="article-111973.r76">[76]</xref><xref ref-type="bibr" rid="article-111973.r93">[93]</xref><xref ref-type="bibr" rid="article-111973.r94">[94]</xref></p>
      </sec>
      <sec id="article-111973.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A small cohort study in the 1970s suggested that most patients with symptomatic Peyronie disease and curvatures experience spontaneous resolution.<xref ref-type="bibr" rid="article-111973.r95">[95]</xref>&#x000a0;However, this has since been refuted in many studies that indicate a spontaneous resolution rate of about 12%, with most patients seeing either no change or worsening of their condition.<xref ref-type="bibr" rid="article-111973.r25">[25]</xref><xref ref-type="bibr" rid="article-111973.r96">[96]</xref><xref ref-type="bibr" rid="article-111973.r97">[97]</xref>&#x000a0;Patients should be counseled that their condition is unlikely to resolve without medical treatment, and a considerable number of men experience worsening symptoms over time. In general, only curvatures &#x0003e;30&#x000b0; are likely to interfere with sexual activity.</p>
        <p>There are 2 clinical phases in Peyronie disease&#x02014;acute and chronic, which are poorly defined.<xref ref-type="bibr" rid="article-111973.r98">[98]</xref>&#x000a0;</p>
        <p>The acute phase typically lasts from 3&#x000a0;to 18 months. During this period, the penile deformity generally progresses, the characteristic plaques form, and pain with erections is commonly reported.<xref ref-type="bibr" rid="article-111973.r51">[51]</xref><xref ref-type="bibr" rid="article-111973.r53">[53]</xref>&#x000a0;The hallmark finding during the active phase has classically been pain, usually with erections, but the reliability of this traditional symptom has recently been questioned.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref>&#x000a0;The lack of progression and stability of symptoms appears to be a more reliable indicator and predictor of disease progression.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref>&#x000a0;Treatment during the acute phase is generally conservative, with nonsteroidal anti-inflammatory drug, penile traction, vacuum erection devices, and various oral agents.</p>
        <p>The chronic phase is characterized by a plateau of symptoms during which the disorder and any penile deformity are stable for at least 3 months, along with the resolution of any pain.&#x000a0;The presence or absence of pain has been one of the more useful distinguishing characteristics between the 2 phases of the disease but is not necessarily a reliable indicator.<xref ref-type="bibr" rid="article-111973.r51">[51]</xref>&#x000a0;The development of calcifications in the plaque is a good indicator of lesional stability and a chronic phase of the disease. The chronic phase is when more aggressive treatment, such as intralesional injections or surgery, is utilized.&#x000a0;</p>
        <p>
<bold>History</bold>
</p>
        <p>Obtaining a detailed history and performing a thorough physical examination is crucial for accurately diagnosing Peyronie disease. This condition can be a delicate and distressing topic for patients as the ramifications on a man's sex life and relationships can be profound. Consequently, clinicians should be empathetic, delicate, professional, and understanding when evaluating patients' symptoms and eliciting their ideas, concerns, and expectations of their condition.</p>
        <p>The psychosocial impact of the condition may warrant input from counselors and therapists as significant depression, emotional difficulties, and serious relationship issues are common and found in more than half of all Peyronie patients.<xref ref-type="bibr" rid="article-111973.r100">[100]</xref><xref ref-type="bibr" rid="article-111973.r101">[101]</xref><xref ref-type="bibr" rid="article-111973.r102">[102]</xref><xref ref-type="bibr" rid="article-111973.r103">[103]</xref>&#x000a0;The impact on the female partner should also be evaluated.<xref ref-type="bibr" rid="article-111973.r104">[104]</xref><xref ref-type="bibr" rid="article-111973.r105">[105]</xref><xref ref-type="bibr" rid="article-111973.r106">[106]</xref></p>
        <p>A comprehensive history should include a detailed presenting complaint and past medical, surgical, and family history, as there is a genetic heritable predisposition to develop Peyronie disease (4%). The sexual history is also particularly relevant in Peyronie disease. Patients typically present for evaluation 6 months after the first appearance of symptoms.<xref ref-type="bibr" rid="article-111973.r23">[23]</xref><xref ref-type="bibr" rid="article-111973.r107">[107]</xref>&#x000a0;Penile curvature is the most common presenting symptom, followed by pain and plaque formation.<xref ref-type="bibr" rid="article-111973.r107">[107]</xref></p>
        <p>Key elements to consider when taking a history of a patient with Peyronie disease include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Timing: Onset and progression of symptoms. Is the patient in the acute or chronic phase?</p>
          </list-item>
          <list-item>
            <p>Deformity: How would the patient describe the penile deformity? What is the direction and degree of curvature? Is there an hourglass deformity, hinge effect, or any other concerning abnormality?</p>
          </list-item>
          <list-item>
            <p>Duration: How long have the symptoms been stable?</p>
          </list-item>
          <list-item>
            <p>Erection: The degree of rigidity, ability to sustain and maintain an erection, and presence of nocturnal erections. Peyronie disease is often associated with erectile dysfunction.</p>
          </list-item>
          <list-item>
            <p>Pain: If pain is present, is it associated with the flaccid or erect state? Both?</p>
          </list-item>
          <list-item>
            <p>Trauma: Any history of penile trauma&#x000a0;or fracture, urologic procedures, or surgeries?</p>
          </list-item>
          <list-item>
            <p>Family history: Is there any family history of Peyronie or Dupuytren disease? Approximately 21% of Peyronie patients also have Dupuytren contractures.<xref ref-type="bibr" rid="article-111973.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Medical&#x000a0;or Surgical history: Diabetes, hypertension, and cardiovascular disease.</p>
          </list-item>
          <list-item>
            <p>Social history: Sexual history, smoking, and recreational drug use.</p>
          </list-item>
          <list-item>
            <p>Psychosocial factors: The condition's impact on the patient's mood, relationships, and self-esteem should be evaluated. The effect on his sexual partner should also be determined.</p>
          </list-item>
        </list>
        <p>
<bold>Examination</bold>
</p>
        <p>Accurate evaluation of penile deformity is critical for determining a baseline and planning treatment. The penis should be examined in flaccid and erect states to provide a clearer understanding of the extent of the deformity and corroboration with the patient's experience.</p>
        <p>Examination in the erect state can be performed after intracavernosal injection of vasoactive substances as recommended by the American Urology Association guidelines.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r108">[108]</xref>&#x000a0;In addition to the length of the penis, the presence of a plaque, and the degree of curvature, attention should be paid to any indentations in the corpora, the presence of an hourglass or bottleneck deformity, and any instability or buckling of the penis with a full erection when placed under bending or axial pressure.<xref ref-type="bibr" rid="article-111973.r51">[51]</xref>&#x000a0;The plaque is most often located dorsally but may occur in any location.<xref ref-type="bibr" rid="article-111973.r109">[109]</xref>&#x000a0;Such an examination is recommended before consideration of any invasive therapy. Photographs from home may be helpful but are rarely sufficient.</p>
        <p>As a general rule, a curvature of 20&#x000b0; or less is considered essentially normal, 30&#x000b0; is considered functionally straight and usable, and 60&#x000b0; or more is probably sexually unusable and may ultimately require surgery. The median penile curvature noted in patients in most studies of Peyronie disease is 48&#x000b0;.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref></p>
        <p>An examination following intracavernosal injections is superior to photographs or vacuum erectile device-assisted erections for accurately determining the type and degree of the Peyronie deformity.<xref ref-type="bibr" rid="article-111973.r51">[51]</xref><xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r110">[110]</xref>&#x000a0;An objective assessment of the degree of curvature is essential for monitoring the disease and evaluating treatment progress,&#x000a0;as patient estimates are notoriously unreliable.<xref ref-type="bibr" rid="article-111973.r111">[111]</xref><xref ref-type="bibr" rid="article-111973.r112">[112]</xref>&#x000a0;More than half of patients tend to overestimate their curvature, and only about 20% are reasonably close.<xref ref-type="bibr" rid="article-111973.r111">[111]</xref>&#x000a0;Even photographs from home are not always helpful, as the erections pictured are often less than fully rigid and at odd angles. For this reason, obtaining an objective measurement, showing it to the patient, and documenting it in the medical record before starting any invasive therapy is recommended.</p>
        <p>The stretched penile length is performed with the penis in the flaccid state. The penis is grasped at the glans and pulled gently at 90&#x000b0; from the body, then the length is measured and recorded.</p>
        <p>Peyronie disease is a clinical diagnosis; laboratory testing has a limited role except when hypogonadism is suspected. In light of the strong correlation with other diseases, no workup&#x000a0;is complete without screening the patient for comorbidities,&#x000a0;including diabetes, cardiovascular disease, and other fibroproliferative conditions such as Dupuytren disease, plantar fasciitis, Ledderhose disease (plantar fibromatosis), and scleroderma, among others.</p>
      </sec>
      <sec id="article-111973.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The most critical components of the evaluation are the patient's history and a thorough physical examination. There is no mandatory or necessary laboratory or imaging testing to complete a Peyronie disease workup. A testosterone level is not required unless indicated for other reasons. However, it is reasonable and advisable to screen for associated conditions, such as connective tissue disorders like Dupuytren disease or diabetes.</p>
        <p>The American Urological Association (AUA), Canadian Urological Association (CUA), and the European Association of Urology (EAU) guidelines recommend performing an in-office intracavernous injection (ICI) test&#x000a0;with&#x000a0;or without penile Doppler duplex ultrasound before any invasive intervention.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref>&#x000a0;A complete duplex ultrasound provides certain advantages, including identifying any calcifications, checking penile vascular flow, and evaluating the patient's erection quality after ICI.&#x000a0;Penile Doppler duplex ultrasound may help locate plaques that are not easily palpated and identify internal calcifications.<xref ref-type="bibr" rid="article-111973.r115">[115]</xref>&#x000a0;This technique may also be helpful in cases where the diagnosis is uncertain.<xref ref-type="bibr" rid="article-111973.r115">[115]</xref></p>
        <p>Levine et al recently published&#x000a0;a calcification grading system. The investigators found that patients with grade 3 or more extensive calcifications (greater than 1.5 cm in any dimension or multiple plaques greater than 1.0 cm) were more likely to undergo surgery when they had satisfactory erectile function.<xref ref-type="bibr" rid="article-111973.r116">[116]</xref> Patients with less severe calcifications of grade 1 (&#x0003c;0.3 cm) or grade 2 (0.3&#x000a0;to 1.5 cm) or no calcifications had no evidence of any increased likelihood to proceed with surgery.<xref ref-type="bibr" rid="article-111973.r116">[116]</xref>&#x000a0;</p>
        <p>Thin-section, high-resolution T2 magnetic resonance imaging (MRI) without fat suppression has also been shown to be an excellent imaging modality for assessing penile pathology, including Peyronie disease.<xref ref-type="bibr" rid="article-111973.r115">[115]</xref><xref ref-type="bibr" rid="article-111973.r117">[117]</xref><xref ref-type="bibr" rid="article-111973.r118">[118]</xref>&#x000a0;Plaques appear as low-signal intensity areas of the thickened tunica albuginea, but calcifications are poorly appreciated.<xref ref-type="bibr" rid="article-111973.r118">[118]</xref>&#x000a0;Due to the high cost and limited availability, the utility of MRI in the routine workup for Peyronie disease is unclear, and it is not currently recommended for routine use.<xref ref-type="bibr" rid="article-111973.r119">[119]</xref></p>
        <p>Experimentally,&#x000a0;penile scintigraphy with technetium Tc 99m human immunoglobulin G was able to differentiate acute-phase Peyronie disease from chronic lesions.<xref ref-type="bibr" rid="article-111973.r120">[120]</xref></p>
        <p>
<bold>Proposed Peyonie Disease Clinical Classification System</bold>
</p>
        <p>Trost, Mulhall, and Hellstrom have proposed a useful evidence-based clinical classification system for Peyronie disease and penile curvature that extends beyond the traditional acute and chronic phases.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref>&#x000a0;This system, called the PTNM classification, encompasses 4 elements&#x02014;Peyronie disease (P), Trauma (T), Non-Peyronie components (N, which includes congenital or maturational issues), and Mode (M, referring to active vs. chronic phases).<xref ref-type="bibr" rid="article-111973.r99">[99]</xref></p>
        <p>Pain is often used to help differentiate the acute and chronic phases of Peyronie disease. However, in developing the PTNM classification system, it was found that pain did not reliably coincide with disease progression.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref></p>
        <p>The classification system categorizes Peyronie disease into four subtypes based on its clinical characteristics&#x02014;classical, calcifying, relapsing&#x000a0;or remitting, and progressive.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref>&#x000a0;</p>
        <p><bold>Calcifying</bold>
<bold>Peyronie disease:</bold>&#x000a0;This disease&#x000a0;is characterized by moderate-to-severe (&#x0003e;1 cm) plaque calcification. Patients with this disease are more likely than average to experience disease progression, pain, and indentations or hourglass deformities. After 1 year, three-fourths of these patients develop clinically stable disease.&#x000a0;Stable calcifying disease is defined as at least 12 months since the original presentation of the disease and&#x000a0;no significant clinical changes in curvature, symptoms, or penile deformities for the last 3 months or a continuous period of clinical stability of at least 6 months.</p>
        <p><bold>Progressive</bold>
<bold>disease:</bold>&#x000a0;This&#x000a0;disease includes cases in which patients report a noticeable worsening of their symptoms at or beyond 3 months from their initial presentation. Disease stability at&#x000a0;3 months suggests that the patient does not have the progressive subtype. Patients with this subtype&#x000a0;often exhibit more severe penile curvatures, shorter periods of relative stability, higher rates of more severe penile shaft indentations, hourglass deformities, loss of penile length, calcification, and discomfort. Stability develops in three-quarters of progressive disease patients after 14 months.&#x000a0;Stable, progressive disease is defined as at least 12 months since the original presentation of the disease and no significant clinical changes in curvature, symptoms, or penile deformities for the last 3 months or a continuous period of clinical stability of at least 6 months.</p>
        <p><bold>Relapsing&#x000a0;or remitting</bold>
<bold>Peyronie disease:</bold>&#x000a0;This disease describes cases where the disorder appears to reactivate an initial period of stability of at least 6 months.&#x000a0;Patients with shorter stable periods likely have progressive disease. Men with relapsing or remitting disease tend to be younger and experience pain for a more extended period, with relatively low rates of penile indentations or hourglass deformities. This subtype accounts for about 12% of all Peyronie disease patients.&#x000a0;Most (75%) develop stable disease after&#x000a0;12 months.&#x000a0;Stable relapsing or remitting disease is defined as at least 1 year since the original disease presentation and no significant clinical changes in curvature, symptoms, or penile deformities for the last&#x000a0;3 months or a continuous period of clinical stability of at least 6 months.</p>
        <p><bold>Classical</bold>&#x000a0;<bold>disease:</bold>&#x000a0;This&#x000a0;disease is essentially a diagnosis of exclusion for men who do not meet the criteria for one of the other subtypes. These men tend to be somewhat older, have a higher percentage of chronic disease, are more likely to use phosphodiesterase type 5 inhibitors, and have spontaneous regression while being less likely to experience pain or loss of penile length than the other subtypes of Peyronie disease.&#x000a0;About 75% become clinically stable after 2 months. Classical Peyronie disease is considered stable after 3 months or more without any significant changes in symptoms, curvature, or penile deformities.</p>
        <p>
<bold>Non-Peyronie Penile Curvatures </bold>
</p>
        <p>Non-Peyronie penile curvatures&#x000a0;are classified into three categories&#x02014;congenital, maturational, or traumatic.<xref ref-type="bibr" rid="article-111973.r99">[99]</xref></p>
        <p><bold>Congenital&#x000a0;or maturational curvature:</bold> This category refers to patients with the disorder from birth, such as chordee, and those where it developed later, usually at puberty or somewhat later. The degree of curvature is typically lateral and &#x0003c;20&#x000b0;.</p>
        <p><bold>Traumatic</bold>
<bold>curvature: </bold>This type can be challenging to distinguish from trauma-induced Peyronie disease. Patients with traumatic curvature are more likely to recall a specific traumatic event, have a loss of penile length, report discomfort, and enjoy a higher rate of intercourse.</p>
        <p>Changes in curvature, symptoms, or deformities 3 months or more after disease onset suggest the progressive subtype.&#x000a0;The presence of calcified plaques indicates the calcifying subtype. In the absence of these features, the patient is classified with classical Peyronie disease. If the disease reactivates after at least 6 months of stability, it is considered relapsing&#x000a0;or remitting.</p>
        <p>This classification can be easily applied with a simple ultrasound (to detect calcification) and four basic questions that are typically asked by clinicians&#x000a0;of newly diagnosed Peyronie patients: <xref ref-type="bibr" rid="article-111973.r99">[99]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>When did the symptoms begin (how long have the symptoms been present?)</p>
          </list-item>
          <list-item>
            <p>How long has the condition remained stable or unchanged?</p>
          </list-item>
          <list-item>
            <p>Did the problem get worse after it was first presented?</p>
          </list-item>
          <list-item>
            <p>Was there any prior disease or trauma?&#x000a0;</p>
          </list-item>
        </list>
        <p>This proposed classification system appears reasonable, well-documented, and clinically useful for future research, but it is still just a proposal and requires external validation. This system was developed at a high-volume referral center and used retrospective surveys and subjective questionnaires, potentially introducing bias. Currently, the proposed classification system does not alter therapy. However, it does help explain the noted variability in the reported duration of the active phase of Peyronie disease.</p>
      </sec>
      <sec id="article-111973.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Clinicians should assess and treat men with&#x000a0;Peyronie disease only when&#x000a0;they have the experience and diagnostic tools to evaluate, appropriately counsel, and treat the condition.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;Clinicians should then discuss all treatment options available and the known benefits and risks or burdens associated with each treatment.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;For some patients, comprehensive counseling regarding the nature of Peyronie disease and the typical disease course may be sufficient to alleviate concerns. There is no agreed-upon minimum curvature necessary before intervention is justified, although invasive therapy for curvatures of less than 30&#x000b0;&#x000a0;is unusual. If the patient is unable to have intercourse due to Peyronie disease and has failed medical therapy, this is generally considered sufficient.&#x000a0;</p>
        <p>The patient's distress over his symptoms, level of concern, and willingness to undergo various types of treatment should be fully considered in the decision-making process, in addition to any objective measures of curvature and erectile function. Patients should be provided reasonable expectations of outcomes from the various available treatments. Patients should be offered psychological support and counseling as appropriate.<xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r121">[121]</xref></p>
        <p>Iontophoresis,&#x000a0;also known as electromotive drug administration, uses an electrical current to enhance the transdermal absorption of topically applied medications. Many studies suggest a potential benefit, particularly for pain management; however, they involve fewer than 100 patients and lack a placebo control arm.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r122">[122]</xref><xref ref-type="bibr" rid="article-111973.r123">[123]</xref><xref ref-type="bibr" rid="article-111973.r124">[124]</xref><xref ref-type="bibr" rid="article-111973.r125">[125]</xref><xref ref-type="bibr" rid="article-111973.r126">[126]</xref><xref ref-type="bibr" rid="article-111973.r127">[127]</xref><xref ref-type="bibr" rid="article-111973.r128">[128]</xref><xref ref-type="bibr" rid="article-111973.r129">[129]</xref><xref ref-type="bibr" rid="article-111973.r130">[130]</xref><xref ref-type="bibr" rid="article-111973.r131">[131]</xref><xref ref-type="bibr" rid="article-111973.r132">[132]</xref>&#x000a0;The AUA, CUA, and International Consortium on Sexual Medicine (ICSM) guidelines do not recommend iontophoresis in Peyronie disease due to insufficient evidence, although the treatment is promising.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r123">[123]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref></p>
        <p>Radiation therapy&#x000a0;was previously used for Peyronie disease, mainly for pain control, but is no longer recommended due to adverse effects, the lack of any proven benefit, and the availability of other treatments.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r134">[134]</xref><xref ref-type="bibr" rid="article-111973.r135">[135]</xref><xref ref-type="bibr" rid="article-111973.r136">[136]</xref><xref ref-type="bibr" rid="article-111973.r137">[137]</xref>&#x000a0;When used, a limited dosage was administered and given only during the acute phase.</p>
        <p>
<bold>Nonsurgical&#x000a0;Treatment</bold>
</p>
        <p>Various oral, mechanical, and injectable therapies are used in the nonsurgical treatment of Peyronie disease.&#x000a0;Oral therapy, vacuum erection devices, and penile traction may be used in the early, acute phase of the disease and later in the chronic phase. Intralesional therapy is generally limited to the chronic phase when the lesion is stable.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;</p>
        <p>However, very few of these therapies are supported by well-designed, double-blind, placebo-controlled, randomized trials. Obstacles to having good literature to support nonsurgical treatments&#x000a0;include the low number of patients enrolled in studies (resulting in low statistical significance), wide heterogeneity of treatments, inadequate randomization, failure to include placebo control groups, lack of objective pre and post-treatment measurements, variable or unstated durations of follow-up, and inconsistent or undefined endpoints.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r138">[138]</xref><xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r142">[142]</xref></p>
        <p>As a result, the evidence supporting many oral and nonsurgical treatments is insufficient, as existing trials generally have poor methodological quality and are inconclusive.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r143">[143]</xref>&#x000a0;Some of the other methodological problems in published studies include:&#x000a0;<xref ref-type="bibr" rid="article-111973.r144">[144]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Failure to use intracavernosal injection therapy to maximize the erection to measure the curvature reliably.</p>
          </list-item>
          <list-item>
            <p>Measurements of plaque size are generally inaccurate except for MRI studies, which are rarely performed in Peyronie disease studies.</p>
          </list-item>
          <list-item>
            <p>Penile pain is self-limiting, making it an unreliable indicator of disease progression.</p>
          </list-item>
          <list-item>
            <p>The relationship between erectile dysfunction and Peyronie disease is complex to measure objectively or quantify.</p>
          </list-item>
          <list-item>
            <p>Patient satisfaction, arguably the most useful outcome statistic, is rarely addressed or reported.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Oral therapy:&#x000a0;</bold>Oral therapy&#x000a0;is highly desired by patients, but there are insufficient high-quality, adequately controlled, randomized studies&#x000a0;to justify the routine use of any oral treatment for Peyronie disease. Most studies are small, short in duration,&#x000a0;lack control groups, and use non-standardized treatment protocols. All such oral therapy use is off-label. Patients who demand oral treatment should be fully informed of the lack of sufficient credible evidence of efficacy.</p>
        <p>Clinicians&#x000a0;may offer nonsteroidal anti-inflammatory agents to help manage pain, but beyond that,&#x000a0;there are no unapproved clinical alternative therapies that have conclusively demonstrated efficacy compared to placebo.<xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r145">[145]</xref> Despite this, many patients are desperate for nonsurgical&#x000a0;therapies, which puts significant pressure on clinicians to provide treatments, even if there is little evidence to support any real benefit.</p>
        <p>Current AUA and CUA guidelines do not recommend&#x000a0;oral therapy with vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, or a combination of vitamin E with L-carnitine due to a lack of documented efficacy or proven ineffectiveness.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r146">[146]</xref><xref ref-type="bibr" rid="article-111973.r147">[147]</xref><xref ref-type="bibr" rid="article-111973.r148">[148]</xref><xref ref-type="bibr" rid="article-111973.r149">[149]</xref><xref ref-type="bibr" rid="article-111973.r150">[150]</xref><xref ref-type="bibr" rid="article-111973.r151">[151]</xref> Studies have examined all of these potential medications, with some showing promising results, although the majority are non-randomized, low-volume, and uncontrolled case studies.</p>
        <p>A few of the most popular and promising oral agents for Peyronie disease are briefly discussed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Antioxidant monotherapy:<bold>&#x000a0;</bold>Antioxidant monotherapy has not been shown to offer any significant benefit and is not recommended by the AUA guidelines.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref> However, a combination of antioxidants and other nonsurgical therapies has shown some efficacy in treating Peyronie disease, with the complete disappearance of the plaques reported in a few cases.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r152">[152]</xref><xref ref-type="bibr" rid="article-111973.r153">[153]</xref>&#x000a0;The antioxidants used include&#x000a0;silymarin, propolis, bilberry, vitamin E,&#x000a0; silymarin, and Ginkgo biloba, but the optimal combination, duration, and dosages have not been determined.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref>&#x000a0;Although promising, the available data on antioxidant therapy is extremely limited, with a serious lack of placebo-controlled trials limiting more widespread use.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Coenzyme Q10:&#x000a0;Coenzyme Q10 is a fat-soluble biochemical cofactor and antioxidant. There are only minimal studies on its use in Peyronie disease, but it appears to give good results with minimal adverse effects.<xref ref-type="bibr" rid="article-111973.r154">[154]</xref><xref ref-type="bibr" rid="article-111973.r155">[155]</xref>&#x000a0;A dose of 300 mg has been suggested.<xref ref-type="bibr" rid="article-111973.r155">[155]</xref><xref ref-type="bibr" rid="article-111973.r156">[156]</xref>&#x000a0;The AUA guidelines do not recommend coenzyme Q10 due to insufficient evidence, but the CUA has suggested that it might be offered as a reasonable treatment option.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r157">[157]</xref> Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/30285386">Coenzyme Q10</ext-link>,"&#x000a0;for more information.<xref ref-type="bibr" rid="article-111973.r156">[156]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colchicine:&#x000a0;Colchicine upregulates collagenase activity while inhibiting collagen deposition and fibrosis.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r158">[158]</xref>&#x000a0;Uncontrolled studies have indicated a benefit in about one-third of patients, but a randomized, double-blind placebo-controlled study showed no benefit compared to placebo.<xref ref-type="bibr" rid="article-111973.r159">[159]</xref><xref ref-type="bibr" rid="article-111973.r160">[160]</xref><xref ref-type="bibr" rid="article-111973.r161">[161]</xref><xref ref-type="bibr" rid="article-111973.r162">[162]</xref><xref ref-type="bibr" rid="article-111973.r163">[163]</xref>&#x000a0;Many patients do not tolerate colchicine due to gastrointestinal adverse effects.<xref ref-type="bibr" rid="article-111973.r164">[164]</xref>&#x000a0;The CUA guidelines state that despite the limited evidence available, colchicine may be considered for clinical use.<xref ref-type="bibr" rid="article-111973.r114">[114]</xref>&#x000a0;Please&#x000a0;see StatPearls' companion resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/28613754">Colchicine</ext-link>,"&#x000a0;for more information.<xref ref-type="bibr" rid="article-111973.r165">[165]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline:<bold>&#x000a0;</bold>Pentoxifylline<bold>&#x000a0;</bold>reduces inflammation by blocking TGF-&#x000df;1, which interferes with collagen type I production.<xref ref-type="bibr" rid="article-111973.r87">[87]</xref><xref ref-type="bibr" rid="article-111973.r166">[166]</xref><xref ref-type="bibr" rid="article-111973.r167">[167]</xref><xref ref-type="bibr" rid="article-111973.r168">[168]</xref>&#x000a0;A single randomized controlled trial showed significant improvement in penile curvature by 23&#x000b0; in 33% of patients, and a small retrospective study (without a control group) showed significant improvement in plaque size and penile curvature, but further studies and additional confirmation are required before pentoxifylline therapy can be routinely recommended.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r166">[166]</xref><xref ref-type="bibr" rid="article-111973.r169">[169]</xref><xref ref-type="bibr" rid="article-111973.r170">[170]</xref><xref ref-type="bibr" rid="article-111973.r171">[171]</xref><xref ref-type="bibr" rid="article-111973.r172">[172]</xref><xref ref-type="bibr" rid="article-111973.r173">[173]</xref>&#x000a0;There is some evidence that it may be helpful in multimodal combination therapy.<xref ref-type="bibr" rid="article-111973.r171">[171]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref>&#x000a0;The typical dosage is 400 mg 3 times daily.<xref ref-type="bibr" rid="article-111973.r168">[168]</xref>&#x000a0;The CUA guidelines indicate that pentoxifylline may be considered for therapeutic use despite the limited data available on its effectiveness.<xref ref-type="bibr" rid="article-111973.r114">[114]</xref> Please&#x000a0;see StatPearls' companion resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/32644522">Pentoxifylline</ext-link>,"&#x000a0;for more information.<xref ref-type="bibr" rid="article-111973.r168">[168]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Phosphodiesterase type 5 inhibitors: There is preliminary evidence that daily tadalafil (5 mg) may significantly slow the progression rate of penile curvature in patients with Peyronie disease if started early.<xref ref-type="bibr" rid="article-111973.r175">[175]</xref><xref ref-type="bibr" rid="article-111973.r176">[176]</xref><xref ref-type="bibr" rid="article-111973.r177">[177]</xref><xref ref-type="bibr" rid="article-111973.r178">[178]</xref><xref ref-type="bibr" rid="article-111973.r179">[179]</xref><xref ref-type="bibr" rid="article-111973.r180">[180]</xref><xref ref-type="bibr" rid="article-111973.r181">[181]</xref>&#x000a0;Phosphodiesterase type 5 inhibitors inhibit collagen deposition by blocking cyclic GMP degradation and reducing pain.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r176">[176]</xref><xref ref-type="bibr" rid="article-111973.r178">[178]</xref><xref ref-type="bibr" rid="article-111973.r182">[182]</xref><xref ref-type="bibr" rid="article-111973.r183">[183]</xref><xref ref-type="bibr" rid="article-111973.r184">[184]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>The rationale for their use is that by increasing and preserving cyclic GMP, phosphodiesterase type 5 inhibitors stimulate nitric oxide production and block collagen synthesis while inducing fibroblast apoptosis and reducing myofibroblastic differentiation.<xref ref-type="bibr" rid="article-111973.r182">[182]</xref><xref ref-type="bibr" rid="article-111973.r184">[184]</xref><xref ref-type="bibr" rid="article-111973.r185">[185]</xref>&#x000a0;</p></list-item><list-item><p>Combination therapy with <italic toggle="yes">C histolyticum</italic> collagenase intralesional injections has been shown to improve outcomes.<xref ref-type="bibr" rid="article-111973.r180">[180]</xref></p></list-item><list-item><p>Experimental in vitro studies suggest a synergistic relationship between phosphodiesterase type 5 inhibitors and statins in slowing the transformation of tunica albuginea fibroblasts into myofibroblasts, thereby reducing the progression of fibrosis in Peyronie disease.<xref ref-type="bibr" rid="article-111973.r186">[186]</xref></p></list-item><list-item><p>Although promising, there are no published, double-blinded, large-scale, placebo-controlled trials to support the routine use of phosphodiesterase type 5 inhibitors for Peyronie disease. However, the European Urology Association guidelines permit their use in all phases of the disease, and patients may experience benefits, particularly for associated erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Potassium para-aminobenzoate: Also known as potaba. This drug is believed to have anti-fibrosis and anti-inflammatory properties and has been shown to inhibit collagen formation in vitro. Potassium para-aminobenzoate&#x000a0;may be useful in patients with a curvature of 30&#x000b0; or less, but there is no clear evidence of any significant benefit otherwise. Randomized studies show no improvement over placebo.<xref ref-type="bibr" rid="article-111973.r112">[112]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r149">[149]</xref><xref ref-type="bibr" rid="article-111973.r150">[150]</xref><xref ref-type="bibr" rid="article-111973.r187">[187]</xref>&#x000a0;The&#x000a0;treatment involves a very large number of tablets, totaling 12 g, taken 4 to 6 times a day, which causes significant gastrointestinal adverse effects that are not easily tolerated by the majority of patients.&#x000a0;Potassium para-aminobenzoate is not recommended by the AUA or ICSM but is allowed by the CUA and the EAU based on 2 studies suggesting efficacy.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r149">[149]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vitamin E:<bold>&#x000a0;</bold>Vitamin E is possibly the most frequently recommended oral agent for Peyronie disease&#x000a0;due to its&#x000a0;ability to reduce free radical activity and oxidative stress in wounds.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r188">[188]</xref>&#x000a0;However, no studies have shown any significant clinical benefit from vitamin E in Peyronie disease, including a recent meta-analysis and a randomized controlled trial.<xref ref-type="bibr" rid="article-111973.r146">[146]</xref><xref ref-type="bibr" rid="article-111973.r151">[151]</xref><xref ref-type="bibr" rid="article-111973.r189">[189]</xref>&#x000a0;Therefore, the current AUA guidelines, the ICSM, the EAU, the CUA, and the AUA Core Curriculum on Peyronie disease do not recommend its use.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref> Please&#x000a0;see StatPearls' companion resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/32491669">Vitamin E</ext-link>," for more information.<xref ref-type="bibr" rid="article-111973.r190">[190]</xref></p>
          </list-item>
        </list>
        <p><bold>Extracorporeal shockwave therapy:&#x000a0;</bold>This&#x000a0;therapy is effective in relieving pain but has consistently failed to demonstrate any benefit in penile length, curvature, or deformity in a number of studies.<xref ref-type="bibr" rid="article-111973.r175">[175]</xref><xref ref-type="bibr" rid="article-111973.r191">[191]</xref><xref ref-type="bibr" rid="article-111973.r192">[192]</xref><xref ref-type="bibr" rid="article-111973.r193">[193]</xref><xref ref-type="bibr" rid="article-111973.r194">[194]</xref><xref ref-type="bibr" rid="article-111973.r195">[195]</xref><xref ref-type="bibr" rid="article-111973.r196">[196]</xref><xref ref-type="bibr" rid="article-111973.r197">[197]</xref><xref ref-type="bibr" rid="article-111973.r198">[198]</xref><xref ref-type="bibr" rid="article-111973.r199">[199]</xref><xref ref-type="bibr" rid="article-111973.r200">[200]</xref>&#x000a0;The treatment disrupts Peyronie plaques directly, causing subsequent tissue remodeling.<xref ref-type="bibr" rid="article-111973.r113">[113]</xref> Extracorporeal shockwave therapy may also increase vascularity in the tunica from a localized inflammatory reaction, which upregulates macrophage activity, resulting in the reabsorption of plaque calcifications.<xref ref-type="bibr" rid="article-111973.r113">[113]</xref> Extracorporeal shockwave therapy appears effective in treating pain but has no significant clinical impact on penile curvature or plaque size.<xref ref-type="bibr" rid="article-111973.r191">[191]</xref><xref ref-type="bibr" rid="article-111973.r198">[198]</xref><xref ref-type="bibr" rid="article-111973.r201">[201]</xref><xref ref-type="bibr" rid="article-111973.r202">[202]</xref><xref ref-type="bibr" rid="article-111973.r203">[203]</xref>&#x000a0;The addition of daily tadalafil (5 mg) can help patients with Peyronie disease who also have erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r175">[175]</xref></p>
        <p>Extracorporeal shockwave therapy&#x000a0;is allowed for pain control under the AUA guidelines, which give it only a weak, conditional recommendation.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref> The reason for this modest recommendation is that&#x000a0;there are other treatments available to treat penile discomfort; the pain is self-limiting and disappears without treatment over time, and obtaining extracorporeal shockwave therapy may be difficult and costly.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;There are also concerns about possible adverse effects such as increased delayed scarring and erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r204">[204]</xref>&#x000a0;Extracorporeal shockwave therapy is approved only for pain control by the CUA, EAU, and ICSM guidelines.<xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
        <p><bold>Intralesional injection therapy:&#x000a0;</bold>Intralesional injection therapy<bold>&#x000a0;</bold>is a viable nonoperative option for the treatment of Peyronie disease&#x000a0;and&#x000a0;is generally the next step in treatment when simpler oral and manipulative (traction) therapies fail.&#x000a0;However, it is typically ineffective if the plaques are calcified, if there is a significant loss of penile volume, for hourglass deformities, penile shaft indentations, or if the curvature is &#x0003e;90&#x000b0;.<xref ref-type="bibr" rid="article-111973.r205">[205]</xref>&#x000a0;All intralesional injections are used only in the stable or chronic phase of Peyronie disease, with a few exceptions as noted.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref>&#x000a0;</p>
        <p>This therapy is typically&#x000a0;combined with careful manual manipulation and modeling by the clinician and patient to reduce the penile curvature.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref> Intralesional injection therapy is generally recommended in patients with a curvature between 30&#x000b0; and 90&#x000b0; who have intact erectile function.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;This therapy is also suggested for patients who do not want surgery and&#x000a0;where less invasive therapies have been ineffective or are otherwise unsuitable.&#x000a0;Patients with penile shaft indentations, hinge effect, hourglass deformities, and curve improvements after treatment of &#x0003c;15&#x000b0; are unlikely to be satisfied with intralesional therapy and ultimately are likely to undergo surgery.<xref ref-type="bibr" rid="article-111973.r206">[206]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dexamethasone is a widely used steroidal anti-inflammatory and immunosuppressive agent.<xref ref-type="bibr" rid="article-111973.r207">[207]</xref><xref ref-type="bibr" rid="article-111973.r208">[208]</xref>&#x000a0;A double-blinded randomized trial failed to show any benefit from intralesional dexamethasone injections regarding penile curvature or plaque size.<xref ref-type="bibr" rid="article-111973.r209">[209]</xref> However, this study only included patients with chronic disease and excluded those in the acute phase where, arguably, anti-inflammatory treatment with dexamethasone injections might have been more effective.<xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r209">[209]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methylprednisolone is another steroid-based anti-inflammatory drug frequently used for arthritis, asthma, and allergic reactions.<xref ref-type="bibr" rid="article-111973.r210">[210]</xref>&#x000a0;In a&#x000a0;prospective single-arm nonrandomized study, 48 patients with acute phase Peyronie disease were treated with low-dose methylprednisolone intralesional injections.<xref ref-type="bibr" rid="article-111973.r211">[211]</xref> Plaque size and other symptoms of Peyronie disease improved, and there were no adverse effects. Neither dexamethasone nor methylprednisolone intralesional injections are recommended by&#x000a0;the&#x000a0;AUA, CUA, or the EAU guidelines.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r139">[139]</xref></p>
          </list-item>
        </list>
        <p>The AUA guidelines state that clinicians may offer intralesional injection therapy with <italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase, interferon-alpha-2b, or verapamil. However, only the collagenase is&#x000a0;approved by the Food and Drug Administration (FDA) for treating Peyronie disease.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;Local anesthesia with a penile block is recommended for pain control before treatment.</p>
        <p><bold><italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase</bold>&#x000a0;<bold>intralesional injections: </bold>These injections are the only FDA-approved therapy for treating Peyronie disease.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r212">[212]</xref>&#x000a0;Collagenase has demonstrated the ability to dissolve excess fibrous tissue enzymatically.<xref ref-type="bibr" rid="article-111973.r213">[213]</xref>&#x000a0;Collagenase was approved by the FDA in December 2013 and has also been approved by the CUA, EAU, Health Canada, and ICSM.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
        <p>Before starting treatment, a detailed discussion with the patient is required regarding possible adverse outcomes and risks, including penile bruising, swelling, pain, failure of the treatment, and corporal rupture.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;Fortunately, penile fractures and corporal ruptures are pretty rare, with a relative risk of &#x0003c;1% in large series.<xref ref-type="bibr" rid="article-111973.r214">[214]</xref>&#x000a0;These ruptures occur within 2 weeks of the collagenase injection and are associated with morning (nocturnal) erections and sexual intercourse.<xref ref-type="bibr" rid="article-111973.r214">[214]</xref>&#x000a0;Four weeks of sexual abstinence is recommended after each therapy cycle to minimize the risk of injury. The recommended standard technique is described below:&#x000a0;<xref ref-type="bibr" rid="article-111973.r141">[141]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The collagenase (0.58 mg) is injected laterally, from side to side, through the fibrous plaque where the curvature is most acute. Each therapy cycle includes&#x000a0;2 separate injection treatment sessions performed 1 to 3 days apart. Several days after the second injection of each therapy cycle, the&#x000a0;clinician performs manual molding, bending, and modeling.</p>
          </list-item>
          <list-item>
            <p>The patient is then instructed to do daily modeling at home for the next&#x000a0;6 weeks, after which he is ready for the next therapy cycle of&#x000a0;2 more injection sessions. Four complete therapy cycles, performed 6 weeks apart, are recommended for 24 weeks.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Collagenase injections should be used cautiously in dorsal plaques and not&#x000a0;used for ventral lesions due to the potential for damage to critical underlying structures.<xref ref-type="bibr" rid="article-111973.r215">[215]</xref> Calcified plaques respond less effectively compared to pure fibrous lesions without calcifications, although there have been a few successful cases reported.<xref ref-type="bibr" rid="article-111973.r216">[216]</xref><xref ref-type="bibr" rid="article-111973.r217">[217]</xref></p>
          </list-item>
        </list>
        <p>A 2021 study involving&#x000a0;296 patients with Peyronie disease showed that two-thirds of the men who did not achieve at least a 10&#x000b0; (or 20%) improvement in their penile curvature after the first&#x000a0;2 therapy cycles could meet this threshold after completing the final&#x000a0;2 treatments.<xref ref-type="bibr" rid="article-111973.r218">[218]</xref>&#x000a0;Patients who fail an entire course of therapy with&#x000a0;<italic toggle="yes">C histolyticum</italic>&#x000a0;collagenase intralesional injections might benefit from repeating it.<xref ref-type="bibr" rid="article-111973.r219">[219]</xref>&#x000a0;No additional benefit has been noted with additional therapy if the first&#x000a0;2 complete protocols were not successful.<xref ref-type="bibr" rid="article-111973.r219">[219]</xref>&#x000a0;</p>
        <p>Modified shortened protocols that use a single (0.9 mg) vial for each injection treatment given in 3 therapy cycles at monthly intervals, with clinician modeling replaced by patient manipulation and penile stretching at home, have been proposed. Results appear similar to those of the standard treatment protocol.<xref ref-type="bibr" rid="article-111973.r220">[220]</xref><xref ref-type="bibr" rid="article-111973.r221">[221]</xref></p>
        <p>The efficacy of&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase&#x000a0;intralesional injection therapy&#x000a0;has been demonstrated in many studies.<xref ref-type="bibr" rid="article-111973.r212">[212]</xref><xref ref-type="bibr" rid="article-111973.r213">[213]</xref><xref ref-type="bibr" rid="article-111973.r215">[215]</xref><xref ref-type="bibr" rid="article-111973.r222">[222]</xref><xref ref-type="bibr" rid="article-111973.r223">[223]</xref><xref ref-type="bibr" rid="article-111973.r224">[224]</xref><xref ref-type="bibr" rid="article-111973.r225">[225]</xref><xref ref-type="bibr" rid="article-111973.r226">[226]</xref><xref ref-type="bibr" rid="article-111973.r227">[227]</xref>&#x000a0;Overall, three-quarters of the men treated with intralesional collagenase injections can expect at least a 25% improvement in their penile curvature, with an average improvement of 34%.<xref ref-type="bibr" rid="article-111973.r212">[212]</xref><xref ref-type="bibr" rid="article-111973.r226">[226]</xref>&#x000a0;A good responder typically observes a reduction in curvature of about 15&#x000b0;/34% (baseline angulation: 30&#x000b0; to 60&#x000b0;) or 25.5&#x000b0;/23% (baseline angulation: 61&#x000b0; to 90&#x000b0;).<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r226">[226]</xref></p>
        <p>The most significant predictor of success in collagenase therapy is the baseline degree of curvature, with the highest percentage benefit observed in patients with a curvature of 60&#x000b0; or more.<xref ref-type="bibr" rid="article-111973.r215">[215]</xref>&#x000a0;Good erectile function, lack of plaque calcifications, and stable disease over 2 years are good predictors of favorable outcomes.</p>
        <p><italic toggle="yes">C histolyticum</italic>&#x000a0;intralesional collagenase therapy for Peyronie disease provides overall patient satisfaction rates of about 50% to 67% 1 year after&#x000a0;treatment.<xref ref-type="bibr" rid="article-111973.r228">[228]</xref>&#x000a0;Longer-term satisfaction is somewhat less,&#x000a0;at&#x000a0;42.5%.<xref ref-type="bibr" rid="article-111973.r228">[228]</xref>&#x000a0;Recently, several studies have examined the use of <italic toggle="yes">C histolyticum</italic> intralesional injections during the acute phase of the disease, and they have all shown good efficacy.<xref ref-type="bibr" rid="article-111973.r229">[229]</xref><xref ref-type="bibr" rid="article-111973.r230">[230]</xref><xref ref-type="bibr" rid="article-111973.r231">[231]</xref><xref ref-type="bibr" rid="article-111973.r232">[232]</xref><xref ref-type="bibr" rid="article-111973.r233">[233]</xref><xref ref-type="bibr" rid="article-111973.r234">[234]</xref>&#x000a0;The use of collagenase penile injections is not a contraindication to surgical correction later if the final results after intralesional therapy are not satisfactory.<xref ref-type="bibr" rid="article-111973.r235">[235]</xref><xref ref-type="bibr" rid="article-111973.r236">[236]</xref></p>
        <p>Combining collagenase injections with mechanical therapies such as vacuum erection devices or penile traction seems reasonable, is recommended by some experts, and has shown some benefits, but definitive studies are lacking.<xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r237">[237]</xref><xref ref-type="bibr" rid="article-111973.r238">[238]</xref><xref ref-type="bibr" rid="article-111973.r239">[239]</xref><xref ref-type="bibr" rid="article-111973.r240">[240]</xref><xref ref-type="bibr" rid="article-111973.r241">[241]</xref>&#x000a0;A 2019 study showed the potential for combining&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase&#x000a0;intralesional injections with traction therapy.<xref ref-type="bibr" rid="article-111973.r239">[239]</xref> The combined treatment group demonstrated substantial improvement in curvature of 49% (33.8&#x000b0;) and additional penile length of 1.9 cm compared to the collagenase therapy-only group, which had a 31% (20.3&#x000b0;) reduction in curvature but no benefit in penile length.<xref ref-type="bibr" rid="article-111973.r239">[239]</xref>&#x000a0;Adding a phosphodiesterase inhibitor has also shown some additional benefits.<xref ref-type="bibr" rid="article-111973.r180">[180]</xref></p>
        <p>Negative predictive factors of collagenase therapy include:&#x000a0;<xref ref-type="bibr" rid="article-111973.r206">[206]</xref><xref ref-type="bibr" rid="article-111973.r226">[226]</xref><xref ref-type="bibr" rid="article-111973.r242">[242]</xref><xref ref-type="bibr" rid="article-111973.r243">[243]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>An hourglass deformity</p>
          </list-item>
          <list-item>
            <p>Baseline penile shaft indentation or narrowing</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Failure to receive all 4 cycles of therapy</p>
          </list-item>
          <list-item>
            <p>Hinge effect</p>
          </list-item>
          <list-item>
            <p>Initial curvature &#x0003e;60&#x000b0;</p>
          </list-item>
          <list-item>
            <p>Less than 2 years duration</p>
          </list-item>
          <list-item>
            <p>Penile buckling</p>
          </list-item>
          <list-item>
            <p>Peyronie plaque calcifications</p>
          </list-item>
        </list>
        <p>The AUA and CUA guidelines give&#x000a0;<italic toggle="yes">C histolyticum</italic>&#x000a0;collagenase injection therapy a moderate recommendation based on grade B (moderate) evidence, and it is approved by the European Medicines Agency and EAU.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r244">[244]</xref>&#x000a0;However, despite its recognized efficacy and guideline recommendations, <italic toggle="yes">C histolyticum</italic>&#x000a0;collagenase may not be available in the European Union, Belgium, Austria, Australia, Canada, or many Asian markets due to its high cost, low utilization, poor demand, and insurance&#x000a0;or government reimbursement issues.<xref ref-type="bibr" rid="article-111973.r245">[245]</xref></p>
        <p><bold>Hyaluronic acid:</bold>&#x000a0;a naturally occurring, non-sulfated glycosaminoglycan normally found in the skin and many other bodily tissues, including the corpora cavernosa and tunica albuginea.<xref ref-type="bibr" rid="article-111973.r246">[246]</xref> Hyaluronic acid&#x000a0;acts as an anti-inflammatory agent by modulating inflammatory cell activation and reducing fibroblastic activity, which&#x000a0;reduces scarring and fibrosis.<xref ref-type="bibr" rid="article-111973.r247">[247]</xref>&#x000a0;In several studies, hyaluronic acid intralesional injections have shown an overall curvature improvement of&#x000a0;5&#x000b0; to 10&#x000b0; but used different dosages, protocols, and durations of therapy.<xref ref-type="bibr" rid="article-111973.r248">[248]</xref><xref ref-type="bibr" rid="article-111973.r249">[249]</xref><xref ref-type="bibr" rid="article-111973.r250">[250]</xref><xref ref-type="bibr" rid="article-111973.r251">[251]</xref><xref ref-type="bibr" rid="article-111973.r252">[252]</xref><xref ref-type="bibr" rid="article-111973.r253">[253]</xref><xref ref-type="bibr" rid="article-111973.r254">[254]</xref>&#x000a0;Supplemental oral hyaluronic acid and intralesional injections were more beneficial than plaque injections alone.<xref ref-type="bibr" rid="article-111973.r253">[253]</xref>&#x000a0;Hyaluronic acid intralesional therapy may be most beneficial in the acute phase of Peyronie disease.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref></p>
        <p>The most recent systematic review and meta-analysis concluded that hyaluronic acid intralesional therapy provided good overall results, but the quality of the available studies was highly variable, and the available data&#x000a0;are quite limited.<xref ref-type="bibr" rid="article-111973.r255">[255]</xref>&#x000a0;The AUA guidelines do not mention hyaluronic acid therapy.&#x000a0;At this time, it is recommended only for use in clinical trials.<xref ref-type="bibr" rid="article-111973.r114">[114]</xref></p>
        <p><bold>Interferon alpha-2b:</bold> injection therapy has shown reasonably good evidence of efficacy in Peyronie disease but in smaller studies compared to&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase intralesional treatment.<xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r256">[256]</xref><xref ref-type="bibr" rid="article-111973.r257">[257]</xref><xref ref-type="bibr" rid="article-111973.r258">[258]</xref><xref ref-type="bibr" rid="article-111973.r259">[259]</xref><xref ref-type="bibr" rid="article-111973.r260">[260]</xref><xref ref-type="bibr" rid="article-111973.r261">[261]</xref>&#x000a0;The suggested administration protocol is&#x000a0;(5&#x000d7;10<sup>6</sup> units of interferon alpha-2b in 10 mL of normal saline every 2 weeks over 3 months, totaling 6 treatments.&#x000a0;</p>
        <p>Interferon alpha-2b reduces fibroblast proliferation, resulting in decreased collagen production, and stimulates collagenase activity.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r262">[262]</xref>&#x000a0;Overall improvement in penile curvature is reported at 25% to 30%, with a 50% reduction in plaque size and less pain.<xref ref-type="bibr" rid="article-111973.r256">[256]</xref><xref ref-type="bibr" rid="article-111973.r257">[257]</xref><xref ref-type="bibr" rid="article-111973.r263">[263]</xref>&#x000a0;Adverse effects include joint pain and muscle aches with fevers and mild flu-like symptoms commonly observed.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r257">[257]</xref>&#x000a0;The AUA guidelines give interferon alpha-2b intralesional injections a moderate recommendation.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;The EAU and CUA also approve it.<xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref>&#x000a0;Despite&#x000a0;its&#x000a0;efficacy and safety, it is not widely used, most likely due to cost, availability, lack of familiarity, and adverse effects.<xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r247">[247]</xref><xref ref-type="bibr" rid="article-111973.r264">[264]</xref></p>
        <p><bold>Verapamil:</bold>&#x000a0;intralesional injections for Peyronie disease appear to offer relatively modest benefits regarding curvature but provide good pain control.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;The rationale for verapamil therapy is evidence that it inhibits the formation of fibroblasts, alters their metabolic pathways, blocks extracellular matrix production, and increases the activity of collagenase and anti-TGF-&#x000df;.<xref ref-type="bibr" rid="article-111973.r265">[265]</xref><xref ref-type="bibr" rid="article-111973.r266">[266]</xref>&#x000a0;Although most studies show some modest overall benefit, results are conflicting, with the largest randomized placebo-controlled trial showing no improvement over placebo.<xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r266">[266]</xref><xref ref-type="bibr" rid="article-111973.r267">[267]</xref><xref ref-type="bibr" rid="article-111973.r268">[268]</xref>&#x000a0;</p>
        <p>Overall, verapamil intralesional therapy results appear inferior to&#x000a0;<italic toggle="yes">C histolyticum</italic>&#x000a0;collagenase,&#x000a0;hyaluronic acid, or interferon alpha-2b injections.<xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r259">[259]</xref>&#x000a0;Pain (10%-15%) and bruising (15%-25%) are the most commonly reported adverse effects.&#x000a0;</p>
        <p>Many published studies with verapamil injections are poorly designed, with conflicting results, highly varying dosage schedules, no standardized injection protocol, different injected medication concentrations, and a lack of statistical comparisons to the control groups.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;A randomized clinical trial comparing intralesional injections of&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase to verapamil injections found the collagenase significantly superior clinically.<xref ref-type="bibr" rid="article-111973.r269">[269]</xref>&#x000a0;Verapamil injection therapy for Peyronie disease is permitted under the AUA, CUA, EAU, and ICSM guidelines, which&#x000a0;give it a weak, conditional recommendation.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
        <p><bold>Penile traction:</bold>&#x000a0;Penile traction<bold>&#x000a0;</bold>therapy&#x000a0;appears reasonably effective in reducing curvature but does not enhance the girth of the penis.&#x000a0;The rationale is that slow continuous stretching of fibrous tissue can result in additional fiber length, changes in the extracellular matrix, boosted mechanotransduction, and tissue remodeling from upregulated collagenase and metalloproteinase activity, as successfully used in Dupuytren contractures, a related disorder involving abnormal collagen deposition resulting in fibrous shrinkage and loss of elasticity.<xref ref-type="bibr" rid="article-111973.r237">[237]</xref><xref ref-type="bibr" rid="article-111973.r270">[270]</xref><xref ref-type="bibr" rid="article-111973.r271">[271]</xref><xref ref-type="bibr" rid="article-111973.r272">[272]</xref><xref ref-type="bibr" rid="article-111973.r273">[273]</xref><xref ref-type="bibr" rid="article-111973.r274">[274]</xref>&#x000a0;If unsuccessful, other treatment modalities are still available.</p>
        <p>Most studies showed a reasonable mean improvement in penile curvature of about 33% (20% to 50%) and a modest benefit in penile length.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r237">[237]</xref><xref ref-type="bibr" rid="article-111973.r275">[275]</xref><xref ref-type="bibr" rid="article-111973.r276">[276]</xref><xref ref-type="bibr" rid="article-111973.r277">[277]</xref><xref ref-type="bibr" rid="article-111973.r278">[278]</xref><xref ref-type="bibr" rid="article-111973.r279">[279]</xref><xref ref-type="bibr" rid="article-111973.r280">[280]</xref><xref ref-type="bibr" rid="article-111973.r281">[281]</xref> Traction therapy can be used in the acute or chronic phase of the disorder but is probably most helpful when used early.<xref ref-type="bibr" rid="article-111973.r237">[237]</xref>&#x000a0;Substantial patient compliance is required for it to be effective.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref>&#x000a0;About half of the patients using these devices report difficulty keeping the traction unit in place, and about 30% also indicate discomfort. As a result, some clinicians recommend wearing the device overnight. An athletic supporter may help hold the traction device and minimize pain or discomfort in some patients.</p>
        <p>There is no standardized protocol for traction therapy, no specific device is recommended, and no guide to the strength of the stretching force or optimal daily duration. However, a minimum of 30 to 90 minutes daily has been suggested, with some protocols going up to 8 hours.<xref ref-type="bibr" rid="article-111973.r275">[275]</xref><xref ref-type="bibr" rid="article-111973.r278">[278]</xref>&#x000a0;Shorter durations of continuous traction are associated with better patient compliance.&#x000a0;The total duration of therapy is typically at least 3 months, but it may be used in the disease's acute and chronic phases.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r275">[275]</xref>&#x000a0;</p>
        <p>Among all the conservative treatments for Peyronie disease, only penile traction therapy has demonstrated statistically significant benefits in penile length, curvature, and successful sexual intercourse, as reported by patients.<xref ref-type="bibr" rid="article-111973.r282">[282]</xref>&#x000a0;No significant adverse events have been reported.<xref ref-type="bibr" rid="article-111973.r283">[283]</xref></p>
        <p>The most recent systemic review and meta-analysis on penile traction therapy for Peyronie disease concluded that this treatment can be a safe and effective option for men with Peyronie disease to reduce penile curvature. However, the review recommended further research with longer follow-up periods.<xref ref-type="bibr" rid="article-111973.r277">[277]</xref>&#x000a0;The European Society for Sexual Medicine considers penile traction therapy a valid treatment option for Peyronie disease, although they find that there is insufficient evidence to justify a definitive recommendation.<xref ref-type="bibr" rid="article-111973.r284">[284]</xref>&#x000a0;The CUA, EAU, and ICSM guidelines allow mechanical traction therapy, especially in combination with other treatment modalities.<xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
        <p>The AUA guidelines do not offer any opinion or recommendation on penile traction therapy, citing the need for more evidence, but the more recent AUA Core Curriculum on Peyronie disease states that the overall consensus from additional, newer studies has suggested a modest benefit in curvature and length from traction.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;Given the available evidence, penile traction appears to be a reasonable clinical trial option before considering more invasive surgical interventions, and it is best used as part of a multimodal treatment program.</p>
        <p><bold>Topical verapamil:&#x000a0;</bold>Topical verapamil&#x000a0;has been studied with conflicting results. In a study, topical verapamil failed to penetrate the tunica albuginea.<xref ref-type="bibr" rid="article-111973.r285">[285]</xref>&#x000a0;However, a double-blinded study involving 18 men with Peyronie disease compared topical verapamil to placebo and noted resolution of pain in 88% and a decrease of penile curvature in 61% after 3 months.<xref ref-type="bibr" rid="article-111973.r286">[286]</xref>&#x000a0;Unfortunately, no actual measurements were taken for an objective comparison.<xref ref-type="bibr" rid="article-111973.r286">[286]</xref>&#x000a0;Other studies have suggested a possible benefit, but the overall evidence is too scant, with too few participants to be conclusive.<xref ref-type="bibr" rid="article-111973.r286">[286]</xref></p>
        <p>Adverse&#x000a0;effects are minimal, with mild skin irritation, erythema, and pruritus reported infrequently. The AUA and CUA guidelines do not currently recommend topical verapamil, citing the need for more studies and evidence, but it is allowed by the EAU and ICSM.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref></p>
        <p><bold>Vacuum erection devices:&#x000a0;</bold>Vacuum erection devices have shown a comparable benefit to traction therapy, but their application, duration, and usage have not been standardized.<xref ref-type="bibr" rid="article-111973.r237">[237]</xref><xref ref-type="bibr" rid="article-111973.r287">[287]</xref><xref ref-type="bibr" rid="article-111973.r288">[288]</xref><xref ref-type="bibr" rid="article-111973.r289">[289]</xref>&#x000a0;The rationale for vacuum erection devices<bold>&#x000a0;</bold>use is as follows:&#x000a0;<xref ref-type="bibr" rid="article-111973.r69">[69]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Negative pressure from the vacuum and restricted venous outflow&#x000a0;dilate the cavernous sinuses and improve corporal oxygenation.<xref ref-type="bibr" rid="article-111973.r290">[290]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Vacuum erection devices also appear to downregulate&#x000a0;TGF-&#x000df;1, which blocks fibrosis.<xref ref-type="bibr" rid="article-111973.r291">[291]</xref></p>
          </list-item>
          <list-item>
            <p>Evidence from traction therapy suggests that regular, mechanical penile stretching and manual manipulation may result in plaque micro-fragmentation, allowing the lesion to be remodeled at a reduced angle.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r281">[281]</xref><xref ref-type="bibr" rid="article-111973.r292">[292]</xref></p>
          </list-item>
        </list>
        <p>Vacuum erection devices have been shown to promote tissue healing after radical prostatectomy surgery,&#x000a0;but it remains somewhat unclear if the same benefit occurs in Peyronie disease.<xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r290">[290]</xref>&#x000a0;Most reports showed improvement or stabilization of the curvature in 90% of patients but generally required regular, prolonged use (over 6 hours daily) without using the constriction band and only during the acute phase.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r237">[237]</xref><xref ref-type="bibr" rid="article-111973.r288">[288]</xref><xref ref-type="bibr" rid="article-111973.r289">[289]</xref>&#x000a0;However, several studies reported good responses after using the device for only 10 minutes twice daily.<xref ref-type="bibr" rid="article-111973.r288">[288]</xref><xref ref-type="bibr" rid="article-111973.r289">[289]</xref>&#x000a0;When combined with other treatment modalities, the AUA and EAU guidelines give vacuum therapy a weak recommendation.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref></p>
        <p>
<bold>Summary of Nonsurgical&#x000a0;Treatment&#x000a0;</bold>
</p>
        <p>There is a significant lack of large-scale, well-designed studies supporting nonsurgical therapy for Peyronie disease, despite high patient demand for such treatments. The best available data suggest the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Potassium para-aminobenzoate (Potaba), vitamin E, carnitine, arginine, tamoxifen,&#x000a0;procarbazine, omega-3 fatty acids, botulinum toxin injections, intralesional corticosteroids, radiation therapy, and iontophoresis are not recommended.</p>
          </list-item>
          <list-item>
            <p>Among oral therapies, phosphodiesterase type 5 inhibitors (tadalafil 5 mg daily, possibly with a statin), combination antioxidants, pentoxifylline, and coenzyme Q10 offer the best evidence of possible efficacy.</p>
          </list-item>
          <list-item>
            <p>Penile traction and vacuum erection devices may be used in both the acute and chronic phases of the disease but are most effective when used early.</p>
          </list-item>
          <list-item>
            <p>Intralesional injection therapy with&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase&#x000a0;is approved by the&#x000a0;FDA for use in stable or chronic phases of Peyronie disease. This therapy is considered reasonably effective, safe, and practical.&#x000a0;Interferon alpha-2b may also be used for intralesional injection therapy.</p>
          </list-item>
          <list-item>
            <p>A recent comprehensive review of the available evidence determined that the best nonsurgical&#x000a0;therapies are&#x000a0;intralesional injections of collagenase (or interferon-alpha-2b) and penile traction devices used alone or together.<xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r180">[180]</xref></p>
          </list-item>
          <list-item>
            <p>Multimodality treatment has shown evidence of improved efficacy; therefore, combination and multimodal therapy should be considered.<xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r152">[152]</xref><xref ref-type="bibr" rid="article-111973.r180">[180]</xref><xref ref-type="bibr" rid="article-111973.r238">[238]</xref><xref ref-type="bibr" rid="article-111973.r293">[293]</xref><xref ref-type="bibr" rid="article-111973.r294">[294]</xref><xref ref-type="bibr" rid="article-111973.r295">[295]</xref><xref ref-type="bibr" rid="article-111973.r296">[296]</xref><xref ref-type="bibr" rid="article-111973.r297">[297]</xref>&#x000a0;The optimal multimodal combination therapy has not yet been reliably identified.<xref ref-type="bibr" rid="article-111973.r297">[297]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Surgical Management</bold>
</p>
        <p>Surgery is the durable and effective treatment for symptomatic Peyronie disease, particularly when severe enough to prevent intercourse and where less invasive therapies have failed.<xref ref-type="bibr" rid="article-111973.r56">[56]</xref> Surgery is not recommended during the acute phase as the penile curvature and deformities must first be stable and unchanged for at least 3 months, although many surgeons prefer to wait at least 6 to&#x000a0;12 months.<xref ref-type="bibr" rid="article-111973.r56">[56]</xref>&#x000a0;</p>
        <p>The goal of surgical correction is to achieve a functionally straight penis suitable for sexual intercourse. Patients should clearly understand that&#x000a0;although&#x000a0;the penis&#x000a0;is straighter, it may appear shorter, and results and ultimate patient satisfaction cannot be guaranteed.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r112">[112]</xref><xref ref-type="bibr" rid="article-111973.r298">[298]</xref> Preoperative measurement and documentation of penile length are recommended. The expert consensus opinion is that a penis is considered functionally straight if the remaining curvature after surgery is&#x000a0;less than 20&#x000b0;.<xref ref-type="bibr" rid="article-111973.r133">[133]</xref>&#x000a0;Surgery to correct small curvatures or defects solely for cosmetic reasons in an otherwise fully functional (capable of intercourse, no erectile dysfunction) penis is not generally recommended.</p>
        <p>Indications&#x000a0;for surgical therapy of Peyronie disease include a deformity that impairs satisfactory sexual relations, stable deformity without pain for at least 3 months (some surgeons recommend 12 months or longer), extensive plaque calcification, patient desire for more definitive treatment, and failed nonsurgical therapy.<xref ref-type="bibr" rid="article-111973.r56">[56]</xref><xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r114">[114]</xref>&#x000a0;Procedure decision-making should include consideration of the nature and location of the Peyronie lesion, magnitude of penile deformity, baseline erection function, penile dimensions, surgeon's experience, and patient preference.<xref ref-type="bibr" rid="article-111973.r299">[299]</xref></p>
        <p>Surgical options include penile plication, plaque incision or excision with a graft, or penile prosthesis placement.<xref ref-type="bibr" rid="article-111973.r300">[300]</xref>&#x000a0;In general, penile plication is indicated for curvatures &#x0003c;60&#x000b0;, minimal deformities, and good erectile function. Plaque incision or excision with grafting procedures are generally used for curvatures &#x0003e;60&#x000b0; or significant deformities in patients with good erections.&#x000a0;Patients with substantial Peyronie disease curvatures and erectile dysfunction are typically best served by penile prosthesis implantation.&#x000a0;</p>
        <p>Surgical&#x000a0;procedures are briefly described below:</p>
        <p><bold>Penile plication (tunica shortening):</bold> This surgery is optimal for patients with good preoperative penile rigidity and erection with or without pharmacotherapy (phosphodiesterase type 5 inhibitors, intracavernosal injections), adequate penile length for satisfactory intercourse (loosely defined as 13 cm or more), an uncomplicated curvature of less than 60&#x000b0;, and do not have a significant hinge defect, buckling, or hourglass deformity.</p>
        <p>These procedures are sometimes described as penile shortening surgeries, as they reduce the length of the contralateral side of the penis. More complex curvatures and defects may also be managed with penile plication surgery but may require more&#x000a0;extensive surgery and a larger number of stitches.<xref ref-type="bibr" rid="article-111973.r301">[301]</xref>&#x000a0;Overall, more than 85% of patients undergoing tunical shortening (penile plication) surgery can expect acceptable penile straightening.</p>
        <p>Penile plication procedures start by making a skin incision that exposes the tunica opposite the Peyronie affected (convex) side. The incision can be a small lateral skin incision directly over the area of interest, a midline incision, or a circumcising incision with degloving to expose the tunica. If the Peyronie plaque is in the proximal penile shaft,&#x000a0;a penoscrotal incision may be preferred.&#x000a0;The intention is to surgically shorten the contralateral tunica so the penis becomes straight. Permanent, nonabsorbable, braided sutures are used, and the knots should be buried. Sutures should be placed no further than 5 mm apart. If necessary, more than one row of plication sutures may be used. There are many variations regarding the precise technique or method used.</p>
        <p>Four commonly used techniques are briefly described below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nesbit procedure: This procedure was the first practical surgical penile plication technique for penile curvature. Nesbit first described the technique in 1965 as a treatment for congenital penile curvature,<xref ref-type="bibr" rid="article-111973.r302">[302]</xref>&#x000a0;which later became a mainstay for the surgical correction of Peyronie disease.<xref ref-type="bibr" rid="article-111973.r303">[303]</xref><xref ref-type="bibr" rid="article-111973.r304">[304]</xref>&#x000a0;The Nesbit procedure excises an elliptical horizontal wedge of the tunica albuginea from the contralateral (concave) side of the penis opposite the plaque. The penis straightens when this defect is closed.<xref ref-type="bibr" rid="article-111973.r303">[303]</xref><xref ref-type="bibr" rid="article-111973.r305">[305]</xref><xref ref-type="bibr" rid="article-111973.r306">[306]</xref><xref ref-type="bibr" rid="article-111973.r307">[307]</xref><xref ref-type="bibr" rid="article-111973.r308">[308]</xref><xref ref-type="bibr" rid="article-111973.r309">[309]</xref></p>
          </list-item>
          <list-item>
            <p>Yachia Technique: A variation of this technique is to make a vertical incision in the tunica, again on the contralateral side to the Peyronie lesion, and close it transversely (horizontally) in a&#x000a0;Heineke-Mikulicz fashion.<xref ref-type="bibr" rid="article-111973.r221">[221]</xref><xref ref-type="bibr" rid="article-111973.r310">[310]</xref><xref ref-type="bibr" rid="article-111973.r311">[311]</xref><xref ref-type="bibr" rid="article-111973.r312">[312]</xref><xref ref-type="bibr" rid="article-111973.r313">[313]</xref><xref ref-type="bibr" rid="article-111973.r314">[314]</xref>&#x000a0;The tunica is not excised in this variation.<xref ref-type="bibr" rid="article-111973.r221">[221]</xref><xref ref-type="bibr" rid="article-111973.r310">[310]</xref></p>
          </list-item>
          <list-item>
            <p>Tunica albuginea plication: This procedure starts with 2 parallel incisions (1 to 1.5 cm long), which are made transversely on the contralateral (converse) tunica.&#x000a0;The incisions should be no more than 1 cm apart and only deep enough to separate the external longitudinal fibers of the tunica without penetrating or damaging the inner circular fibers. The superficial tunica between the 2 incisions can be removed, and the defect closed with vertical mattress stitches.<xref ref-type="bibr" rid="article-111973.r298">[298]</xref><xref ref-type="bibr" rid="article-111973.r315">[315]</xref><xref ref-type="bibr" rid="article-111973.r316">[316]</xref><xref ref-type="bibr" rid="article-111973.r317">[317]</xref><xref ref-type="bibr" rid="article-111973.r318">[318]</xref><xref ref-type="bibr" rid="article-111973.r319">[319]</xref><xref ref-type="bibr" rid="article-111973.r320">[320]</xref><xref ref-type="bibr" rid="article-111973.r321">[321]</xref><xref ref-type="bibr" rid="article-111973.r322">[322]</xref>&#x000a0;A modified technique of extra-tunical grafting combined with tunica albuginea plication has been successfully used for men with Peyronie disease who have corporal indentation without hinge effect or penile buckling.<xref ref-type="bibr" rid="article-111973.r323">[323]</xref></p>
          </list-item>
          <list-item>
            <p>Lue or 16-dot plication technique: In&#x000a0;this technique, several stitches can be placed and tied in an interrupted fashion, going across the tunica horizontally, causing it to fold over on itself using a permanent Lembert-type suture.<xref ref-type="bibr" rid="article-111973.r324">[324]</xref><xref ref-type="bibr" rid="article-111973.r324">[324]</xref><xref ref-type="bibr" rid="article-111973.r325">[325]</xref><xref ref-type="bibr" rid="article-111973.r326">[326]</xref><xref ref-type="bibr" rid="article-111973.r327">[327]</xref>&#x000a0;As the stitches are tied, the penile length on that side will diminish by the degree of tunical tissue inversion.<xref ref-type="bibr" rid="article-111973.r324">[324]</xref><xref ref-type="bibr" rid="article-111973.r325">[325]</xref><xref ref-type="bibr" rid="article-111973.r326">[326]</xref><xref ref-type="bibr" rid="article-111973.r327">[327]</xref>&#x000a0;Multiple parallel plications may be needed for optimal results.<xref ref-type="bibr" rid="article-111973.r324">[324]</xref>&#x000a0;The advantage of this technique is that it does not require any incision or excision of the tunica. Still, it may not manage more significant degrees of curvature&#x000a0;and other surgeries.</p>
          </list-item>
        </list>
        <p>Penile shortening is reported in more than 40% of men with Peyronie disease who undergo plication procedures.&#x000a0;Another 15% experienced a recurrence of their curvature.</p>
        <p>Patients can typically resume sexual activity after 4&#x000a0;to 6 weeks of recovery. In addition to the surgeries mentioned, other penile plication procedures include the Giammusso procedure, the Lemberger procedure, the 24-dot procedure, the Essed-Schroeder tunica plication, and the penoscrotal plication procedure.</p>
        <p>Potential complications include perceived loss of penile length due to shortening of the long (concave) side of the penis, penile instability, pain, persistence or recurrence of penile curvature, hematoma, urethral injury, and sensory loss from trauma or injury to the neurovascular bundle during dorsal plication procedures.<xref ref-type="bibr" rid="article-111973.r328">[328]</xref>&#x000a0;Dorsal neurovascular injuries can be avoided by making tunica incisions and placing sutures further lateral on either side.&#x000a0;Erectile dysfunction is rare in patients who did not have erection difficulties preoperatively, especially if the tunica is not fully incised.<xref ref-type="bibr" rid="article-111973.r309">[309]</xref><xref ref-type="bibr" rid="article-111973.r328">[328]</xref>&#x000a0;Surgical correction of ventral curvatures can be extremely challenging, as dissection and elevation of the neurovascular bundle&#x000a0;or resection of the deep dorsal penile vein may be necessary.</p>
        <p><bold>Plaque incision or excision and grafting (tunica lengthening)</bold>: The indications for this technique include normal preprocedural erectile rigidity, with or without oral pharmacotherapy; complex penile deformity; simple deformity &#x0003c;60&#x000b0;; a large plaque; destabilizing hourglass or hinge effect; and short penile length. For an incisional procedure, a horizontal incision is made on the plaque at the point of maximal curvature on the convex side of the penis. The graft material is then placed within the defect to help lengthen the shorter side of the penis.</p>
        <p>An excisional procedure involves removing some or all of the plaque and placing a graft over the resulting defect. Larger excisions tend to have poorer outcomes, so only the minimal amount of tissue necessary is removed as needed for straightening.<xref ref-type="bibr" rid="article-111973.r329">[329]</xref><xref ref-type="bibr" rid="article-111973.r330">[330]</xref>&#x000a0;Graft materials include autologous grafts, allografts, and xenografts. Synthetic grafts are no longer recommended due to increased infection risk, contracture of the graft material over time, graft-related inflammation resulting in increased local fibrosis, and possible allergic responses.<xref ref-type="bibr" rid="article-111973.r331">[331]</xref><xref ref-type="bibr" rid="article-111973.r332">[332]</xref><xref ref-type="bibr" rid="article-111973.r333">[333]</xref><xref ref-type="bibr" rid="article-111973.r334">[334]</xref></p>
        <p>All allografts and xenografts are processed sheets of the collagen matrix and are the generally preferred graft material. Synthetic grafts are not recommended.</p>
        <list list-type="bullet">
          <list-item>
            <p>Autografts:&#x000a0;Rectus sheath, tunica vaginalis, dermal graft, buccal mucosa, fascia lata, venous patch.</p>
          </list-item>
          <list-item>
            <p>Allografts: Pericardium, processed human pericardial grafting, fascia lata process human grafting, 4-layer&#x000a0;three-dimensional printed graft.</p>
          </list-item>
          <list-item>
            <p>Xenografts: Porcine 4-layer small intestinal submucosa, porcine 1-layer small intestinal submucosa, bovine pericardium, collagen sponge coated with the human coagulation factors fibrinogen and thrombin.</p>
          </list-item>
          <list-item>
            <p>A self-adherent collagen-fleece hemostatic patch is also available, which can be used alone or with a penile prosthesis. The patch has a low rate of complications and does not require suturing.<xref ref-type="bibr" rid="article-111973.r335">[335]</xref><xref ref-type="bibr" rid="article-111973.r336">[336]</xref><xref ref-type="bibr" rid="article-111973.r337">[337]</xref></p>
          </list-item>
        </list>
        <p>In general, incisional procedures are preferred.<xref ref-type="bibr" rid="article-111973.r338">[338]</xref><xref ref-type="bibr" rid="article-111973.r339">[339]</xref>&#x000a0;Long-term (5-year) patient satisfaction is reported to be at 60%.<xref ref-type="bibr" rid="article-111973.r340">[340]</xref></p>
        <p>Postoperative penile rehabilitation with vacuum erection devices, penile traction, and phosphodiesterase type 5 inhibitors has been suggested to minimize loss of penile length and erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r341">[341]</xref><xref ref-type="bibr" rid="article-111973.r342">[342]</xref>&#x000a0;About 50% of patients benefit from or require manual modeling after surgery.<xref ref-type="bibr" rid="article-111973.r343">[343]</xref></p>
        <p>Complications include postoperative erectile dysfunction (up to 50%), infection requiring graft removal, penile hematoma, pain, and recurrence of the curvature.<xref ref-type="bibr" rid="article-111973.r142">[142]</xref>&#x000a0;Recurrent curvature is believed to be due to a failure to wait until the Peyronie plaque has fully stabilized or the use of absorbable sutures. Although non-absorbable sutures are typically preferred, long-duration absorbable suture material (polydioxanone) has been used successfully.<xref ref-type="bibr" rid="article-111973.r303">[303]</xref><xref ref-type="bibr" rid="article-111973.r344">[344]</xref></p>
        <p>Up to one-fifth of patients with normal erectile function develop erectile dysfunction after reconstructive surgery for Peyronie disease, and up to 40% may report penile shortening depending on the specific technique used and the graft material selected.<xref ref-type="bibr" rid="article-111973.r340">[340]</xref></p>
        <p><bold>Penile prosthesis placement:</bold>&#x000a0;This technique can be used with or without modeling, plication, or plaque incision&#x000a0;or excision and grafting, and it is most suitable for men with significant erectile dysfunction and significant Peyronie disease, severe deformity refractory to medical therapy, or profound penile instability. Prosthesis placement can be complicated due to Peyronie plaque and associated corporal fibrosis, making dilation of the corpora difficult and increasing the risk of corporal perforation.</p>
        <p>Options for penile prostheses include malleable and inflatable devices. Most&#x000a0;patients prefer the inflatable prosthesis. Balloon cylinders with limited maximum expansion are recommended.&#x000a0;Inflatable devices are far more costly compared to malleable prostheses, which may be a factor in some areas.&#x000a0;In many cases, the placement of a prosthesis alone may be sufficient to correct the curvature.<xref ref-type="bibr" rid="article-111973.r345">[345]</xref><xref ref-type="bibr" rid="article-111973.r346">[346]</xref>&#x000a0;Repeated activations of an inflatable penile prosthesis tend to gradually decrease any remaining penile curvature over time.<xref ref-type="bibr" rid="article-111973.r347">[347]</xref>&#x000a0;</p>
        <p>Establishing whether a 20&#x000b0; penile angle is considered acceptable by the patient preoperatively or if a completely straight penis is desired postoperatively is crucial. Expert consensus suggests that a penis is considered functionally straight if the residual curvature after surgery is less than 20&#x000b0;.<xref ref-type="bibr" rid="article-111973.r133">[133]</xref>&#x000a0;</p>
        <p>If there is a remaining curvature of 20&#x000b0; or more after penile prosthesis placement,&#x000a0;penile remodeling can be performed.<xref ref-type="bibr" rid="article-111973.r348">[348]</xref>&#x000a0;This&#x000a0;remodeling process is accomplished by manually bending the penile shaft opposite the direction of the angulation while the prosthesis is inflated.<xref ref-type="bibr" rid="article-111973.r348">[348]</xref>&#x000a0;Tubing to the pumping mechanism from the cylinders should be clamped to avoid damaging the mechanism during this procedure. Successful remodeling typically produces a characteristic snap or cracking sound. If this is still insufficient to straighten the penis, a plaque incision or excision with a graft&#x000a0;is necessary.<xref ref-type="bibr" rid="article-111973.r349">[349]</xref>&#x000a0;</p>
        <p>Overall success, defined as a straight penis, in multiple studies, is reported as 85% to 100%, with patient satisfaction rates generally &#x0003e;70%.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref>&#x000a0;Long-term patient satisfaction is reported to be about 60%. This procedure is indicated for the most complex penile deformities and instability, especially in patients with pre-existing erectile dysfunction.<xref ref-type="bibr" rid="article-111973.r350">[350]</xref> Please&#x000a0;see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/33085439">Penile Prosthesis Implantation</ext-link>," for more information.<xref ref-type="bibr" rid="article-111973.r351">[351]</xref>&#x000a0;</p>
        <p><bold>Experimental Restorative Therapies for Peyronie Disease</bold>&#x000a0;</p>
        <p>Platelet-rich plasma, stem cell therapy, and laser treatments have been investigated for efficacy in treating Peyronie disease.<xref ref-type="bibr" rid="article-111973.r201">[201]</xref></p>
        <p>Many studies on platelet-rich plasma penile injection therapy have effectively reduced curvature and plaque size.<xref ref-type="bibr" rid="article-111973.r201">[201]</xref><xref ref-type="bibr" rid="article-111973.r352">[352]</xref><xref ref-type="bibr" rid="article-111973.r353">[353]</xref><xref ref-type="bibr" rid="article-111973.r354">[354]</xref><xref ref-type="bibr" rid="article-111973.r355">[355]</xref><xref ref-type="bibr" rid="article-111973.r356">[356]</xref>&#x000a0;The combination of percutaneous needle tunneling platelet-rich plasma injections and external vacuum therapy has shown promising results in a prospective, nonrandomized pilot study.<xref ref-type="bibr" rid="article-111973.r357">[357]</xref>&#x000a0;In this study, 54 patients with Peyronie disease underwent&#x000a0;6 sessions of percutaneous needle tunneling together with simultaneous platelet-rich plasma injections followed immediately by external vacuum therapy. The treated patients showed significant improvement as the median curvature angle improved from 45&#x000b0; at baseline to 30&#x000b0; after treatment.<xref ref-type="bibr" rid="article-111973.r357">[357]</xref>&#x000a0;Another study with an additional 36 patients showed similar results.<xref ref-type="bibr" rid="article-111973.r358">[358]</xref></p>
        <p>Animal studies and early human trials with adipose-derived or mesenchymal stem cells have provided promising results in shrinking plaque size and reducing curvature.<xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r201">[201]</xref><xref ref-type="bibr" rid="article-111973.r359">[359]</xref><xref ref-type="bibr" rid="article-111973.r360">[360]</xref><xref ref-type="bibr" rid="article-111973.r361">[361]</xref><xref ref-type="bibr" rid="article-111973.r362">[362]</xref>&#x000a0;Stem cell therapy with stromal vascular fraction appears particularly promising. Stromal vascular fraction comprises adipose-derived stem cells, endothelial precursor cells, and immune-modulating cells. This cellular mixture synergistically promotes epithelial cellular differentiation and angiogenesis.<xref ref-type="bibr" rid="article-111973.r362">[362]</xref></p>
        <p>Low-intensity laser diode and laser photobiomodulation have also demonstrated potential in limited studies, with one report indicating excellent results in 60% of patients&#x000a0;1&#x000a0;year after treatment.<xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r363">[363]</xref><xref ref-type="bibr" rid="article-111973.r364">[364]</xref> Despite these promising findings, standardization of the procedure and confirmatory studies are needed before this can be considered for general clinical use.</p>
        <p>Other experimental treatments being evaluated include pirfenidone, a synthetic pyridone drug&#x000a0;with anti-inflammatory, antioxidant, and antifibrosis properties used to treat idiopathic pulmonary fibrosis that inhibits&#x000a0;TGF-&#x003b2;1 production; nintedanib, a tyrosine kinase&#x000a0;inhibitor; IL-13; lysyl oxidase 2; &#x003b2;-thymosins; nitric oxide donors;&#x000a0;matrix metalloproteinases&#x000a0;or anti-tissue inhibitor of metalloproteinase 1, which reduce collagen synthesis;&#x000a0;and&#x000a0;antifibrotic agents, such as decorin, follistatin, and Smad 7.<xref ref-type="bibr" rid="article-111973.r365">[365]</xref><xref ref-type="bibr" rid="article-111973.r366">[366]</xref><xref ref-type="bibr" rid="article-111973.r367">[367]</xref>&#x000a0;Specific inhibitors such as TGF-&#x003b2;1, platelet-derived growth factors,&#x000a0;endothelin-1, and connective tissue growth factors are also being evaluated.&#x000a0;</p>
        <p>All of these innovative restorative therapies appear to be safe and promising. However, they are still considered investigational and are therefore not currently recommended by the AUA or the EAU due to insufficient quality clinical evidence of safety and efficacy. The available studies generally have significantly variable protocols, small sample sizes, short follow-up periods, and no control groups.<xref ref-type="bibr" rid="article-111973.r201">[201]</xref><xref ref-type="bibr" rid="article-111973.r352">[352]</xref><xref ref-type="bibr" rid="article-111973.r354">[354]</xref><xref ref-type="bibr" rid="article-111973.r355">[355]</xref>&#x000a0;Further research with large, high-quality, randomized controlled trials and adequate long-term follow-up are needed to determine optimal therapies, treatment protocols, effectiveness, therapeutic duration, and safety.<xref ref-type="bibr" rid="article-111973.r201">[201]</xref></p>
        <p>A recent study indicated significant off-label use of these restorative therapies in the United States.<xref ref-type="bibr" rid="article-111973.r368">[368]</xref> Often, patients are not informed about the investigational nature of these treatments or the actual scientific information on their effectiveness.<xref ref-type="bibr" rid="article-111973.r368">[368]</xref> The&#x000a0;treatments are not standardized, there is often a lack of scientific data to support claims made to patients, and health insurance does not cover these unapproved therapies, so there is considerable out-of-pocket cost to the patient.<xref ref-type="bibr" rid="article-111973.r368">[368]</xref> Clinicians are involved in about two-thirds of the clinics providing these off-label therapies, and less than 8% are urologists.<xref ref-type="bibr" rid="article-111973.r368">[368]</xref></p>
      </sec>
      <sec id="article-111973.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Congenital penile curvature may appear similar to Peyronie disease, but congenital penile curvature is a lifelong condition. The curvature is typically a ventral bowing without acute angulation, with no plaques. True Peyronie disease is acquired and typically dorsal, with acute, sharply angled curvatures being the most common.<xref ref-type="bibr" rid="article-111973.r51">[51]</xref>&#x000a0;Indentations, hourglass deformities, and other penile abnormalities are typically absent in congenital curvatures.</p>
        <p>Chordee is a ventral penile curvature typically&#x000a0;associated with hypospadias and is considered an arrest of normal embryological development. Surgical management is typically performed after 6 months of age.</p>
        <p>Management should include intraoperative artificial erection tests at the time of repair to identify the point of maximal curvature and then to perform penile plication. If hypospadias is also present, it should be corrected during the same surgical procedure. Penile fracture involves trauma or contusion&#x000a0;resulting in a fracture of the tunica albuginea during sexual intercourse. The typical story involves the sound of a pop with an immediate onset of severe pain and detumescence of the penis. On examination, there is typically penile swelling, ecchymosis, and possible palpable defect in the corpora cavernosa. Diagnosis can be made&#x000a0;through physical examination and patient history, along with an MRI of the penis, which demonstrates excellent sensitivity for detecting penile fracture.</p>
        <p>Treatment involves penile exploration with a circumferential incision through a subcoronal approach and closure of the cavernosal injury. If there is concern for urethral injury, a cystoscopy should be performed, and any urethral injury should be repaired in the same setting. Penile pain syndrome has a sporadic etiology that could include local conditions such as dermatitis, infection, or ischemia; referred pain from the bladder, prostate, lower back, or hips; neuropathic pain resulting from injury to the dorsal nerve, pudendal nerve, or cauda equina; or psychiatric conditions. Persistent pain can be managed by treating the underlying disease.</p>
      </sec>
      <sec id="article-111973.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The overall prognosis for Peyronie disease is favorable due to the availability of multiple treatment options, both surgical and nonsurgical. For many patients, conservative approaches such as oral medications, intralesional injections, traction therapy, and vacuum erection devices can lead to significant improvement in symptoms, including curvature and pain. In more severe cases, surgical interventions such as penile plication, grafting, or penile prosthesis implantation are effective in restoring function and alleviating deformity. The variety of treatment options allows for personalized care, contributing to positive outcomes for most patients, especially with early diagnosis and intervention.</p>
      </sec>
      <sec id="article-111973.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications include penile ecchymosis, swelling, pain, corporal rupture, erectile dysfunction, and failure to correct the curvature.<xref ref-type="bibr" rid="article-111973.r369">[369]</xref>&#x000a0;In addition to all of the other associated problems of pain, embarrassment, and sexual performance issues, men with Peyronie disease suffer an 18% higher frequency of relationship separations per year compared to men of age and socio-economic status without penile disorder.<xref ref-type="bibr" rid="article-111973.r370">[370]</xref></p>
        <p>Surgical complications might consist of infection, urethral injury, penile shortening, pain, hematoma, loss of penile sensation, erectile dysfunction, and recurrence of the curvature.&#x000a0;</p>
      </sec>
      <sec id="article-111973.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Surgical patients generally have an elastic compression dressing placed immediately after the procedure. This&#x000a0;dressing may be removed and replaced with a nonconstricting dressing when appropriate, typically 6 hours postoperatively. The use of an external vacuum erection device several times a day for 6 months is recommended by some, starting 30 days after surgery.<xref ref-type="bibr" rid="article-111973.r371">[371]</xref>&#x000a0;</p>
        <p>Patients who received an inflatable penile prosthesis should inflate the device several times daily as soon as this is tolerable, typically 4&#x000a0;to 6 weeks after surgery.</p>
        <p>Routine follow-up after surgical reconstruction is recommended every 3 months until the penis is completely healed and stable, typically a year after surgery. Yearly checkups afterward are generally&#x000a0;sufficient.</p>
      </sec>
      <sec id="article-111973.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Peyronie disease can be challenging to manage as there are many treatment options, mostly of unproven efficacy. The embarrassing nature of the disorder and the natural reluctance of many patients to seek medical help often results in delayed diagnosis.</p>
        <p>Patients should understand that this disorder is likely more prevalent than expected, and numerous options exist to manage it. Intralesional&#x000a0;<italic toggle="yes">Clostridium histolyticum</italic> collagenase intralesional injections are the most effective nonsurgical therapy. Surgical options require stable disease but generally offer excellent results.</p>
      </sec>
      <sec id="article-111973.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Summary of Therapies for Peyronie Disease</bold>
</p>
        <p>
<bold>Conservative treatments:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A combination of antioxidants has shown some promising results.<xref ref-type="bibr" rid="article-111973.r60">[60]</xref><xref ref-type="bibr" rid="article-111973.r69">[69]</xref><xref ref-type="bibr" rid="article-111973.r113">[113]</xref><xref ref-type="bibr" rid="article-111973.r133">[133]</xref><xref ref-type="bibr" rid="article-111973.r139">[139]</xref><xref ref-type="bibr" rid="article-111973.r140">[140]</xref><xref ref-type="bibr" rid="article-111973.r141">[141]</xref><xref ref-type="bibr" rid="article-111973.r142">[142]</xref><xref ref-type="bibr" rid="article-111973.r174">[174]</xref><xref ref-type="bibr" rid="article-111973.r285">[285]</xref><xref ref-type="bibr" rid="article-111973.r286">[286]</xref></p>
          </list-item>
          <list-item>
            <p>Coenzyme Q10 may be beneficial and can be used with other treatments.&#x000a0;Coenzyme Q10 is inexpensive and unlikely to cause any harm. Although its effectiveness for Peyronie disease is not yet conclusively proven, it offers other potential health benefits.</p>
          </list-item>
          <list-item>
            <p>Colchicine is not generally recommended as its efficacy is unclear.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Combination therapy with phosphodiesterase type 5 inhibitors and statins may improve outcomes when used together.</p>
          </list-item>
          <list-item>
            <p>Extracorporeal shockwave therapy is beneficial only for pain relief in the acute phase of the disease. Other treatments may be more readily available and cost-effective.</p>
          </list-item>
          <list-item>
            <p>Intralesional&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase injections have the strongest evidence of efficacy among nonsurgical therapies.</p>
          </list-item>
          <list-item>
            <p>Intralesional interferon therapy is an effective alternative to&#x000a0;<italic toggle="yes">C histolyticum&#x000a0;</italic>collagenase injections and is probably underutilized.</p>
          </list-item>
          <list-item>
            <p>Intralesional hyaluronic acid injections appear promising but are recommended only in clinical trials.</p>
          </list-item>
          <list-item>
            <p>Intralesional therapy should only be used in the chronic or stable phase of Peyronie disease.</p>
          </list-item>
          <list-item>
            <p>Multimodality therapy, including coenzyme Q10, tadalafil, statins, antioxidants, pentoxifylline, and traction therapy, before or with intralesional injections may be worth considering before surgery.</p>
          </list-item>
          <list-item>
            <p>Pentoxifylline appears promising, and some data indicate possible efficacy.</p>
          </list-item>
          <list-item>
            <p>Tadalafil at a dosage of 5 mg daily (possibly with a statin) and coenzyme Q10 offer the best evidence of efficacy among oral agents. Other medications, such as colchicine, pentoxifylline, potaba, carnitine, arginine, and vitamin E, are not recommended.</p>
          </list-item>
          <list-item>
            <p>Topical verapamil has provided conflicting outcomes in studies; therefore, it is not recommended.<xref ref-type="bibr" rid="article-111973.r285">[285]</xref><xref ref-type="bibr" rid="article-111973.r286">[286]</xref></p>
          </list-item>
          <list-item>
            <p>Traction is a promising nonsurgical therapy for Peyronie disease, but no standardized protocol exists. The need for prolonged usage and the lack of standardization protocols limit its use. An athletic supporter and overnight device application may help minimize patient discomfort and device displacement.</p>
          </list-item>
          <list-item>
            <p>Traction is possibly most useful as an adjunct to other oral or intralesional therapies.</p>
          </list-item>
          <list-item>
            <p>Verapamil gel can be considered where available.</p>
          </list-item>
        </list>
        <p>
<bold>Surgical procedures:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Indications for surgery include a lesion that is stable and pain-free for at least 3 months (some prefer to wait at least 1 year), failure of more conservative therapies, sufficient deformity to interfere with intercourse, and calcified Peyronie plaques.</p>
          </list-item>
          <list-item>
            <p>Plication procedures are recommended when the penile curvature is &#x0003c;60&#x000b0;, and the patient has a good erectile function.</p>
          </list-item>
          <list-item>
            <p>Incisional&#x000a0;or excisional procedures with grafting are indicated for patients who are not candidates for plication, such as where the curvature is &#x0003e;60&#x000b0;, complex regulations, unstable penile shaft deformities, large Peyronie plaques, or a short penis. The patient should also have good erectile function.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Surgical patients who also have erectile dysfunction are best served with the placement of a penile prosthesis.</p>
          </list-item>
          <list-item>
            <p>If an inflatable penile prosthesis is implanted, selecting balloon cylinders with limited or restricted maximal expansion is suggested.</p>
          </list-item>
          <list-item>
            <p>Manual remodeling after penile prosthesis may be necessary in some cases.</p>
          </list-item>
          <list-item>
            <p>Thinning of the plaque using a dental drill with a carbide burr attachment has been attempted. Although initial results were encouraging, the incidence of penile shortening, plaque recurrence, and return of penile angulation was unacceptable, so the technique has been abandoned.<xref ref-type="bibr" rid="article-111973.r372">[372]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-111973.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The extremely embarrassing nature of this disorder is&#x000a0;why men rarely discuss this issue with their primary care providers unless prompted. Nevertheless, primary care providers&#x000a0;are vital in identifying patients potentially suffering from Peyronie disease. The sensitive nature of the problem requires delicate handling by primary care providers&#x000a0;and the other healthcare professionals involved in the patient's care.&#x000a0;</p>
        <p>An effective technique is to ask the patient, How is your sex life? Is everything working OK for you? This question should be posed in a conversational tone and in a manner where the intonation suggests no suspicion that there may be a sexual problem. If the patient hesitates or delays in responding positively, it indicates a need for the clinician to gently inquire further, as those with no issues are likely to respond affirmatively right away.</p>
        <p>Primary care clinicians&#x000a0;must be able to have an open and nonjudgemental discussion with their patients regarding their sexual activity and satisfaction with their sexual ability, as this is often the first opportunity to uncover issues such as Peyronie disease. Primary care clinicians&#x000a0;should communicate that penile curvature and Peyronie plaques are treatable conditions, and the affected patients should be referred to a urologist for further treatment. Urologists can provide various solutions, advancing the patient's care toward resolution. Medical professionals must coordinate care and communicate effectively to ensure optimal patient outcomes.&#x000a0;</p>
        <p>Effective coordination and communication among medical professionals are essential to ensure optimal patient outcomes. The key lies in the early identification of the patient's problem and timely referral to the appropriate medical specialist.</p>
      </sec>
      <sec id="article-111973.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=111973&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=111973">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mens-health/peyronie-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=111973">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/111973/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=111973">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-111973.s18">
        <title>References</title>
        <ref id="article-111973.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musitelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jallous</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A brief historical survey of "Peyronie's disease".</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>1737</fpage>
            <page-range>1737-46</page-range>
            <pub-id pub-id-type="pmid">18179461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lambertini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Valastro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Natural History of Peyronie's Disease.</article-title>
            <source>World J Mens Health</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-405</page-range>
            <pub-id pub-id-type="pmid">32648381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Ladaga</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: pathophysiology.</article-title>
            <source>Prog Clin Biol Res</source>
            <year>1991</year>
            <volume>370</volume>
            <fpage>355</fpage>
            <page-range>355-8</page-range>
            <pub-id pub-id-type="pmid">1924469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nam</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Does testosterone deficiency exaggerate the clinical symptoms of Peyronie's disease?</article-title>
            <source>Int J Urol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>796</fpage>
            <page-range>796-800</page-range>
            <pub-id pub-id-type="pmid">21883492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nyberg</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bias</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens.</article-title>
            <source>J Urol</source>
            <year>1982</year>
            <month>Jul</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-51</page-range>
            <pub-id pub-id-type="pmid">6980996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen-Brady</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Pastuszak</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Significant familial clustering of Peyronie's disease in close and distant relatives.</article-title>
            <source>Andrology</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1361</fpage>
            <page-range>1361-1367</page-range>
            <pub-id pub-id-type="pmid">35770847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabrielsen</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: is it genetic or not?</article-title>
            <source>Transl Androl Urol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>Suppl 2</issue>
            <fpage>S262</fpage>
            <page-range>S262-S268</page-range>
            <pub-id pub-id-type="pmid">32257867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hotaling</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pastuszak</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Erectile Dysfunction and Peyronie's Disease: Genetic Diseases?</article-title>
            <source>Eur Urol Focus</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>572</fpage>
            <page-range>572-574</page-range>
            <pub-id pub-id-type="pmid">31474580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herati</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pastuszak</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>The Genetic Basis of Peyronie Disease: A Review.</article-title>
            <source>Sex Med Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">27872008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ellins</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Donald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Halcox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Systemic vascular endothelial dysfunction in Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>2688</fpage>
            <page-range>2688-93</page-range>
            <pub-id pub-id-type="pmid">18638002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Meyers</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Marquart</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <chapter-title>Plantar Fibromatosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">32491606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nugteren</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Nijman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>van Driel</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>The association between Peyronie's and Dupuytren's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>142</fpage>
            <page-range>142-5</page-range>
            <pub-id pub-id-type="pmid">21633367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Walthall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>UH</given-names>
              </name>
            </person-group>
            <chapter-title>Dupuytren Contracture</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30252330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelbard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Rosenbloom</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie's disease, Dupuytren disease and diabetes.</article-title>
            <source>Endocrinol Diabetes Metab</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>e00195</fpage>
            <pub-id pub-id-type="pmid">33855203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Buchanan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Sina</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Plantar Fasciitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">28613727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thieu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Durbin-Johnson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rothschild</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Peyronie's Disease-Like Symptoms in Men Presenting With Dupuytren Contractures.</article-title>
            <source>Sex Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>e135</fpage>
            <page-range>e135-e141</page-range>
            <pub-id pub-id-type="pmid">28676223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ferrando</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cordero</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>[Idiopathic pulmonary fibrosis and Peyronie's disease].</article-title>
            <source>Arch Bronconeumol</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>549</fpage>
            <page-range>549-50</page-range>
            <pub-id pub-id-type="pmid">9453825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyles</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Krishan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease is associated with Paget's disease of bone.</article-title>
            <source>J Bone Miner Res</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>929</fpage>
            <page-range>929-34</page-range>
            <pub-id pub-id-type="pmid">9169352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akbal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tanidir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozgen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sim&#x0015f;ek</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Erectile dysfunction and Peyronie's disease in patient with retroperitoenal fibrosis.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2008</year>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>971</fpage>
            <page-range>971-5</page-range>
            <pub-id pub-id-type="pmid">18437523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Zahran</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Penile curvature associated with scleroderma.</article-title>
            <source>Urology</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <pub-id pub-id-type="pmid">11489727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A novel case of polyfibromatosis and interstitial granulomatous dermatitis with arthritis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>55</volume>
            <issue>2 Suppl</issue>
            <fpage>S32</fpage>
            <page-range>S32-7</page-range>
            <pub-id pub-id-type="pmid">16843121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simeon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Fonollosa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vilardell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ordi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solans</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impotence and Peyronie's disease in systemic sclerosis.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>1994</year>
            <season>Jul-Aug</season>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>464</fpage>
            <pub-id pub-id-type="pmid">7955618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stuntz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perlaky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>des Vignes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kyriakides</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence of Peyronie's Disease in the United States: A Population-Based Study.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>e0150157</fpage>
            <pub-id pub-id-type="pmid">26907743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tefekli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kandirali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tunc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: a silent consequence of diabetes mellitus.</article-title>
            <source>Asian J Androl</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-9</page-range>
            <pub-id pub-id-type="pmid">16372122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tefekli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oktar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tunc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tellaloglu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A retrospective review of 307 men with Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>168</volume>
            <issue>3</issue>
            <fpage>1075</fpage>
            <page-range>1075-9</page-range>
            <pub-id pub-id-type="pmid">12187226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Tayeb</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease in diabetic patients being screened for erectile dysfunction.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>1026</fpage>
            <page-range>1026-30</page-range>
            <pub-id pub-id-type="pmid">16094040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianazza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belladelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Masci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gianesini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zaffuto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carcano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deh&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease development and management in diabetic men.</article-title>
            <source>Andrology</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>372</fpage>
            <page-range>372-378</page-range>
            <pub-id pub-id-type="pmid">35771713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Etiology of Peyronie's Disease: Pathogenesis and Genetic Contributions.</article-title>
            <source>Sex Med Rev</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>314</fpage>
            <page-range>314-323</page-range>
            <pub-id pub-id-type="pmid">31540807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegelbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zachary</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The association of Peyronie's disease with HLA B7 cross-reactive antigens. A case report of identical twins.</article-title>
            <source>Cleve Clin J Med</source>
            <year>1987</year>
            <season>Sep-Oct</season>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>427</fpage>
            <page-range>427-30</page-range>
            <pub-id pub-id-type="pmid">3499260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrieri</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Serraino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palmiotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nucci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sasso</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A case-control study on risk factors for Peyronie's disease.</article-title>
            <source>J Clin Epidemiol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-5</page-range>
            <pub-id pub-id-type="pmid">9636000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chilton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Westwood</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Pryor</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Factors associated in the aetiology of peyronie's disease.</article-title>
            <source>Br J Urol</source>
            <year>1982</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>748</fpage>
            <page-range>748-50</page-range>
            <pub-id pub-id-type="pmid">7150935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Can</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>&#x000d6;zbir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atalay</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>&#x000c7;ak&#x00131;r</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Culha</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Canat</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>The relationship between testosterone levels and Peyronie's disease.</article-title>
            <source>Andrologia</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>e13727</fpage>
            <pub-id pub-id-type="pmid">32589321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Morgentaler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship.</article-title>
            <source>J Sex Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1729</fpage>
            <page-range>1729-1735</page-range>
            <pub-id pub-id-type="pmid">19473459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Testosterone Levels Are Not Associated With Magnitude of Deformity in Men With Peyronie's Disease.</article-title>
            <source>J Sex Med</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1283</fpage>
            <page-range>1283-1289</page-range>
            <pub-id pub-id-type="pmid">31303573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candela</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oreggia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cazzaniga</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Belladelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baudo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Serum testosterone levels are not associated with the severity of penile curvature in men with Peyronie's disease-findings from a cross-sectional study.</article-title>
            <source>Int J Impot Res</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>832</fpage>
            <page-range>832-838</page-range>
            <pub-id pub-id-type="pmid">32764741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjekic</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Vlajinac</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Sipetic</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Marinkovic</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for Peyronie's disease: a case-control study.</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>570</fpage>
            <page-range>570-4</page-range>
            <pub-id pub-id-type="pmid">16469028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teloken</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Siegrist</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease following radical prostatectomy: incidence and predictors.</article-title>
            <source>J Sex Med</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>1254</fpage>
            <page-range>1254-61</page-range>
            <pub-id pub-id-type="pmid">20500447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>La Pera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pescatori</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boffini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Andriani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Natali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaggi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Catuogno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giustini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taggi</surname>
                <given-names>F</given-names>
              </name>
              <collab>SIMONA Study Group</collab>
            </person-group>
            <article-title>Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years.</article-title>
            <source>Eur Urol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>525</fpage>
            <page-range>525-30</page-range>
            <pub-id pub-id-type="pmid">11752860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Peyronie's disease among patients with erectile dysfunction.</article-title>
            <source>Eur Urol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>564</fpage>
            <page-range>564-9</page-range>
            <pub-id pub-id-type="pmid">16386353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usta</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Jabren</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanabria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>171</volume>
            <issue>2 Pt 1</issue>
            <fpage>775</fpage>
            <page-range>775-9</page-range>
            <pub-id pub-id-type="pmid">14713809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casab&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bechara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheliz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rey</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk factors of Peyronie's disease. What does our clinical experience show?</article-title>
            <source>J Sex Med</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>518</fpage>
            <page-range>518-23</page-range>
            <pub-id pub-id-type="pmid">20955309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Akman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Canguven</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akbulut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kucukdurmaz</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients.</article-title>
            <source>J Androl</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <page-range>502-8</page-range>
            <pub-id pub-id-type="pmid">21233397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schroeder-Printzen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Weiske</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Vosshenrich</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sexual dysfunction in Peyronie's disease: an analysis of 222 patients without previous local plaque therapy.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>325</fpage>
            <page-range>325-8</page-range>
            <pub-id pub-id-type="pmid">8976290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical Presentation of Peyronie's Disease: A Retrospective Study of 564 Cases.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2024</year>
            <month>May</month>
            <day>29</day>
            <volume>14</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">38893650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases.</article-title>
            <source>Res Rep Urol</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>95</fpage>
            <page-range>95-103</page-range>
            <pub-id pub-id-type="pmid">27486570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segundo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, Risk Factors, and Erectile Dysfunction Associated With Peyronie's Disease Among Men Seeking Urological Care.</article-title>
            <source>Sex Med</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-236</page-range>
            <pub-id pub-id-type="pmid">32007472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arafa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El-Badry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ezz-Eldine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shamloul</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction.</article-title>
            <source>Int J Impot Res</source>
            <year>2007</year>
            <season>Mar-Apr</season>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-7</page-range>
            <pub-id pub-id-type="pmid">16915304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindsay</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Schain</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Grambsch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>LT</given-names>
              </name>
            </person-group>
            <article-title>The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984.</article-title>
            <source>J Urol</source>
            <year>1991</year>
            <month>Oct</month>
            <volume>146</volume>
            <issue>4</issue>
            <fpage>1007</fpage>
            <page-range>1007-9</page-range>
            <pub-id pub-id-type="pmid">1895413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sommer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwarzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wassmer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>379</fpage>
            <page-range>379-83</page-range>
            <pub-id pub-id-type="pmid">12454689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dibenedetti</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zografos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ziemiecki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United States.</article-title>
            <source>Adv Urol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>282503</fpage>
            <pub-id pub-id-type="pmid">22110491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guhring</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An analysis of the natural history of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>175</volume>
            <issue>6</issue>
            <fpage>2115</fpage>
            <page-range>2115-8; discussion 2118</page-range>
            <pub-id pub-id-type="pmid">16697815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reifenrath</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of Peyronie's disease: results of a large survey.</article-title>
            <source>BJU Int</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>88</volume>
            <issue>7</issue>
            <fpage>727</fpage>
            <page-range>727-30</page-range>
            <pub-id pub-id-type="pmid">11890244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Alex</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease in teenagers.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>302</fpage>
            <page-range>302-8</page-range>
            <pub-id pub-id-type="pmid">21981606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perimenis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Athanasopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gyftopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsenis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbalias</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: epidemiology and clinical presentation of 134 cases.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2001</year>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>691</fpage>
            <page-range>691-4</page-range>
            <pub-id pub-id-type="pmid">11989566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cazzaniga</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Matloob</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ventimiglia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oreggia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schifano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Candela</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Trends in reported male sexual dysfunction over the past decade: an evolving landscape.</article-title>
            <source>Int J Impot Res</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>596</fpage>
            <page-range>596-602</page-range>
            <pub-id pub-id-type="pmid">32612274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feyisetan</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's Disease: A Brief Overview.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e37037</fpage>
            <pub-id pub-id-type="pmid">37143639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ghaly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Moty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>171</volume>
            <issue>6 Pt 1</issue>
            <fpage>2350</fpage>
            <page-range>2350-3</page-range>
            <pub-id pub-id-type="pmid">15126819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiraishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimabukuro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuyama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of Peyronie's disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>2716</fpage>
            <page-range>2716-23</page-range>
            <pub-id pub-id-type="pmid">22897619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Thakafi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Hathal</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up.</article-title>
            <source>Transl Androl Urol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-9</page-range>
            <pub-id pub-id-type="pmid">27298774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alterowitz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Culkin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Faraday</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Heidelbaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sadeghi-Nejad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seftel</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <collab>American Urological Association Education and Research, Inc.,</collab>
            </person-group>
            <article-title>Peyronie's Disease: AUA Guideline.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>194</volume>
            <issue>3</issue>
            <fpage>745</fpage>
            <page-range>745-53</page-range>
            <pub-id pub-id-type="pmid">26066402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Fibrin deposition in Peyronie's disease plaque.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>311</fpage>
            <page-range>311-5</page-range>
            <pub-id pub-id-type="pmid">8976287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haag</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Eickelberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Szardening-Kirchner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diemer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>425</fpage>
            <page-range>425-30</page-range>
            <pub-id pub-id-type="pmid">17630104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Sismour</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Isolation and characterization of collagen in Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>141</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-31</page-range>
            <pub-id pub-id-type="pmid">2918606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Expanding the paradigm for plaque development in Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>15 Suppl 5</volume>
            <fpage>S93</fpage>
            <page-range>S93-102</page-range>
            <pub-id pub-id-type="pmid">14551585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davila</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ferrini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>9</issue>
            <fpage>830</fpage>
            <page-range>830-8</page-range>
            <pub-id pub-id-type="pmid">12780843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szardening-Kirchner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Haag</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Eickelberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease.</article-title>
            <source>World J Urol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-30</page-range>
            <pub-id pub-id-type="pmid">18704440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: an anatomically-based hypothesis and beyond.</article-title>
            <source>Int J Impot Res</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-3</page-range>
            <pub-id pub-id-type="pmid">12454694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Salabas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Din&#x000e7;er</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology of Peyronie's disease.</article-title>
            <source>Arab J Urol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-7</page-range>
            <pub-id pub-id-type="pmid">26558092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lipshultz</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities.</article-title>
            <source>Res Rep Urol</source>
            <year>2023</year>
            <volume>15</volume>
            <fpage>55</fpage>
            <page-range>55-67</page-range>
            <pub-id pub-id-type="pmid">36756281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hotaling</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pastuszak</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease.</article-title>
            <source>World J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-261</page-range>
            <pub-id pub-id-type="pmid">31190155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luangkhot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rutchik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puglia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Melman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Collagen alterations in the corpus cavernosum of men with sexual dysfunction.</article-title>
            <source>J Urol</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>148</volume>
            <issue>2 Pt 1</issue>
            <fpage>467</fpage>
            <page-range>467-71</page-range>
            <pub-id pub-id-type="pmid">1635159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Theodoro</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leonel</surname>
                <given-names>MLP</given-names>
              </name>
              <name>
                <surname>Mader</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nader</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pinhal</surname>
                <given-names>MAS</given-names>
              </name>
            </person-group>
            <article-title>Extracellular matrix alterations in the Peyronie's disease.</article-title>
            <source>J Adv Res</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-461</page-range>
            <pub-id pub-id-type="pmid">28721300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Hassoba</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Pillarisetty</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dahiya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>158</volume>
            <issue>4</issue>
            <fpage>1391</fpage>
            <page-range>1391-4</page-range>
            <pub-id pub-id-type="pmid">9302128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davila</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Magee</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Zuniga</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque.</article-title>
            <source>Urology</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>645</fpage>
            <page-range>645-8</page-range>
            <pub-id pub-id-type="pmid">15833499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haag</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Szardening-Kirchner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diemer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Eickelberg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease.</article-title>
            <source>Eur Urol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>51</volume>
            <issue>1</issue>
            <fpage>255</fpage>
            <page-range>255-61</page-range>
            <pub-id pub-id-type="pmid">16782264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The microscopic pathology of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>282</fpage>
            <page-range>282-4</page-range>
            <pub-id pub-id-type="pmid">8976280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Schlossberg</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Proposal: trauma as the cause of the Peyronie's lesion.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>285</fpage>
            <page-range>285-90</page-range>
            <pub-id pub-id-type="pmid">8976281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diegelmann</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Cellular and biochemical aspects of normal and abnormal wound healing: an overview.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>298</fpage>
            <page-range>298-302</page-range>
            <pub-id pub-id-type="pmid">8976284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gholami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: a review.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>169</volume>
            <issue>4</issue>
            <fpage>1234</fpage>
            <page-range>1234-41</page-range>
            <pub-id pub-id-type="pmid">12629334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jalkut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>New discoveries in the basic science understanding of Peyronie's disease.</article-title>
            <source>Curr Urol Rep</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-84</page-range>
            <pub-id pub-id-type="pmid">15541219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lubrano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shankey</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Basic fibroblast growth factor expression in Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>419</fpage>
            <page-range>419-23</page-range>
            <pub-id pub-id-type="pmid">11176387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Carlo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts.</article-title>
            <source>J Urol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>179</volume>
            <issue>6</issue>
            <fpage>2447</fpage>
            <page-range>2447-55</page-range>
            <pub-id pub-id-type="pmid">18433786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review.</article-title>
            <source>Adv Urol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>4653512</fpage>
            <pub-id pub-id-type="pmid">28744308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease.</article-title>
            <source>Nat Clin Pract Urol</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>291</fpage>
            <page-range>291-7</page-range>
            <pub-id pub-id-type="pmid">16474811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willscher</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Cwazka</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Novicki</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-5</page-range>
            <pub-id pub-id-type="pmid">458986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pierpaoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lubrano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shankey</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>288</fpage>
            <page-range>288-93</page-range>
            <pub-id pub-id-type="pmid">14961053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brancato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.</article-title>
            <source>Inflamm Allergy Drug Targets</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-57</page-range>
            <pub-id pub-id-type="pmid">22309083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somers</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Leffell</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Chromosome abnormalities in Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1987</year>
            <month>Apr</month>
            <volume>137</volume>
            <issue>4</issue>
            <fpage>672</fpage>
            <page-range>672-5</page-range>
            <pub-id pub-id-type="pmid">3560320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Hauptmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmelz</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Bein</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hackstein</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>169</volume>
            <issue>1</issue>
            <fpage>369</fpage>
            <page-range>369-72</page-range>
            <pub-id pub-id-type="pmid">12478192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitsui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamabe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uetani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie's Disease.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Jun</month>
            <day>14</day>
            <volume>24</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">37373277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Magee</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ferrini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vernet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gene expression in Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>361</fpage>
            <page-range>361-74</page-range>
            <pub-id pub-id-type="pmid">12454687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rainer</surname>
                <given-names>QC</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bajic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Masterson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Implications of Calcification in Peyronie's Disease, A Review of the Literature.</article-title>
            <source>Urology</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>152</volume>
            <fpage>52</fpage>
            <page-range>52-59</page-range>
            <pub-id pub-id-type="pmid">33476600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brock</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>von Heyden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>The anatomy of the tunica albuginea in the normal penis and Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <page-range>276-81</page-range>
            <pub-id pub-id-type="pmid">8976279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Histological and ultrastructural alterations in an animal model of Peyronie's disease.</article-title>
            <source>Br J Urol</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>445</fpage>
            <page-range>445-52</page-range>
            <pub-id pub-id-type="pmid">9523668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>The natural history of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1970</year>
            <month>Jan</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-6</page-range>
            <pub-id pub-id-type="pmid">5415725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelbard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dorey</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The natural history of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>144</volume>
            <issue>6</issue>
            <fpage>1376</fpage>
            <page-range>1376-9</page-range>
            <pub-id pub-id-type="pmid">2231932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berookhim</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alex</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Deformity stabilization and improvement in men with untreated Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-6</page-range>
            <pub-id pub-id-type="pmid">24053665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piraino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ames</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okoye</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clavell-Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>A Consistent Lack of Consistency in Defining the Acute and Chronic Phases of Peyronie's Disease: A Review of the Contemporary Literature.</article-title>
            <source>Sex Med Rev</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>698</fpage>
            <page-range>698-713</page-range>
            <pub-id pub-id-type="pmid">37051957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Creation of a Novel Classification System (PTNM) for Peyronie's Disease and Penile Curvature Using Evidence-Based Criteria.</article-title>
            <source>J Urol</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>212</volume>
            <issue>3</issue>
            <fpage>470</fpage>
            <page-range>470-482</page-range>
            <pub-id pub-id-type="pmid">39115123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Catania</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Althof</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>1977</fpage>
            <page-range>1977-84</page-range>
            <pub-id pub-id-type="pmid">18564146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Psychological impact of Peyronie's disease: a review.</article-title>
            <source>J Sex Med</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>653</fpage>
            <page-range>653-60</page-range>
            <pub-id pub-id-type="pmid">23153101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terrier</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Psychological aspects of Peyronie's disease.</article-title>
            <source>Transl Androl Urol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-5</page-range>
            <pub-id pub-id-type="pmid">27298775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Turek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for emotional and relationship problems in Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>2179</fpage>
            <page-range>2179-84</page-range>
            <pub-id pub-id-type="pmid">18638001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kern</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abdelsayed</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's Disease: What About the Female Sexual Partner?</article-title>
            <source>Sex Med Rev</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-235</page-range>
            <pub-id pub-id-type="pmid">33341426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illiano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trama</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ruffo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romeo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riccardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fabi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrieri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crocetto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iacono</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Costantini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease may negatively impact the sexual experience of a couple and female sexual function: a single center study.</article-title>
            <source>Transl Androl Urol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>555</fpage>
            <page-range>555-562</page-range>
            <pub-id pub-id-type="pmid">33718058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bajic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's Disease and the Female Sexual Partner: A Comparison of the Male and Female Experience.</article-title>
            <source>J Sex Med</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>2456</fpage>
            <page-range>2456-2461</page-range>
            <pub-id pub-id-type="pmid">33067161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pryor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentations of Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>414</fpage>
            <page-range>414-7</page-range>
            <pub-id pub-id-type="pmid">12454695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohebshalom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guhring</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Measurement of penile curvature in Peyronie's disease patients: comparison of three methods.</article-title>
            <source>J Sex Med</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>199</fpage>
            <page-range>199-203</page-range>
            <pub-id pub-id-type="pmid">17233785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baskin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Duckett</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Penile curvature.</article-title>
            <source>Urology</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-56</page-range>
            <pub-id pub-id-type="pmid">8804484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pradeep</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Padilla-Maldonado</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Bowman</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cernigliaro</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Imaging techniques for diagnosing and managing Peyronie disease.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2024</year>
            <month>Aug</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">39136717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rumohr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lipshultz</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Correlation of degree of penile curvature between patient estimates and objective measures among men with Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>862</fpage>
            <page-range>862-5</page-range>
            <pub-id pub-id-type="pmid">19284472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Perovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The management of Peyronie's disease: evidence-based 2010 guidelines.</article-title>
            <source>J Sex Med</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>2359</fpage>
            <page-range>2359-74</page-range>
            <pub-id pub-id-type="pmid">20497306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatzimouratidis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eardley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hatzichristou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moncada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vardi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wespes</surname>
                <given-names>E</given-names>
              </name>
              <collab>European Association of Urology</collab>
            </person-group>
            <article-title>EAU guidelines on penile curvature.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>543</fpage>
            <page-range>543-52</page-range>
            <pub-id pub-id-type="pmid">22658761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bella</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2018</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>E197</fpage>
            <page-range>E197-E209</page-range>
            <pub-id pub-id-type="pmid">29792593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andresen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wegner</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Banzer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Imaging modalities in Peyronie's disease. An intrapersonal comparison of ultrasound sonography, X-ray in mammography technique, computerized tomography, and nuclear magnetic resonance in 20 patients.</article-title>
            <source>Eur Urol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-34; discussion 135</page-range>
            <pub-id pub-id-type="pmid">9693248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Farrel</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification.</article-title>
            <source>J Sex Med</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>3121</fpage>
            <page-range>3121-8</page-range>
            <pub-id pub-id-type="pmid">24119147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkham</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Illing</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>MR imaging of nonmalignant penile lesions.</article-title>
            <source>Radiographics</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>837</fpage>
            <page-range>837-53</page-range>
            <pub-id pub-id-type="pmid">18480487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajamohan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ganesh</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>MR imaging of penile pathology and prostheses.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2024</year>
            <month>Jul</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">39066812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paw&#x00142;owska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bianek-Bodzak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Imaging modalities and clinical assesment in men affected with Peyronie's disease.</article-title>
            <source>Pol J Radiol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>33</fpage>
            <page-range>33-7</page-range>
            <pub-id pub-id-type="pmid">22802839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erdogru</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ksal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Yildiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ng&#x000f6;r</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baykara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Penile scintigraphy with 99mTc-human immunoglobulin G: a novel method for distinguishing the unstable and stable phases of Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>703</fpage>
            <page-range>703-6</page-range>
            <pub-id pub-id-type="pmid">12410752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hartzell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shabsigh</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Impact of Peyronie's Disease on the Patient: Gaps in Our Current Understanding.</article-title>
            <source>J Sex Marital Ther</source>
            <year>2016</year>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-90</page-range>
            <pub-id pub-id-type="pmid">25405853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brunckhorst</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alnajjar</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Cakir</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Muneer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of non-surgical management in Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>523</fpage>
            <page-range>523-532</page-range>
            <pub-id pub-id-type="pmid">36289392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eslami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tahmasbi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rahimi-Mamaghani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanaie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bettocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sedigh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Soleimanzadeh</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Investigating iontophoresis as a therapeutic approach for Peyronie's disease: a systematic review.</article-title>
            <source>Sex Med Rev</source>
            <year>2024</year>
            <month>Aug</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">39186947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenfield</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>177</volume>
            <issue>3</issue>
            <fpage>972</fpage>
            <page-range>972-5</page-range>
            <pub-id pub-id-type="pmid">17296390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehrsai</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Namdari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salavati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dehghani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allameh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pourmand</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease.</article-title>
            <source>Andrology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-32</page-range>
            <pub-id pub-id-type="pmid">23258641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Stasi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Giannantoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Capelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giurioli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jannini</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Vespasiani</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>171</volume>
            <issue>4</issue>
            <fpage>1605</fpage>
            <page-range>1605-8</page-range>
            <pub-id pub-id-type="pmid">15017231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wylie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davies-South</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Structured Self-Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie's Disease.</article-title>
            <source>Adv Urol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>957013</fpage>
            <pub-id pub-id-type="pmid">24803927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Stasi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Giannantoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jannini</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Storti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vespasiani</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>9</issue>
            <fpage>825</fpage>
            <page-range>825-9</page-range>
            <pub-id pub-id-type="pmid">12780842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuygun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ozok</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Gucuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Imamoglu</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2009</year>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-8</page-range>
            <pub-id pub-id-type="pmid">18592390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guazzoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brausi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scattoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rigatti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pizzini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.</article-title>
            <source>J Androl</source>
            <year>2000</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">10670523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r131">
          <label>131</label>
          <element-citation publication-type="book">
            <source>The Use of the Electromotive Drug Administration System in Patients with Overactive Bladder: A Review of the Clinical Effectiveness, Safety, and Cost-Effectiveness [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2014</year>
            <month>09</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">25392902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garrido Abad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coloma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herranz</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Formoso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Arjona</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Transdermal iontophoresis with verapamil and dexamethasone in the acute phase of peyronie's disease. Our experience.</article-title>
            <source>Arch Esp Urol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>8</issue>
            <fpage>745</fpage>
            <page-range>745-51</page-range>
            <pub-id pub-id-type="pmid">23117682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kagioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garaffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shamsodini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sadeghi-Nejad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Management Guidelines on Peyronie's Disease.</article-title>
            <source>J Sex Med</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>905</fpage>
            <page-range>905-23</page-range>
            <pub-id pub-id-type="pmid">27215686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Incrocci</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Radiation therapy in Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>1435</fpage>
            <page-range>1435-41</page-range>
            <pub-id pub-id-type="pmid">22781084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pietsch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Anzeneder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bruckbauer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zirbs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutermuth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hofmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brockow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Biedermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eberlein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Superficial radiation therapy in peyronie's disease: An effective and well-tolerated therapy.</article-title>
            <source>Adv Radiat Oncol</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>548</fpage>
            <page-range>548-551</page-range>
            <pub-id pub-id-type="pmid">30370354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sangkum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic advances in the treatment of Peyronie's disease.</article-title>
            <source>Andrology</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>650</fpage>
            <page-range>650-60</page-range>
            <pub-id pub-id-type="pmid">26097120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furlow</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Swenson</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy.</article-title>
            <source>J Urol</source>
            <year>1975</year>
            <month>Jul</month>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-71</page-range>
            <pub-id pub-id-type="pmid">1142503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaeffer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Nonsurgical interventions for Peyronie disease: 2011 update.</article-title>
            <source>J Androl</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">21350241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kozub</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suleja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ch&#x00142;osta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kupilas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miszczyk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current trends in non-surgical management of Peyronie's disease-A narrative review.</article-title>
            <source>Andrology</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>505</fpage>
            <page-range>505-517</page-range>
            <pub-id pub-id-type="pmid">37593783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosentino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Nauta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferraioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lucignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ricapito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gadda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iafrate</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dal Moro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruiz-Casta&#x000f1;e</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bettocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sofikitis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Conservative treatment of Peyronie's disease: a guide.</article-title>
            <source>World J Urol</source>
            <year>2024</year>
            <month>May</month>
            <day>13</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>317</fpage>
            <pub-id pub-id-type="pmid">38740620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r141">
          <label>141</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cacciatore</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Presicce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iannuzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Testa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papalia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarpa</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Esperto</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Intralesional and topical treatments for Peyronie's disease: a narrative review of current knowledge.</article-title>
            <source>Asian J Androl</source>
            <year>2024</year>
            <month>Aug</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">39177048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bettocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cilesiz</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dimitropoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>G&#x000fc;l</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez Salamanca</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Milenkovic</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Modgil</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Serefoglu</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Tharakan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <collab>EAU Working Group on Male Sexual and Reproductive Health</collab>
            </person-group>
            <article-title>European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility.</article-title>
            <source>Eur Urol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>603</fpage>
            <page-range>603-620</page-range>
            <pub-id pub-id-type="pmid">34511305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ergun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Risk</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dahm</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Non-surgical therapies for Peyronie's disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2023</year>
            <month>Jul</month>
            <day>17</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD012206</fpage>
            <pub-id pub-id-type="pmid">37490423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease intervention trials: methodological challenges and issues.</article-title>
            <source>J Sex Med</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>848</fpage>
            <page-range>848-61</page-range>
            <pub-id pub-id-type="pmid">19138374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Pyun</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Medical Treatment for Peyronie's Disease: Systematic Review and Network Bayesian Meta-Analysis.</article-title>
            <source>World J Mens Health</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-147</page-range>
            <pub-id pub-id-type="pmid">37382281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarinejad</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kolahi</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study.</article-title>
            <source>J Urol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>178</volume>
            <issue>4 Pt 1</issue>
            <fpage>1398</fpage>
            <page-range>1398-403; discussion 1403</page-range>
            <pub-id pub-id-type="pmid">17706714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teloken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rhoden</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Grazziotin</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Sogari</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Souto</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Tamoxifen versus placebo in the treatment of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>162</volume>
            <issue>6</issue>
            <fpage>2003</fpage>
            <page-range>2003-5</page-range>
            <pub-id pub-id-type="pmid">10569556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oosterlinck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Renders</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Peyronie's disease with procarbazine.</article-title>
            <source>Br J Urol</source>
            <year>1975</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-20</page-range>
            <pub-id pub-id-type="pmid">1148623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Schnitker</surname>
                <given-names>J</given-names>
              </name>
              <collab>Peyronie's Disease Study Group of Andrological Group of German Urologists</collab>
            </person-group>
            <article-title>Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study.</article-title>
            <source>Eur Urol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>530</fpage>
            <page-range>530-5; discussion 535-6</page-range>
            <pub-id pub-id-type="pmid">15774254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?</article-title>
            <source>Tech Urol</source>
            <year>1997</year>
            <season>Fall</season>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-9</page-range>
            <pub-id pub-id-type="pmid">9422444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r151">
          <label>151</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarinejad</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kolahi</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Expression of Concern: Comparison of Vitamin E and Propionyl-L-Carnitine, Separately or in Combination, in Patients With Early Chronic Peyronie's Disease: A Double-Blind, Placebo Controlled, Randomized Study.</article-title>
            <source>J Urol</source>
            <year>2023</year>
            <month>Jan</month>
            <day>10</day>
            <fpage>101097JU0000000000003118</fpage>
            <pub-id pub-id-type="pmid">36626346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Full Regression of Peyronie's Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report.</article-title>
            <source>Antioxidants (Basel)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>26</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">36139736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r153">
          <label>153</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fabiani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.</article-title>
            <source>Res Rep Urol</source>
            <year>2017</year>
            <volume>9</volume>
            <fpage>129</fpage>
            <page-range>129-139</page-range>
            <pub-id pub-id-type="pmid">28791261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Disappearance of Plaque Following Treatment with Antioxidants in Peyronie's Disease Patients-A Report of 3 Cases.</article-title>
            <source>Clin Pract</source>
            <year>2022</year>
            <month>Dec</month>
            <day>09</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1020</fpage>
            <page-range>1020-1033</page-range>
            <pub-id pub-id-type="pmid">36547113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarinejad</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study.</article-title>
            <source>Int J Impot Res</source>
            <year>2010</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>298</fpage>
            <page-range>298-309</page-range>
            <pub-id pub-id-type="pmid">20720560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r156">
          <label>156</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Keenaghan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Coenzyme Q10</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30285386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tienforti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoxha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Pasquale</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Rizza</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barbonetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Analysis of evidence on nutraceutical interventions for Peyronie's disease: a guideline-based critical review.</article-title>
            <source>Sex Med Rev</source>
            <year>2024</year>
            <month>Sep</month>
            <day>25</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>747</fpage>
            <page-range>747-753</page-range>
            <pub-id pub-id-type="pmid">38807529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r158">
          <label>158</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shankey</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Lubrano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents.</article-title>
            <source>Int J Impot Res</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>12 Suppl 3</volume>
            <fpage>S25</fpage>
            <page-range>S25-31</page-range>
            <pub-id pub-id-type="pmid">11002396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akkus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Breza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Is colchicine effective in Peyronie's disease? A pilot study.</article-title>
            <source>Urology</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-5</page-range>
            <pub-id pub-id-type="pmid">8048212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r160">
          <label>160</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarinejad</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study.</article-title>
            <source>Int J Impot Res</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-43</page-range>
            <pub-id pub-id-type="pmid">14973528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r161">
          <label>161</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tefekli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ksal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome.</article-title>
            <source>Int J Impot Res</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-75</page-range>
            <pub-id pub-id-type="pmid">11045911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r162">
          <label>162</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto Castro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Leva Vallejo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Regueiro Lopez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Anglada Curado</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Alvarez Kindelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Requena Tapia</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>522</fpage>
            <page-range>522-4</page-range>
            <pub-id pub-id-type="pmid">12656907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r163">
          <label>163</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Uluocak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akbulut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nane</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side.</article-title>
            <source>Andrologia</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-33</page-range>
            <pub-id pub-id-type="pmid">21219379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r164">
          <label>164</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: a difficult sexual dysfunction problem.</article-title>
            <source>West J Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>169</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-9</page-range>
            <pub-id pub-id-type="pmid">9771158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r165">
          <label>165</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sadiq</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Colchicine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">28613754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r166">
          <label>166</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Banie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline attenuates transforming growth factor-&#x003b2;1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.</article-title>
            <source>J Sex Med</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>2077</fpage>
            <page-range>2077-2085</page-range>
            <pub-id pub-id-type="pmid">20367772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r167">
          <label>167</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Banie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1.</article-title>
            <source>J Sex Med</source>
            <year>2010</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>1787</fpage>
            <page-range>1787-97</page-range>
            <pub-id pub-id-type="pmid">20384945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r168">
          <label>168</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Annamaraju</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baradhi</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <chapter-title>Pentoxifylline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">32644522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r169">
          <label>169</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Clavijo</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Flechner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Breyer</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.</article-title>
            <source>Asian J Androl</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>322</fpage>
            <page-range>322-5</page-range>
            <pub-id pub-id-type="pmid">21102473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r170">
          <label>170</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alizadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fallah</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline.</article-title>
            <source>Glob J Health Sci</source>
            <year>2014</year>
            <month>Sep</month>
            <day>18</day>
            <volume>6</volume>
            <issue>7 Spec No</issue>
            <fpage>23</fpage>
            <page-range>23-30</page-range>
            <pub-id pub-id-type="pmid">25363175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r171">
          <label>171</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gazzard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alharbi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rompr&#x000e9;-Brodeur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease.</article-title>
            <source>Sex Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-463</page-range>
            <pub-id pub-id-type="pmid">31445974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r172">
          <label>172</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brant</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Peyronie's disease with oral pentoxifylline.</article-title>
            <source>Nat Clin Pract Urol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-5; quiz 116</page-range>
            <pub-id pub-id-type="pmid">16470210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r173">
          <label>173</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vitarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dachille</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fabiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gennaro</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.</article-title>
            <source>Res Rep Urol</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">26770906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r174">
          <label>174</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kayes</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in managing Peyronie's disease.</article-title>
            <source>F1000Res</source>
            <year>2020</year>
            <volume>9</volume>
            <pub-id pub-id-type="pmid">32518629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r175">
          <label>175</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imbimbo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Creta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.</article-title>
            <source>Int J Androl</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-5</page-range>
            <pub-id pub-id-type="pmid">22085227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r176">
          <label>176</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozturk</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Yesil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goktug</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Gucuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tuygun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sener</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Nalbant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Imamoglu</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.</article-title>
            <source>Ir J Med Sci</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>183</volume>
            <issue>3</issue>
            <fpage>449</fpage>
            <page-range>449-53</page-range>
            <pub-id pub-id-type="pmid">24190613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r177">
          <label>177</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spirito</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Rocca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Girolamo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trama</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sciorio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sokolakis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Creta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arcaniolo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis.</article-title>
            <source>Int J Impot Res</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-134</page-range>
            <pub-id pub-id-type="pmid">36513814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r178">
          <label>178</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Deyoung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes.</article-title>
            <source>J Sex Med</source>
            <year>2011</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1472</fpage>
            <page-range>1472-7</page-range>
            <pub-id pub-id-type="pmid">21324095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r179">
          <label>179</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Shaiji</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: evolving surgical management and the role of phosphodiesterase 5 inhibitors.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2009</year>
            <month>Aug</month>
            <day>31</day>
            <volume>9</volume>
            <fpage>822</fpage>
            <page-range>822-45</page-range>
            <pub-id pub-id-type="pmid">19734958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r180">
          <label>180</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Urz&#x000ec;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cacciamani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Polito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giammusso</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morgia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mondaini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil 25 mg ODT&#x000a0;+ Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.</article-title>
            <source>J Sex Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1472</fpage>
            <page-range>1472-1477</page-range>
            <pub-id pub-id-type="pmid">30245025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r181">
          <label>181</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsertsvadze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yazdi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bella</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Garritty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2009</year>
            <month>Nov</month>
            <day>03</day>
            <volume>151</volume>
            <issue>9</issue>
            <fpage>650</fpage>
            <page-range>650-61</page-range>
            <pub-id pub-id-type="pmid">19884626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r182">
          <label>182</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kovanecz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nolazco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>625</fpage>
            <page-range>625-33</page-range>
            <pub-id pub-id-type="pmid">16469038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r183">
          <label>183</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilg</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mateus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bustin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Muneer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bivalacqua</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cellek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.</article-title>
            <source>J Sex Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1848</fpage>
            <page-range>1848-1864</page-range>
            <pub-id pub-id-type="pmid">32771352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r184">
          <label>184</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vernet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Magee</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bou-Gharios</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.</article-title>
            <source>Nitric Oxide</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>262</fpage>
            <page-range>262-76</page-range>
            <pub-id pub-id-type="pmid">12446175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r185">
          <label>185</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valente</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Vernet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.</article-title>
            <source>Nitric Oxide</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-44</page-range>
            <pub-id pub-id-type="pmid">14996430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r186">
          <label>186</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilg</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cellek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2023</year>
            <month>Jun</month>
            <day>28</day>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>925</fpage>
            <page-range>925-934</page-range>
            <pub-id pub-id-type="pmid">37082866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r187">
          <label>187</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>du G</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.</article-title>
            <source>World J Mens Health</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">27169128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r188">
          <label>188</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shindel</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Bullock</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Urologist practice patterns in the management of Peyronie's disease: a nationwide survey.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>954</fpage>
            <page-range>954-964</page-range>
            <pub-id pub-id-type="pmid">18042214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r189">
          <label>189</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pyrgidis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Sokolakis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dimitriadis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mykoniatis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Conservative Combination Therapies for Active and Stable Peyronie's Disease: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol Focus</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1520</fpage>
            <page-range>1520-1530</page-range>
            <pub-id pub-id-type="pmid">34924336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r190">
          <label>190</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Medina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Vitamin E</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32491669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r191">
          <label>191</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Shockwave Therapy in Peyronie's Disease: Systematic Review and Meta-Analysis.</article-title>
            <source>J Sex Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>1705</fpage>
            <page-range>1705-1714</page-range>
            <pub-id pub-id-type="pmid">34511369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r192">
          <label>192</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imbimbo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mangiapia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Creta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease.</article-title>
            <source>Eur Urol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>363</fpage>
            <page-range>363-9</page-range>
            <pub-id pub-id-type="pmid">19473751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r193">
          <label>193</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chitale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morsey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swift</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sethia</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>106</volume>
            <issue>9</issue>
            <fpage>1352</fpage>
            <page-range>1352-6</page-range>
            <pub-id pub-id-type="pmid">20438568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r194">
          <label>194</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meisner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gschwend</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lahme</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study.</article-title>
            <source>J Sex Med</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>2815</fpage>
            <page-range>2815-21</page-range>
            <pub-id pub-id-type="pmid">23898925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r195">
          <label>195</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>161</fpage>
            <page-range>161-6</page-range>
            <pub-id pub-id-type="pmid">27250868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r196">
          <label>196</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lynn</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience.</article-title>
            <source>BJU Int</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>466</fpage>
            <page-range>466-8</page-range>
            <pub-id pub-id-type="pmid">10971273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r197">
          <label>197</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strebel</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sautter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hauri</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity.</article-title>
            <source>Int J Impot Res</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>448</fpage>
            <page-range>448-51</page-range>
            <pub-id pub-id-type="pmid">14973523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r198">
          <label>198</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rassweiler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Scheitlin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Goezen</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Radecke</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Long-term experiences with high-energy shock wave therapy in the management chronic phase Peyronie's disease using two different electromagnetic lithotripters.</article-title>
            <source>World J Urol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>07</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>124</fpage>
            <pub-id pub-id-type="pmid">38453751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r199">
          <label>199</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Mauro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Della Camera</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mondaini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gacci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study.</article-title>
            <source>World J Mens Health</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>339</fpage>
            <page-range>339-346</page-range>
            <pub-id pub-id-type="pmid">30929330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r200">
          <label>200</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis.</article-title>
            <source>BMC Urol</source>
            <year>2023</year>
            <month>Sep</month>
            <day>12</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <pub-id pub-id-type="pmid">37700253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r201">
          <label>201</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mesquita</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>TFN</given-names>
              </name>
              <name>
                <surname>Velasquez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Favorito</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dornbush</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petrella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evidence of restorative therapies in the treatment of Peyronie disease: A narrative review.</article-title>
            <source>Int Braz J Urol</source>
            <year>2024</year>
            <season>Nov-Dec</season>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>703</fpage>
            <page-range>703-713</page-range>
            <pub-id pub-id-type="pmid">39133793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r202">
          <label>202</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krieger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Pastuszak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Shockwave Therapy in the Treatment of Peyronie's Disease.</article-title>
            <source>Sex Med Rev</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-507</page-range>
            <pub-id pub-id-type="pmid">30926460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r203">
          <label>203</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdessater</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akakpo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kanbar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seisen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chartier-Kastler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Drouin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Roupret</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.</article-title>
            <source>Asian J Androl</source>
            <year>2022</year>
            <season>Jan-Feb</season>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-49</page-range>
            <pub-id pub-id-type="pmid">34045390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r204">
          <label>204</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akin-Olugbade</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Deveci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donohue</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kobylarz</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Palese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>635</fpage>
            <page-range>635-42</page-range>
            <pub-id pub-id-type="pmid">17618733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r205">
          <label>205</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khooblall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bole</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lundy</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bajic</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Expanded Utilization of Intralesional Therapies for Treatment of Peyronie's Disease.</article-title>
            <source>Res Rep Urol</source>
            <year>2023</year>
            <volume>15</volume>
            <fpage>205</fpage>
            <page-range>205-216</page-range>
            <pub-id pub-id-type="pmid">37366388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r206">
          <label>206</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Heslop</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Houlihan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bajic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Helo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Influence of Indentation Deformity on Outcomes With Intralesional Collagenase Clostridium Histolyticum Monotherapy for Peyronie's Disease.</article-title>
            <source>Urology</source>
            <year>2020</year>
            <month>May</month>
            <volume>139</volume>
            <fpage>122</fpage>
            <page-range>122-128</page-range>
            <pub-id pub-id-type="pmid">32057793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r207">
          <label>207</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>AFY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Pandemic aspect of dexamethasone: Molecular mechanisms and clinical application.</article-title>
            <source>J Chin Med Assoc</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-247</page-range>
            <pub-id pub-id-type="pmid">33433137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r208">
          <label>208</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Dexamethasone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">29489240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r209">
          <label>209</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatampour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sohrabi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazdak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghadimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Salehi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kazemi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.</article-title>
            <source>Am J Clin Exp Urol</source>
            <year>2022</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">35291415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r210">
          <label>210</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ocejo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Methylprednisolone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31335060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r211">
          <label>211</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ure</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: A single-centre, preliminary prospective non-randomised study.</article-title>
            <source>Int J Clin Pract</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>e13754</fpage>
            <pub-id pub-id-type="pmid">33058393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r212">
          <label>212</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelbard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tursi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>190</volume>
            <issue>1</issue>
            <fpage>199</fpage>
            <page-range>199-207</page-range>
            <pub-id pub-id-type="pmid">23376148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r213">
          <label>213</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jordan</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>180</fpage>
            <page-range>180-7</page-range>
            <pub-id pub-id-type="pmid">18173766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r214">
          <label>214</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nackeeran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Masterson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Penile Fracture After Intralesional Collagenase Clostridium histolyticum in Peyronie's Disease.</article-title>
            <source>Urology</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>183</volume>
            <fpage>117</fpage>
            <page-range>117-120</page-range>
            <pub-id pub-id-type="pmid">37949243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r215">
          <label>215</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flores</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Punjani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salter</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bernie</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schofield</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Predictors of Curvature Improvement in Men With Peyronie's Disease Treated With Intralesional Collagenase Clostridium Histolyticum.</article-title>
            <source>J Sex Med</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1680</fpage>
            <page-range>1680-1686</page-range>
            <pub-id pub-id-type="pmid">36127227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r216">
          <label>216</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wymer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Plaque Calcification: An Important Predictor of Collagenase Clostridium Histolyticum Treatment Outcomes for Men With Peyronie's Disease.</article-title>
            <source>Urology</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>119</volume>
            <fpage>109</fpage>
            <page-range>109-114</page-range>
            <pub-id pub-id-type="pmid">29908867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r217">
          <label>217</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Atuluru</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zucker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nackeeran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kava</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie's Disease with Calcified Plaques.</article-title>
            <source>Eur Urol Focus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-59</page-range>
            <pub-id pub-id-type="pmid">36272924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r218">
          <label>218</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burgon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Helo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Continuing Collagenase Clostridium Histolyticum Injections Among Initial Nonresponders Results in Significant Curvature Improvements in the Majority of Peyronie's Disease Men.</article-title>
            <source>J Sex Med</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>1092</fpage>
            <page-range>1092-1098</page-range>
            <pub-id pub-id-type="pmid">34020925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r219">
          <label>219</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Sigalos</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Yoffe</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Modiri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Gaither</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Santamaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Regets</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Eleswarapu</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis.</article-title>
            <source>J Sex Med</source>
            <year>2023</year>
            <month>Feb</month>
            <day>14</day>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-204</page-range>
            <pub-id pub-id-type="pmid">36763912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r220">
          <label>220</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel Raheem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalejaiye</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abdel-Raheem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Garaffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Christopher</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.</article-title>
            <source>BJU Int</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>717</fpage>
            <page-range>717-723</page-range>
            <pub-id pub-id-type="pmid">28612401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r221">
          <label>221</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Licht</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Modified Nesbit procedure for the treatment of Peyronie's disease: a comparative outcome analysis.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>158</volume>
            <issue>2</issue>
            <fpage>460</fpage>
            <page-range>460-3</page-range>
            <pub-id pub-id-type="pmid">9224323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r222">
          <label>222</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelbard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorey</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-8</page-range>
            <pub-id pub-id-type="pmid">8417217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r223">
          <label>223</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel Raheem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdel-Raheem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.</article-title>
            <source>Sex Med Rev</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-535</page-range>
            <pub-id pub-id-type="pmid">28874327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r224">
          <label>224</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhillon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>75</volume>
            <issue>12</issue>
            <fpage>1405</fpage>
            <page-range>1405-12</page-range>
            <pub-id pub-id-type="pmid">26201462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r225">
          <label>225</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>780956</fpage>
            <pub-id pub-id-type="pmid">35252236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r226">
          <label>226</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipshultz</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Seftel</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tursi</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.</article-title>
            <source>BJU Int</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>650</fpage>
            <page-range>650-6</page-range>
            <pub-id pub-id-type="pmid">25711400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r227">
          <label>227</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJG</given-names>
              </name>
              <name>
                <surname>Tue Nguyen</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Alzweri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Virasoro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tapscott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gelbard</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>201</volume>
            <issue>4</issue>
            <fpage>777</fpage>
            <page-range>777-782</page-range>
            <pub-id pub-id-type="pmid">30672843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r228">
          <label>228</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saffati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naeem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lipshultz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Satisfaction With Collagenase Clostridium Histolyticum for Peyronie's Disease: Clinical Predictors and Side Effect Profile.</article-title>
            <source>Urol Pract</source>
            <year>2024</year>
            <month>Sep</month>
            <day>03</day>
            <fpage>101097UPJ0000000000000696</fpage>
            <pub-id pub-id-type="pmid">39241009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r229">
          <label>229</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Garc&#x000ed;a</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Angulo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cerezo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Turo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Ballesteros</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carballido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Salamanca</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling.</article-title>
            <source>BJU Int</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>124</volume>
            <issue>6</issue>
            <fpage>1055</fpage>
            <page-range>1055-1062</page-range>
            <pub-id pub-id-type="pmid">31033130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r230">
          <label>230</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HMT</given-names>
              </name>
              <name>
                <surname>Yousif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Virasoro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tapscott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gelbard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJG</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional Analysis.</article-title>
            <source>Urology</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>145</volume>
            <fpage>147</fpage>
            <page-range>147-151</page-range>
            <pub-id pub-id-type="pmid">32777367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r231">
          <label>231</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Francesco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Mauro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polloni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martinez-Salamanca</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mondaini</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Collagenase Clostridium histolyticum (Xiapex<sup>&#x000ae;</sup>) in Patients with the Acute Phase of Peyronie's Disease.</article-title>
            <source>Clin Drug Investig</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>583</fpage>
            <page-range>583-588</page-range>
            <pub-id pub-id-type="pmid">32342279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r232">
          <label>232</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Collagenase Clostridium Histolyticum in Peyronie's Disease Men With Ventral Curvatures.</article-title>
            <source>Urology</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>129</volume>
            <fpage>119</fpage>
            <page-range>119-125</page-range>
            <pub-id pub-id-type="pmid">30910455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r233">
          <label>233</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Khatib</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Towe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.</article-title>
            <source>World J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">31093703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r234">
          <label>234</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HMT</given-names>
              </name>
              <name>
                <surname>Anaissie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeLay</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJG</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.</article-title>
            <source>J Sex Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1220</fpage>
            <page-range>1220-1225</page-range>
            <pub-id pub-id-type="pmid">28874331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r235">
          <label>235</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.</article-title>
            <source>J Sex Med</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>259</fpage>
            <page-range>259-64</page-range>
            <pub-id pub-id-type="pmid">25345351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r236">
          <label>236</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Djinovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Romero-Otero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Egydio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Preto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiriac&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cacciamani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salamanca</surname>
                <given-names>JIM</given-names>
              </name>
              <name>
                <surname>Mondani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie's disease in a multicenter clinical study.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Jan</month>
            <day>08</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>166</fpage>
            <pub-id pub-id-type="pmid">33420247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r237">
          <label>237</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avant</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Penile Traction Therapy and Vacuum Erection Devices in Peyronie's Disease.</article-title>
            <source>Sex Med Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>338</fpage>
            <page-range>338-348</page-range>
            <pub-id pub-id-type="pmid">29631979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r238">
          <label>238</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abern</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>288</fpage>
            <page-range>288-95</page-range>
            <pub-id pub-id-type="pmid">22024053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r239">
          <label>239</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Toussi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.</article-title>
            <source>J Sex Med</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>891</fpage>
            <page-range>891-900</page-range>
            <pub-id pub-id-type="pmid">30956106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r240">
          <label>240</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-G&#x000f3;mez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Rojo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alonso-Isa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medina-Polo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santos-P&#x000e9;rez de la Blanca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Justo-Quintas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parnham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Antol&#x000ed;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romero-Otero</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study.</article-title>
            <source>Int J Impot Res</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-331</page-range>
            <pub-id pub-id-type="pmid">32366987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r241">
          <label>241</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sangkum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ates</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>194</volume>
            <issue>3</issue>
            <fpage>754</fpage>
            <page-range>754-8</page-range>
            <pub-id pub-id-type="pmid">25804087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r242">
          <label>242</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature.</article-title>
            <source>World J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-285</page-range>
            <pub-id pub-id-type="pmid">31250098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r243">
          <label>243</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes.</article-title>
            <source>J Sex Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>1005</fpage>
            <page-range>1005-1011</page-range>
            <pub-id pub-id-type="pmid">32127330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r244">
          <label>244</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel Raheem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garaffa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.</article-title>
            <source>Minerva Urol Nefrol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>380</fpage>
            <page-range>380-385</page-range>
            <pub-id pub-id-type="pmid">29761688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r245">
          <label>245</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shiff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bal</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Southall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blachman-Braun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grenier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flannigan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Insurance approval rates for collagenase clostridium histolyticum prior to discontinuation: a Canada-wide analysis.</article-title>
            <source>Int J Impot Res</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>581</fpage>
            <page-range>581-587</page-range>
            <pub-id pub-id-type="pmid">37626201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r246">
          <label>246</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goulas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papakonstantinou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karakiulakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mirtsou-Fidani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kalinderis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hatzichristou</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Tissue structure-specific distribution of glycosaminoglycans in the human penis.</article-title>
            <source>Int J Biochem Cell Biol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>975</fpage>
            <page-range>975-82</page-range>
            <pub-id pub-id-type="pmid">11084377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r247">
          <label>247</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teloken</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Medical Management of Peyronie's Disease: Review of the Clinical Evidence.</article-title>
            <source>Med Sci (Basel)</source>
            <year>2019</year>
            <month>Sep</month>
            <day>18</day>
            <volume>7</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31540526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r248">
          <label>248</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costantini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cavallini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liguori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Favilla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Grande</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Achille</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Silvani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study.</article-title>
            <source>Sex Med</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>e83</fpage>
            <page-range>e83-8</page-range>
            <pub-id pub-id-type="pmid">26984291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r249">
          <label>249</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Favilla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Zucchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siracusa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Privitera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Madonia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cavallini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liguori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Achille</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Silvani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torrisi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mirone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Morgia</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study.</article-title>
            <source>Andrology</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>771</fpage>
            <page-range>771-775</page-range>
            <pub-id pub-id-type="pmid">28718527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r250">
          <label>250</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gennaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1595</fpage>
            <page-range>1595-602</page-range>
            <pub-id pub-id-type="pmid">26257044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r251">
          <label>251</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schifano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Capogrosso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scroppo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zerbinati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Deh&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The Application of Hyaluronic Acid Injections in Functional and Aesthetic Andrology: A Narrative Review.</article-title>
            <source>Gels</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36826290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r252">
          <label>252</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cilio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rocca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Celentano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Creta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Califano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>M</given-names>
              </name>
              <collab>YAU Working Group Sexual and Reproductive Health</collab>
            </person-group>
            <article-title>Intraplaque injections of hyaluronic acid for the treatment of stable-phase Peyronie's disease: a retrospective single-center experience.</article-title>
            <source>Asian J Androl</source>
            <year>2024</year>
            <month>May</month>
            <day>01</day>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-271</page-range>
            <pub-id pub-id-type="pmid">38305689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r253">
          <label>253</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tiscione</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Favilla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puglisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zucchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malossini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bjerklund Johansen</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Oral Administration and Intralesional Injection of Hyaluronic Acid <italic>Versus</italic> Intralesional Injection Alone in Peyronie's Disease: Results from a Phase III Study.</article-title>
            <source>World J Mens Health</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>526</fpage>
            <page-range>526-532</page-range>
            <pub-id pub-id-type="pmid">33151042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r254">
          <label>254</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verrienti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laruccia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Campi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Mauro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Falcone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cacciamani</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Garaffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Intralesional Hyaluronic Acid <italic>vs</italic>. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study.</article-title>
            <source>World J Mens Health</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-357</page-range>
            <pub-id pub-id-type="pmid">32009312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r255">
          <label>255</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Hammad</surname>
                <given-names>MAM</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Abou Chawareb</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Banton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SSH</given-names>
              </name>
              <name>
                <surname>Perito</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Raheem</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronic acid and urology: a systematic review and meta-analysis.</article-title>
            <source>Sex Med Rev</source>
            <year>2024</year>
            <month>Sep</month>
            <day>06</day>
            <pub-id pub-id-type="pmid">39238469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r256">
          <label>256</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Knoedler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mandava</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>McCaslin</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Sangkum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Intralesional Injection of Interferon-&#x003b1;2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>194</volume>
            <issue>6</issue>
            <fpage>1704</fpage>
            <page-range>1704-7</page-range>
            <pub-id pub-id-type="pmid">26144333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r257">
          <label>257</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kendirci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cockerham</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Venable</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Honig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Nehra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Templeton</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Pryor</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>176</volume>
            <issue>1</issue>
            <fpage>394</fpage>
            <page-range>394-8</page-range>
            <pub-id pub-id-type="pmid">16753449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r258">
          <label>258</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacy</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Intralesional interferon-alpha-2b for the treatment of Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>336</fpage>
            <page-range>336-9</page-range>
            <pub-id pub-id-type="pmid">12454683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r259">
          <label>259</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Cacciamani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cocci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Morgia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serefoglu</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Albersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verze</surname>
                <given-names>P</given-names>
              </name>
              <collab>EAU-YAU Men&#x02019;s Health Working Group</collab>
            </person-group>
            <article-title>Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>J Sex Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-299</page-range>
            <pub-id pub-id-type="pmid">30692028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r260">
          <label>260</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokhal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Jhanwar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Prospective study to evaluate the clinical outcome of intralesional interferon-&#x003b1;2b in the management of Peyronie's disease.</article-title>
            <source>Urol Ann</source>
            <year>2018</year>
            <season>Apr-Jun</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-158</page-range>
            <pub-id pub-id-type="pmid">29719326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r261">
          <label>261</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trost</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Ates</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of intralesional interferon-&#x003b1;2B for the treatment of Peyronie disease.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>190</volume>
            <issue>6</issue>
            <fpage>2194</fpage>
            <page-range>2194-9</page-range>
            <pub-id pub-id-type="pmid">23688848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r262">
          <label>262</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duncan</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nseyo</surname>
                <given-names>UO</given-names>
              </name>
            </person-group>
            <article-title>Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma.</article-title>
            <source>Scand J Urol Nephrol</source>
            <year>1991</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-94</page-range>
            <pub-id pub-id-type="pmid">1651559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r263">
          <label>263</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kendirci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Matern</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Nowfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sikka</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease.</article-title>
            <source>J Sex Med</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>709</fpage>
            <page-range>709-15</page-range>
            <pub-id pub-id-type="pmid">16422829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r264">
          <label>264</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>El-Khatib</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Yafi</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Intralesional Injection Therapy and Atypical Peyronie's Disease: A Systematic Review.</article-title>
            <source>Sex Med Rev</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>434</fpage>
            <page-range>434-444</page-range>
            <pub-id pub-id-type="pmid">32660728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r265">
          <label>265</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eickelberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1996</year>
            <month>May</month>
            <day>28</day>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>5478</fpage>
            <page-range>5478-82</page-range>
            <pub-id pub-id-type="pmid">8643600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r266">
          <label>266</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.</article-title>
            <source>Urology</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>620</fpage>
            <page-range>620-6</page-range>
            <pub-id pub-id-type="pmid">9586617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r267">
          <label>267</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haghpanah</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Badiee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afrasiabi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Haghpanah</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2009</year>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>467</fpage>
            <page-range>467-71</page-range>
            <pub-id pub-id-type="pmid">19199072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r268">
          <label>268</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toscano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rezende</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Mello</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Paulillo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study.</article-title>
            <source>Int Braz J Urol</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>1005</fpage>
            <page-range>1005-1009</page-range>
            <pub-id pub-id-type="pmid">24893912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r269">
          <label>269</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intralesional collagenase <italic>Clostridium histolyticum</italic> vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.</article-title>
            <source>Investig Clin Urol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>563</fpage>
            <page-range>563-568</page-range>
            <pub-id pub-id-type="pmid">36068002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r270">
          <label>270</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reale</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The palmar fascia after treatment by the continuous extension technique for Dupuytren's contracture.</article-title>
            <source>J Hand Surg Br</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>528</fpage>
            <page-range>528-33</page-range>
            <pub-id pub-id-type="pmid">7964108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r271">
          <label>271</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tarlton</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Van der Stappen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The continuous elongation technique for severe Dupuytren's disease. A biochemical mechanism.</article-title>
            <source>J Hand Surg Br</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>522</fpage>
            <page-range>522-7</page-range>
            <pub-id pub-id-type="pmid">7964107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r272">
          <label>272</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The use of skeletal traction in the treatment of severe primary Dupuytren's disease.</article-title>
            <source>J Bone Joint Surg Br</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-9</page-range>
            <pub-id pub-id-type="pmid">9460968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r273">
          <label>273</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurst</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Badalamente</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Nonoperative treatment of Dupuytren's disease.</article-title>
            <source>Hand Clin</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-107, vii</page-range>
            <pub-id pub-id-type="pmid">10050246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r274">
          <label>274</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chernylovskyi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Krakhotkin</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Chaikovskyi</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>NON-SURGICAL TREATMENT OF PEYRONIE'S DISEASE: A COMPREHENSIVE REVIEW.</article-title>
            <source>Wiad Lek</source>
            <year>2021</year>
            <volume>74</volume>
            <issue>3 cz 1</issue>
            <fpage>539</fpage>
            <page-range>539-545</page-range>
            <pub-id pub-id-type="pmid">33813465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r275">
          <label>275</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moncada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krishnappa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Torremade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fraile</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez-Salamanca</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Porst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study.</article-title>
            <source>BJU Int</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>694</fpage>
            <page-range>694-702</page-range>
            <pub-id pub-id-type="pmid">30365247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r276">
          <label>276</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez-Salamanca</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Egui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moncada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Minaya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ballesteros</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Del Portillo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sola</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Carballido</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation.</article-title>
            <source>J Sex Med</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>506</fpage>
            <page-range>506-15</page-range>
            <pub-id pub-id-type="pmid">24261900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r277">
          <label>277</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almsaoud</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Safar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alshahrani</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Alwadai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alkhaldi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Almurayyi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alrweili</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Assiri</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al Jubran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hakami</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The effect of penile traction device in men with Peyronie's disease on penile curvature, penile length, and erectile dysfunction: a systematic review and meta-analysis.</article-title>
            <source>Transl Androl Urol</source>
            <year>2023</year>
            <month>Nov</month>
            <day>30</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>1673</fpage>
            <page-range>1673-1685</page-range>
            <pub-id pub-id-type="pmid">38106680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r278">
          <label>278</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joseph</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hler</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of RestoreX Penile Traction Therapy in Men With Peyronie's Disease: Results From Open Label and Follow-up Phases.</article-title>
            <source>J Sex Med</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>2462</fpage>
            <page-range>2462-2471</page-range>
            <pub-id pub-id-type="pmid">33223425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r279">
          <label>279</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toussi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trost</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>202</volume>
            <issue>3</issue>
            <fpage>599</fpage>
            <page-range>599-610</page-range>
            <pub-id pub-id-type="pmid">30916626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r280">
          <label>280</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gontero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Marco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giubilei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pappagallo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tizzani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mondaini</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study.</article-title>
            <source>J Sex Med</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-66</page-range>
            <pub-id pub-id-type="pmid">19138361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r281">
          <label>281</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Newell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>1468</fpage>
            <page-range>1468-73</page-range>
            <pub-id pub-id-type="pmid">18373527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r282">
          <label>282</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capoccia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emmerson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lankford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ofori-Marfoh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Long-term patient-reported outcomes in men with Peyronie's disease undergoing nonsurgical and nonintralesional injection management.</article-title>
            <source>Int J Impot Res</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">31988423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r283">
          <label>283</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bole</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Helo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A modern review of penile traction monotherapy and combination therapy for the treatment of peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-258</page-range>
            <pub-id pub-id-type="pmid">32152467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r284">
          <label>284</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-G&#x000f3;mez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aversa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alonso-Isa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parnham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serefoglu</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Corona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bettocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reisman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Skrodzka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romero-Otero</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Use of Penile Traction Devices for Peyronie's Disease: Position Statements from the European Society for Sexual Medicine.</article-title>
            <source>Sex Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>100387</fpage>
            <pub-id pub-id-type="pmid">34273788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r285">
          <label>285</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Badwan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulhall</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>168</volume>
            <issue>6</issue>
            <fpage>2483</fpage>
            <page-range>2483-5</page-range>
            <pub-id pub-id-type="pmid">12441945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r286">
          <label>286</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitch</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Easterling</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Talbert</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bordovsky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mosier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study.</article-title>
            <source>J Sex Med</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>477</fpage>
            <page-range>477-84</page-range>
            <pub-id pub-id-type="pmid">17367443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r287">
          <label>287</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model.</article-title>
            <source>J Sex Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1270</fpage>
            <page-range>1270-1276</page-range>
            <pub-id pub-id-type="pmid">28923308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r288">
          <label>288</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raheem</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Garaffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raheem</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kayes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Christopher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>8</issue>
            <fpage>1178</fpage>
            <page-range>1178-80</page-range>
            <pub-id pub-id-type="pmid">20438558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r289">
          <label>289</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacDonald</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Acker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Langille</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Outcome analysis of patients with Peyronie's disease who elect for vacuum erection device therapy.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>E428</fpage>
            <page-range>E428-E431</page-range>
            <pub-id pub-id-type="pmid">32223874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r290">
          <label>290</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoyland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vasdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Adshead</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The use of vacuum erection devices in erectile dysfunction after radical prostatectomy.</article-title>
            <source>Rev Urol</source>
            <year>2013</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-71</page-range>
            <pub-id pub-id-type="pmid">24082845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r291">
          <label>291</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The science of vacuum erectile device in penile rehabilitation after radical prostatectomy.</article-title>
            <source>Transl Androl Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-6</page-range>
            <pub-id pub-id-type="pmid">26816725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r292">
          <label>292</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Modern treatment strategies for penile prosthetics in Peyronie's disease: a contemporary clinical review.</article-title>
            <source>Asian J Androl</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-59</page-range>
            <pub-id pub-id-type="pmid">31424027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r293">
          <label>293</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dell'Atti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Slyusar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cambise</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Multimodal treatments based on Tadalafil during acute phase of Peyronie's disease: experience at two referral academic centers.</article-title>
            <source>Ir J Med Sci</source>
            <year>2024</year>
            <month>Oct</month>
            <volume>193</volume>
            <issue>5</issue>
            <fpage>2301</fpage>
            <page-range>2301-2306</page-range>
            <pub-id pub-id-type="pmid">38861101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r294">
          <label>294</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Apr</month>
            <day>17</day>
            <volume>23</volume>
            <fpage>e936146</fpage>
            <pub-id pub-id-type="pmid">35430575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r295">
          <label>295</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sarnacchiaro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ten-year experience with multimodal treatment for acute phase Peyronie's disease: A real life clinical report.</article-title>
            <source>Actas Urol Esp (Engl Ed)</source>
            <year>2019</year>
            <month>May</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>182</fpage>
            <page-range>182-189</page-range>
            <pub-id pub-id-type="pmid">30704797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r296">
          <label>296</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.</article-title>
            <source>J Med Case Rep</source>
            <year>2022</year>
            <month>Oct</month>
            <day>08</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>359</fpage>
            <pub-id pub-id-type="pmid">36207748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r297">
          <label>297</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capoccia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Review of Peyronie's Disease Treatment.</article-title>
            <source>Curr Urol Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>17</day>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>51</fpage>
            <pub-id pub-id-type="pmid">29774446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r298">
          <label>298</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>2221</fpage>
            <page-range>2221-8; discussion 2229-30</page-range>
            <pub-id pub-id-type="pmid">18637996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r299">
          <label>299</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lenting</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>A surgical algorithm for the treatment of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>158</volume>
            <issue>6</issue>
            <fpage>2149</fpage>
            <page-range>2149-52</page-range>
            <pub-id pub-id-type="pmid">9366333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r300">
          <label>300</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tornehl</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Surgical alternatives for treating Peyronie's disease.</article-title>
            <source>BJU Int</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-83</page-range>
            <pub-id pub-id-type="pmid">15476507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r301">
          <label>301</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>McKibben</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shakir</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morey</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Plication for Severe Peyronie's Deformities Has Similar Long-Term Outcomes to Milder Cases.</article-title>
            <source>J Sex Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1498</fpage>
            <page-range>1498-1505</page-range>
            <pub-id pub-id-type="pmid">30228083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r302">
          <label>302</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NESBIT</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>CONGENITAL CURVATURE OF THE PHALLUS: REPORT OF THREE CASES WITH DESCRIPTION OF CORRECTIVE OPERATION.</article-title>
            <source>J Urol</source>
            <year>1965</year>
            <month>Feb</month>
            <volume>93</volume>
            <fpage>230</fpage>
            <page-range>230-2</page-range>
            <pub-id pub-id-type="pmid">14260875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r303">
          <label>303</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ralph</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>al-Akraa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pryor</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The Nesbit operation for Peyronie's disease: 16-year experience.</article-title>
            <source>J Urol</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>1362</fpage>
            <page-range>1362-3</page-range>
            <pub-id pub-id-type="pmid">7658538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r304">
          <label>304</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pryor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>A new approach to the correction of the penile deformity in Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>622</fpage>
            <page-range>622-3</page-range>
            <pub-id pub-id-type="pmid">501814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r305">
          <label>305</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemberger</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Nesbit's operation for Peyronie's disease.</article-title>
            <source>Br J Urol</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>721</fpage>
            <page-range>721-3</page-range>
            <pub-id pub-id-type="pmid">6534497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r306">
          <label>306</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laungani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abrahams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waterhouse</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Correction of adult penile curvature with a Nesbit operation.</article-title>
            <source>J Urol</source>
            <year>1984</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-8</page-range>
            <pub-id pub-id-type="pmid">6690748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r307">
          <label>307</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coughlin</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Paulson</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Surgical correction of Peyronie's disease: the Nesbit procedure.</article-title>
            <source>J Urol</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>282</fpage>
            <page-range>282-5</page-range>
            <pub-id pub-id-type="pmid">6538238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r308">
          <label>308</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Abbasi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hargreave</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Nesbit procedure for disabling Peyronie's curvature: a median follow-up of 84 months.</article-title>
            <source>Urology</source>
            <year>2003</year>
            <month>May</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>999</fpage>
            <page-range>999-1003</page-range>
            <pub-id pub-id-type="pmid">12736023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r309">
          <label>309</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pendleton</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: current therapy.</article-title>
            <source>Transl Androl Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-23</page-range>
            <pub-id pub-id-type="pmid">26816719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r310">
          <label>310</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yachia</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Modified corporoplasty for the treatment of penile curvature.</article-title>
            <source>J Urol</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-2</page-range>
            <pub-id pub-id-type="pmid">2294269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r311">
          <label>311</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minsky</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Melman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunical shaving and plication).</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>157</volume>
            <issue>4</issue>
            <fpage>1288</fpage>
            <page-range>1288-91</page-range>
            <pub-id pub-id-type="pmid">9120923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r312">
          <label>312</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sassine</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wespes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Modified corporoplasty for penile curvature: 10 years' experience.</article-title>
            <source>Urology</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>419</fpage>
            <page-range>419-21</page-range>
            <pub-id pub-id-type="pmid">8073558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r313">
          <label>313</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daitch</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Angermeier</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Montague</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Modified corporoplasty for penile curvature: long-term results and patient satisfaction.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>162</volume>
            <issue>6</issue>
            <fpage>2006</fpage>
            <page-range>2006-9</page-range>
            <pub-id pub-id-type="pmid">10569557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r314">
          <label>314</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tomada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vendeira</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Penile corporoplasty with Yachia's technique for Peyronie's disease: Single center experience with 117 patients.</article-title>
            <source>Urol Ann</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-71</page-range>
            <pub-id pub-id-type="pmid">24049379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r315">
          <label>315</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rahmadi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Peyronie disease: Our first experience with Ducket Baskin tunica albuginea plication (TAP) technique.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>87</volume>
            <fpage>106451</fpage>
            <pub-id pub-id-type="pmid">34624830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r316">
          <label>316</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seveso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melegari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Francesco</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Macchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romero Otero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taverna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bozzini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Surgical correction of Peyronie's disease via tunica albuginea plication: long-term follow-up.</article-title>
            <source>Andrology</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-52</page-range>
            <pub-id pub-id-type="pmid">29195031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r317">
          <label>317</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nooter</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease and congenital penile curvature: long-term results of operative treatment with the plication procedure.</article-title>
            <source>Br J Urol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>497</fpage>
            <page-range>497-500</page-range>
            <pub-id pub-id-type="pmid">7820430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r318">
          <label>318</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klevmark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talseth</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Congenital and acquired curvature of the penis treated surgically by plication of the tunica albuginea.</article-title>
            <source>Br J Urol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>501</fpage>
            <page-range>501-6</page-range>
            <pub-id pub-id-type="pmid">7820431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r319">
          <label>319</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiounn</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Missirliu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zerbib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larrouy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dje</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Debr&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Corporeal plication for surgical correction of penile curvature. Experience with 60 patients.</article-title>
            <source>Eur Urol</source>
            <year>1998</year>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>401</fpage>
            <page-range>401-4</page-range>
            <pub-id pub-id-type="pmid">9612685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r320">
          <label>320</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cormio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zizzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bettocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berardi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sblendorio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Traficante</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selvaggi</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Tunica albuginea plication for the correction of penile curvature.</article-title>
            <source>Scand J Urol Nephrol</source>
            <year>2002</year>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-10</page-range>
            <pub-id pub-id-type="pmid">12201925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r321">
          <label>321</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantoro</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Polito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catanzariti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montesi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lacetera</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Muzzonigro</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Penile plication for Peyronie's disease: our results with mean follow-up of 103 months on 89 patients.</article-title>
            <source>Int J Impot Res</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>156</fpage>
            <page-range>156-9</page-range>
            <pub-id pub-id-type="pmid">24572996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r322">
          <label>322</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudak</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Morey</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Adibi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bagrodia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Favorable patient reported outcomes after penile plication for wide array of peyronie disease abnormalities.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>189</volume>
            <issue>3</issue>
            <fpage>1019</fpage>
            <page-range>1019-24</page-range>
            <pub-id pub-id-type="pmid">23017514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r323">
          <label>323</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roadman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Quesada-Olarte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Langbo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mossack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Experience With Extra-Tunical Grafting and Tunica Albuginea Plication for Correction of Indentation Deformity in Men With Peyronie's Disease.</article-title>
            <source>Urology</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>186</volume>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">38395079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r324">
          <label>324</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gholami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Correction of penile curvature using the 16-dot plication technique: a review of 132 patients.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>May</month>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>2066</fpage>
            <page-range>2066-9</page-range>
            <pub-id pub-id-type="pmid">11956440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r325">
          <label>325</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;ayan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>A&#x0015f;c&#x00131;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Efesoy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kocamano&#x0011f;lu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akbay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yaman</surname>
                <given-names>&#x000d6;</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Patient's Satisfaction and Long-term Results of 2 Penile Plication Techniques: Lessons Learned From 387 Patients With Penile Curvature.</article-title>
            <source>Urology</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>129</volume>
            <fpage>106</fpage>
            <page-range>106-112</page-range>
            <pub-id pub-id-type="pmid">30954611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r326">
          <label>326</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Modified 16-Dot plication technique for correction of penile curvature: prevention of knot-related complications.</article-title>
            <source>Int J Impot Res</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>117</fpage>
            <page-range>117-121</page-range>
            <pub-id pub-id-type="pmid">29736012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r327">
          <label>327</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brant</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Bella</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>16-Dot procedure for penile curvature.</article-title>
            <source>J Sex Med</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-80</page-range>
            <pub-id pub-id-type="pmid">17367422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r328">
          <label>328</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Surgery for Peyronie's disease.</article-title>
            <source>Asian J Androl</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-34</page-range>
            <pub-id pub-id-type="pmid">23178395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r329">
          <label>329</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelbard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Expanding contractures of the tunica albuginea due to Peyronie's disease with temporalis fascia free grafts.</article-title>
            <source>J Urol</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>145</volume>
            <issue>4</issue>
            <fpage>772</fpage>
            <page-range>772-6</page-range>
            <pub-id pub-id-type="pmid">2005698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r330">
          <label>330</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalkin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Venogenic impotence following dermal graft repair for Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>849</fpage>
            <page-range>849-51</page-range>
            <pub-id pub-id-type="pmid">1843616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r331">
          <label>331</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiffman</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Gursel</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Laor</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Use of Dacron patch graft in Peyronie disease.</article-title>
            <source>Urology</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-40</page-range>
            <pub-id pub-id-type="pmid">3155581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r332">
          <label>332</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faerber</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Konnak</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Results of combined Nesbit penile plication with plaque incision and placement of Dacron patch in patients with severe Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>May</month>
            <volume>149</volume>
            <issue>5 Pt 2</issue>
            <fpage>1319</fpage>
            <page-range>1319-20</page-range>
            <pub-id pub-id-type="pmid">8479026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r333">
          <label>333</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganabathi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zimmern</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease: surgical treatment based on penile rigidity.</article-title>
            <source>J Urol</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>153</volume>
            <issue>3 Pt 1</issue>
            <fpage>662</fpage>
            <page-range>662-6</page-range>
            <pub-id pub-id-type="pmid">7861510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r334">
          <label>334</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokarica</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parazajder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mazuran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gilja</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of Peyronie's disease based on penile length and degree of curvature.</article-title>
            <source>Int J Impot Res</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-4</page-range>
            <pub-id pub-id-type="pmid">15215882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r335">
          <label>335</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenhammer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sayedahmed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fritsche</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000fc;bler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome after grafting with small intestinal submucosa and collagen fleece in patients with Peyronie's disease: a matched pair analysis.</article-title>
            <source>Int J Impot Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>256</fpage>
            <page-range>256-262</page-range>
            <pub-id pub-id-type="pmid">30194372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r336">
          <label>336</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Evolution of the surgical sealing patch TachoSil<sup>&#x000ae;</sup> in Peyronie's disease reconstructive surgery: technique and contemporary literature review.</article-title>
            <source>World J Urol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>315</fpage>
            <page-range>315-321</page-range>
            <pub-id pub-id-type="pmid">31053920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r337">
          <label>337</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatzichristodoulou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000fc;ltekin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>&#x000d6;zkara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akkus</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>First worldwide correction of ventral Peyronie's disease utilizing rigicon inflatable penile prosthesis combined with plaque incision &#x00026; grafting with collagen fleece (PICS-technique) for residual curvature.</article-title>
            <source>Int J Impot Res</source>
            <year>2024</year>
            <month>Mar</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">38480871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r338">
          <label>338</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadio&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tefekli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demirel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tellalo&#x0011f;lu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of Peyronie's disease with incision and venous patch technique.</article-title>
            <source>Int J Impot Res</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">10356666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r339">
          <label>339</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arena</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peracchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>di Stefano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortellini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease--incision and dorsal vein grafting combined with contralateral plication in straightening the penis.</article-title>
            <source>Scand J Urol Nephrol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-5</page-range>
            <pub-id pub-id-type="pmid">10452294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r340">
          <label>340</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montorsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salonia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bua</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guazzoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barbagli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chiesa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pizzini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rigatti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>163</volume>
            <issue>6</issue>
            <fpage>1704</fpage>
            <page-range>1704-8</page-range>
            <pub-id pub-id-type="pmid">10799165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r341">
          <label>341</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Papagiannopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie's disease: measured lengths and patient perceptions.</article-title>
            <source>J Sex Med</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>2396</fpage>
            <page-range>2396-403</page-range>
            <pub-id pub-id-type="pmid">22900621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r342">
          <label>342</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Greenfield</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction.</article-title>
            <source>J Sex Med</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-7</page-range>
            <pub-id pub-id-type="pmid">16422892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r343">
          <label>343</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Worldwide Survey on Peyronie's Disease Surgical Practice Patterns Among Surgeons.</article-title>
            <source>J Sex Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>568</fpage>
            <page-range>568-575</page-range>
            <pub-id pub-id-type="pmid">29550462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r344">
          <label>344</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Doddi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Regula</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Melveger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Polydioxanone (PDS), a novel monofilament synthetic absorbable suture.</article-title>
            <source>Surg Gynecol Obstet</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>153</volume>
            <issue>4</issue>
            <fpage>497</fpage>
            <page-range>497-507</page-range>
            <pub-id pub-id-type="pmid">6792722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r345">
          <label>345</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Akman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cakan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mamadov</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of Peyronie's disease: a single center experience with 145 patients.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>432</fpage>
            <page-range>432-9</page-range>
            <pub-id pub-id-type="pmid">17467161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r346">
          <label>346</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dimitriou</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's disease.</article-title>
            <source>Int J Impot Res</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-51</page-range>
            <pub-id pub-id-type="pmid">11045907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r347">
          <label>347</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiBlasio</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kurta</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Botta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malcolm</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Derweesh</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wake</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Peyronie's disease compromises the durability and component-malfunction rates in patients implanted with an inflatable penile prosthesis.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>106</volume>
            <issue>5</issue>
            <fpage>691</fpage>
            <page-range>691-4</page-range>
            <pub-id pub-id-type="pmid">20128775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r348">
          <label>348</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Delk</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis.</article-title>
            <source>J Urol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>1121</fpage>
            <page-range>1121-3</page-range>
            <pub-id pub-id-type="pmid">8072079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r349">
          <label>349</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Application of pericardial graft in the surgical management of Peyronie's disease.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>May</month>
            <volume>163</volume>
            <issue>5</issue>
            <fpage>1445</fpage>
            <page-range>1445-7</page-range>
            <pub-id pub-id-type="pmid">10751854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r350">
          <label>350</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kad&#x00131;o&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000fc;rcan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rakhmonovich</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Dursun</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of complex curvature in Peyronie's disease.</article-title>
            <source>World J Urol</source>
            <year>2024</year>
            <month>Apr</month>
            <day>30</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <pub-id pub-id-type="pmid">38689034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r351">
          <label>351</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cavayero</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <chapter-title>Penile Prosthesis Implantation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">33085439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r352">
          <label>352</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asmundo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Durukan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>von Rohden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>CFS</given-names>
              </name>
              <name>
                <surname>Fode</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Platelet-rich plasma therapy in erectile dysfunction and Peyronie's disease: a systematic review of the literature.</article-title>
            <source>World J Urol</source>
            <year>2024</year>
            <month>May</month>
            <day>29</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>359</fpage>
            <pub-id pub-id-type="pmid">38811395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r353">
          <label>353</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ledesma</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Velasquez</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Egemba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costantini-Mesquita</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deebel</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update.</article-title>
            <source>Int J Impot Res</source>
            <year>2024</year>
            <month>Feb</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">38424354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r354">
          <label>354</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alkandari</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Touma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carrier</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence.</article-title>
            <source>Sex Med Rev</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-352</page-range>
            <pub-id pub-id-type="pmid">34219010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r355">
          <label>355</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fidel</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Bal</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kharazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roque</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sidhom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bouhadana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petrella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An overview of the Canadian landscape on the use of restorative therapies for erectile dysfunction and Peyronie's disease.</article-title>
            <source>Can Urol Assoc J</source>
            <year>2024</year>
            <month>Jul</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">39037510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r356">
          <label>356</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schirmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boutin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yiou</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: Pilot study.</article-title>
            <source>Prog Urol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>856</fpage>
            <page-range>856-861</page-range>
            <pub-id pub-id-type="pmid">35778315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r357">
          <label>357</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zugail</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Alshuaibi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lombion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie's disease in the outpatient setting: a pilot study.</article-title>
            <source>Int J Impot Res</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-145</page-range>
            <pub-id pub-id-type="pmid">37550385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r358">
          <label>358</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshuaibi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zugail</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lombion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>New protocol in the treatment of Peyronie's disease by combining platelet-rich plasma, percutaneous needle tunneling, and penile modeling: Preliminary results.</article-title>
            <source>Fr J Urol</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>102526</fpage>
            <pub-id pub-id-type="pmid">37777436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r359">
          <label>359</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>The Immunological Microenvironment and the Emerging Role of Stem Cells Therapy in Peyronie's Disease: A Systematic Narrative Review.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>24</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36614220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r360">
          <label>360</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manfredi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sokolakis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schifano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pyrgidis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sansone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-G&#x000f3;mez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Albersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Romero-Otero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fode</surname>
                <given-names>M</given-names>
              </name>
              <collab>ESSM Scientific Collaboration and Partnership (ESCAP)</collab>
            </person-group>
            <article-title>Cell therapy for male sexual dysfunctions: systematic review and position statements from the European Society for Sexual Medicine.</article-title>
            <source>Sex Med</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>qfad071</fpage>
            <pub-id pub-id-type="pmid">38344213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r361">
          <label>361</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Intratunical injection of rat-derived bone marrow mesenchymal stem cells prevents fibrosis and is associated with increased Smad7 expression in a rat model of Peyronie's disease.</article-title>
            <source>Stem Cell Res Ther</source>
            <year>2022</year>
            <month>Jul</month>
            <day>30</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>390</fpage>
            <pub-id pub-id-type="pmid">35908015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r362">
          <label>362</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haney</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Gabrielson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJG</given-names>
              </name>
            </person-group>
            <article-title>The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies.</article-title>
            <source>Sex Med Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-320</page-range>
            <pub-id pub-id-type="pmid">29960873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r363">
          <label>363</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dell'Atti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ronchi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Low-intensity laser diode plus extracorporeal shock wave therapy: a new treatment strategy in the management of Peyronie's disease.</article-title>
            <source>World J Urol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>2563</fpage>
            <page-range>2563-2568</page-range>
            <pub-id pub-id-type="pmid">37490060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r364">
          <label>364</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Laser Photobiomodulation of the Induratio Penis Plastica or La Peyronie's Syndrome.</article-title>
            <source>Photobiomodul Photomed Laser Surg</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-291</page-range>
            <pub-id pub-id-type="pmid">34941426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r365">
          <label>365</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-30</page-range>
            <pub-id pub-id-type="pmid">25604027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r366">
          <label>366</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalm</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dik</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Thio</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>van den Blink</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Hagen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>van Daele</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>[Fibrosing disorders: insights into pathogenesis and new treatment options].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2015</year>
            <volume>159</volume>
            <fpage>A8345</fpage>
            <pub-id pub-id-type="pmid">26058763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r367">
          <label>367</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kadowitz</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Drugs of the future for Peyronie's disease.</article-title>
            <source>Med Hypotheses</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>305</fpage>
            <page-range>305-11</page-range>
            <pub-id pub-id-type="pmid">22154542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r368">
          <label>368</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sencaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghomeshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zucker</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Stem-Cell, Shockwave, and Platelet Rich Plasma Therapy for the Treatment of Erectile Dysfunction and Peyronie's Disease: A Survey of Clinics Across the USA.</article-title>
            <source>Urology</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>178</volume>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">37076023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r369">
          <label>369</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furtado</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Osadchiy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Andino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Eleswarapu</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Collagenase Clostridium histolyticum for Peyronie's disease: a contemporary atlas of complications and their management.</article-title>
            <source>Sex Med Rev</source>
            <year>2024</year>
            <month>Jun</month>
            <day>26</day>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>491</fpage>
            <page-range>491-496</page-range>
            <pub-id pub-id-type="pmid">38491199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r370">
          <label>370</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henningsohn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuja-Halkola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cederl&#x000f6;f</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk of relationship separation in men with Peyronie's disease in a matched Swedish cohort.</article-title>
            <source>Sci Rep</source>
            <year>2024</year>
            <month>Sep</month>
            <day>10</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>21143</fpage>
            <pub-id pub-id-type="pmid">39256558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r371">
          <label>371</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lue</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>El-Sakka</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Lengthening shortened penis caused by Peyronie's disease using circular venous grafting and daily stretching with a vacuum erection device.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>161</volume>
            <issue>4</issue>
            <fpage>1141</fpage>
            <page-range>1141-4</page-range>
            <pub-id pub-id-type="pmid">10081856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-111973.r372">
          <label>372</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauck</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Bschleipfer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Diemer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schroeder-Printzen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Weidner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Long-term results of plaque thinning with carbide burs, small incisions and venous grafting for correcting complex penile curvature in Peyronie's disease: poor results of an "ideal" approach.</article-title>
            <source>J Urol</source>
            <year>2002</year>
            <month>May</month>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>2070</fpage>
            <page-range>2070-3</page-range>
            <pub-id pub-id-type="pmid">11956441</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
